id	sid	tid	token	lemma	pos
dpc-2357	1	1	dermatology	dermatology	NOUN
dpc-2357	1	2	:	:	PUNCT
dpc-2357	1	3	practical	practical	ADJ
dpc-2357	1	4	and	and	CCONJ
dpc-2357	1	5	conceptual	conceptual	ADJ
dpc-2357	1	6	original	original	ADJ
dpc-2357	1	7	article	article	NOUN
dpc-2357	1	8	|	|	ADV
dpc-2357	1	9	dermatol	dermatol	ADJ
dpc-2357	1	10	pract	pract	NOUN
dpc-2357	1	11	concept	concept	NOUN
dpc-2357	1	12	.	.	PUNCT
dpc-2357	2	1	2022;12(4):e2022201	2022;12(4):e2022201	NUM
dpc-2357	2	2	1	1	NUM
dpc-2357	2	3	papulopustular	papulopustular	ADJ
dpc-2357	2	4	rosacea	rosacea	NOUN
dpc-2357	2	5	treated	treat	VERB
dpc-2357	2	6	with	with	ADP
dpc-2357	2	7	ivermectin	ivermectin	NOUN
dpc-2357	2	8	1	1	NUM
dpc-2357	2	9	%	%	NOUN
dpc-2357	2	10	cream	cream	NOUN
dpc-2357	2	11	:	:	PUNCT
dpc-2357	2	12	remission	remission	NOUN
dpc-2357	2	13	of	of	ADP
dpc-2357	2	14	the	the	DET
dpc-2357	2	15	demodex	demodex	NOUN
dpc-2357	2	16	mite	mite	NOUN
dpc-2357	2	17	infestation	infestation	NOUN
dpc-2357	2	18	over	over	ADP
dpc-2357	2	19	time	time	NOUN
dpc-2357	2	20	and	and	CCONJ
dpc-2357	2	21	evaluation	evaluation	NOUN
dpc-2357	2	22	of	of	ADP
dpc-2357	2	23	clinical	clinical	ADJ
dpc-2357	2	24	relapses	relapse	NOUN
dpc-2357	2	25	ilaria	ilaria	PROPN
dpc-2357	2	26	trave1	trave1	PROPN
dpc-2357	2	27	,	,	PUNCT
dpc-2357	2	28	claudia	claudia	PROPN
dpc-2357	2	29	micalizzi1	micalizzi1	PROPN
dpc-2357	2	30	,	,	PUNCT
dpc-2357	2	31	emanuele	emanuele	PROPN
dpc-2357	2	32	cozzani1	cozzani1	PROPN
dpc-2357	2	33	,	,	PUNCT
dpc-2357	2	34	giulia	giulia	PROPN
dpc-2357	2	35	gasparini1	gasparini1	PROPN
dpc-2357	2	36	,	,	PUNCT
dpc-2357	2	37	aurora	aurora	PROPN
dpc-2357	2	38	parodi1	parodi1	NOUN
dpc-2357	2	39	1	1	NUM
dpc-2357	2	40	section	section	NOUN
dpc-2357	2	41	of	of	ADP
dpc-2357	2	42	dermatology	dermatology	NOUN
dpc-2357	2	43	department	department	PROPN
dpc-2357	2	44	of	of	ADP
dpc-2357	2	45	health	health	PROPN
dpc-2357	2	46	sciences	sciences	PROPN
dpc-2357	2	47	,	,	PUNCT
dpc-2357	2	48	university	university	PROPN
dpc-2357	2	49	of	of	ADP
dpc-2357	2	50	genoa	genoa	PROPN
dpc-2357	2	51	,	,	PUNCT
dpc-2357	2	52	irccs	ircc	VERB
dpc-2357	2	53	ospedale	ospedale	PROPN
dpc-2357	2	54	policlinico	policlinico	PROPN
dpc-2357	2	55	san	san	PROPN
dpc-2357	2	56	martino	martino	PROPN
dpc-2357	2	57	,	,	PUNCT
dpc-2357	2	58	genoa	genoa	PROPN
dpc-2357	2	59	,	,	PUNCT
dpc-2357	2	60	italy	italy	PROPN
dpc-2357	2	61	key	key	ADJ
dpc-2357	2	62	words	word	NOUN
dpc-2357	2	63	:	:	PUNCT
dpc-2357	2	64	ivermectin	ivermectin	NOUN
dpc-2357	2	65	,	,	PUNCT
dpc-2357	2	66	rosacea	rosacea	NOUN
dpc-2357	2	67	,	,	PUNCT
dpc-2357	2	68	papulopustular	papulopustular	ADJ
dpc-2357	2	69	rosacea	rosacea	NOUN
dpc-2357	2	70	citation	citation	NOUN
dpc-2357	2	71	:	:	PUNCT
dpc-2357	3	1	trave	trave	PROPN
dpc-2357	3	2	i	i	PRON
dpc-2357	3	3	,	,	PUNCT
dpc-2357	3	4	micalizzi	micalizzi	PROPN
dpc-2357	3	5	c	c	PROPN
dpc-2357	3	6	,	,	PUNCT
dpc-2357	3	7	cozzani	cozzani	ADJ
dpc-2357	3	8	e	e	NOUN
dpc-2357	3	9	,	,	PUNCT
dpc-2357	3	10	gasparini	gasparini	VERB
dpc-2357	3	11	g	g	NOUN
dpc-2357	3	12	,	,	PUNCT
dpc-2357	3	13	parodi	parodi	PROPN
dpc-2357	3	14	a.	a.	NOUN
dpc-2357	3	15	papulopustular	papulopustular	ADJ
dpc-2357	3	16	rosacea	rosacea	PROPN
dpc-2357	3	17	treated	treat	VERB
dpc-2357	3	18	with	with	ADP
dpc-2357	3	19	ivermectin	ivermectin	NOUN
dpc-2357	3	20	1	1	NUM
dpc-2357	3	21	%	%	NOUN
dpc-2357	3	22	cream	cream	NOUN
dpc-2357	3	23	:	:	PUNCT
dpc-2357	3	24	remission	remission	NOUN
dpc-2357	3	25	of	of	ADP
dpc-2357	3	26	the	the	DET
dpc-2357	3	27	demodex	demodex	NOUN
dpc-2357	3	28	mite	mite	NOUN
dpc-2357	3	29	infestation	infestation	NOUN
dpc-2357	3	30	over	over	ADP
dpc-2357	3	31	the	the	DET
dpc-2357	3	32	time	time	NOUN
dpc-2357	3	33	and	and	CCONJ
dpc-2357	3	34	evaluation	evaluation	NOUN
dpc-2357	3	35	of	of	ADP
dpc-2357	3	36	clinical	clinical	ADJ
dpc-2357	3	37	relapses	relapse	NOUN
dpc-2357	3	38	.	.	PUNCT
dpc-2357	4	1	dermatol	dermatol	NOUN
dpc-2357	4	2	pract	pract	PROPN
dpc-2357	4	3	concept	concept	NOUN
dpc-2357	4	4	.	.	PUNCT
dpc-2357	5	1	2022;12(4):e2022201	2022;12(4):e2022201	X
dpc-2357	5	2	.	.	PUNCT
dpc-2357	6	1	doi	doi	NOUN
dpc-2357	6	2	:	:	PUNCT
dpc-2357	6	3	https://doi.org/10.5826/dpc.1204a201	https://doi.org/10.5826/dpc.1204a201	PROPN
dpc-2357	6	4	accepted	accept	VERB
dpc-2357	6	5	:	:	PUNCT
dpc-2357	6	6	march	march	PROPN
dpc-2357	6	7	3	3	NUM
dpc-2357	6	8	,	,	PUNCT
dpc-2357	6	9	2022	2022	NUM
dpc-2357	6	10	;	;	PUNCT
dpc-2357	6	11	published	publish	VERB
dpc-2357	6	12	:	:	PUNCT
dpc-2357	6	13	october	october	PROPN
dpc-2357	6	14	2022	2022	NUM
dpc-2357	7	1	copyright	copyright	NOUN
dpc-2357	7	2	:	:	PUNCT
dpc-2357	7	3	©	©	PROPN
dpc-2357	7	4	2022	2022	NUM
dpc-2357	7	5	trave	trave	NOUN
dpc-2357	7	6	et	et	PROPN
dpc-2357	7	7	al	al	PROPN
dpc-2357	7	8	.	.	PUNCT
dpc-2357	8	1	this	this	PRON
dpc-2357	8	2	is	be	AUX
dpc-2357	8	3	an	an	DET
dpc-2357	8	4	open	open	ADJ
dpc-2357	8	5	-	-	PUNCT
dpc-2357	8	6	access	access	NOUN
dpc-2357	8	7	article	article	NOUN
dpc-2357	8	8	distributed	distribute	VERB
dpc-2357	8	9	under	under	ADP
dpc-2357	8	10	the	the	DET
dpc-2357	8	11	terms	term	NOUN
dpc-2357	8	12	of	of	ADP
dpc-2357	8	13	the	the	DET
dpc-2357	8	14	creative	creative	ADJ
dpc-2357	8	15	commons	common	NOUN
dpc-2357	8	16	attribution	attribution	NOUN
dpc-2357	8	17	-	-	PUNCT
dpc-2357	8	18	noncommercial	noncommercial	ADJ
dpc-2357	8	19	license	license	NOUN
dpc-2357	8	20	(	(	PUNCT
dpc-2357	8	21	by	by	ADP
dpc-2357	8	22	-	-	PUNCT
dpc-2357	8	23	nc-4.0	nc-4.0	NOUN
dpc-2357	8	24	)	)	PUNCT
dpc-2357	8	25	,	,	PUNCT
dpc-2357	8	26	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-2357	8	27	,	,	PUNCT
dpc-2357	8	28	which	which	PRON
dpc-2357	8	29	permits	permit	VERB
dpc-2357	8	30	unrestricted	unrestricted	ADJ
dpc-2357	8	31	noncommercial	noncommercial	ADJ
dpc-2357	8	32	use	use	NOUN
dpc-2357	8	33	,	,	PUNCT
dpc-2357	8	34	distribution	distribution	NOUN
dpc-2357	8	35	,	,	PUNCT
dpc-2357	8	36	and	and	CCONJ
dpc-2357	8	37	reproduction	reproduction	NOUN
dpc-2357	8	38	in	in	ADP
dpc-2357	8	39	any	any	DET
dpc-2357	8	40	medium	medium	NOUN
dpc-2357	8	41	,	,	PUNCT
dpc-2357	8	42	provided	provide	VERB
dpc-2357	8	43	the	the	DET
dpc-2357	8	44	original	original	ADJ
dpc-2357	8	45	authors	author	NOUN
dpc-2357	8	46	and	and	CCONJ
dpc-2357	8	47	source	source	NOUN
dpc-2357	8	48	are	be	AUX
dpc-2357	8	49	credited	credit	VERB
dpc-2357	8	50	.	.	PUNCT
dpc-2357	9	1	funding	funding	NOUN
dpc-2357	9	2	:	:	PUNCT
dpc-2357	9	3	none	none	NOUN
dpc-2357	9	4	.	.	PUNCT
dpc-2357	10	1	competing	compete	VERB
dpc-2357	10	2	interests	interest	NOUN
dpc-2357	10	3	:	:	PUNCT
dpc-2357	10	4	none	none	NOUN
dpc-2357	10	5	.	.	PUNCT
dpc-2357	11	1	authorship	authorship	NOUN
dpc-2357	11	2	:	:	PUNCT
dpc-2357	11	3	all	all	DET
dpc-2357	11	4	authors	author	NOUN
dpc-2357	11	5	have	have	AUX
dpc-2357	11	6	contributed	contribute	VERB
dpc-2357	11	7	significantly	significantly	ADV
dpc-2357	11	8	to	to	ADP
dpc-2357	11	9	this	this	DET
dpc-2357	11	10	publication	publication	NOUN
dpc-2357	11	11	.	.	PUNCT
dpc-2357	12	1	corresponding	correspond	VERB
dpc-2357	12	2	author	author	NOUN
dpc-2357	12	3	:	:	PUNCT
dpc-2357	12	4	ilaria	ilaria	PROPN
dpc-2357	12	5	trave	trave	PROPN
dpc-2357	12	6	,	,	PUNCT
dpc-2357	12	7	section	section	NOUN
dpc-2357	12	8	of	of	ADP
dpc-2357	12	9	dermatology	dermatology	NOUN
dpc-2357	12	10	department	department	PROPN
dpc-2357	12	11	of	of	ADP
dpc-2357	12	12	health	health	PROPN
dpc-2357	12	13	sciences	sciences	PROPN
dpc-2357	12	14	,	,	PUNCT
dpc-2357	12	15	university	university	PROPN
dpc-2357	12	16	of	of	ADP
dpc-2357	12	17	genoa	genoa	PROPN
dpc-2357	12	18	,	,	PUNCT
dpc-2357	12	19	irccs	ircc	VERB
dpc-2357	12	20	ospedale	ospedale	PROPN
dpc-2357	12	21	policlinico	policlinico	PROPN
dpc-2357	12	22	san	san	PROPN
dpc-2357	12	23	martino	martino	PROPN
dpc-2357	12	24	,	,	PUNCT
dpc-2357	12	25	genoa	genoa	PROPN
dpc-2357	12	26	,	,	PUNCT
dpc-2357	12	27	italy	italy	PROPN
dpc-2357	12	28	.	.	PUNCT
dpc-2357	13	1	tell	tell	VERB
dpc-2357	13	2	:	:	PUNCT
dpc-2357	13	3	0105555750	0105555750	NUM
dpc-2357	13	4	e	e	X
dpc-2357	13	5	-	-	NOUN
dpc-2357	13	6	mail	mail	NOUN
dpc-2357	13	7	:	:	PUNCT
dpc-2357	13	8	ilaria.trave@gmail.com	ilaria.trave@gmail.com	X
dpc-2357	13	9	introduction	introduction	NOUN
dpc-2357	13	10	:	:	PUNCT
dpc-2357	13	11	topical	topical	ADJ
dpc-2357	13	12	ivermectin	ivermectin	NOUN
dpc-2357	13	13	is	be	AUX
dpc-2357	13	14	an	an	DET
dpc-2357	13	15	anti	anti	ADJ
dpc-2357	13	16	-	-	ADJ
dpc-2357	13	17	inflammatory	inflammatory	ADJ
dpc-2357	13	18	and	and	CCONJ
dpc-2357	13	19	anti	anti	ADJ
dpc-2357	13	20	-	-	ADJ
dpc-2357	13	21	demodex	demodex	ADJ
dpc-2357	13	22	drug	drug	NOUN
dpc-2357	13	23	for	for	ADP
dpc-2357	13	24	papulopustular	papulopustular	ADJ
dpc-2357	13	25	rosacea	rosacea	NOUN
dpc-2357	13	26	.	.	PUNCT
dpc-2357	14	1	rosacea	rosacea	NOUN
dpc-2357	14	2	is	be	AUX
dpc-2357	14	3	a	a	DET
dpc-2357	14	4	relapsing	relapse	VERB
dpc-2357	14	5	disease	disease	NOUN
dpc-2357	14	6	and	and	CCONJ
dpc-2357	14	7	the	the	DET
dpc-2357	14	8	time	time	NOUN
dpc-2357	14	9	between	between	ADP
dpc-2357	14	10	recurrences	recurrence	NOUN
dpc-2357	14	11	should	should	AUX
dpc-2357	14	12	be	be	AUX
dpc-2357	14	13	considered	consider	VERB
dpc-2357	14	14	alongside	alongside	ADP
dpc-2357	14	15	efficacy	efficacy	NOUN
dpc-2357	14	16	.	.	PUNCT
dpc-2357	15	1	objectives	objective	NOUN
dpc-2357	15	2	:	:	PUNCT
dpc-2357	15	3	the	the	DET
dpc-2357	15	4	aims	aim	NOUN
dpc-2357	15	5	of	of	ADP
dpc-2357	15	6	this	this	DET
dpc-2357	15	7	study	study	NOUN
dpc-2357	15	8	were	be	AUX
dpc-2357	15	9	to	to	PART
dpc-2357	15	10	assess	assess	VERB
dpc-2357	15	11	the	the	DET
dpc-2357	15	12	time	time	NOUN
dpc-2357	15	13	of	of	ADP
dpc-2357	15	14	first	first	ADJ
dpc-2357	15	15	relapse	relapse	NOUN
dpc-2357	15	16	and	and	CCONJ
dpc-2357	15	17	relapse	relapse	NOUN
dpc-2357	15	18	rates	rate	NOUN
dpc-2357	15	19	of	of	ADP
dpc-2357	15	20	demodex	demodex	NOUN
dpc-2357	15	21	mite	mite	NOUN
dpc-2357	15	22	infestation	infestation	NOUN
dpc-2357	15	23	and	and	CCONJ
dpc-2357	15	24	papulopustular	papulopustular	ADJ
dpc-2357	15	25	rosacea	rosacea	NOUN
dpc-2357	15	26	.	.	PUNCT
dpc-2357	16	1	methods	method	NOUN
dpc-2357	16	2	:	:	PUNCT
dpc-2357	16	3	we	we	PRON
dpc-2357	16	4	conducted	conduct	VERB
dpc-2357	16	5	a	a	DET
dpc-2357	16	6	prospective	prospective	ADJ
dpc-2357	16	7	study	study	NOUN
dpc-2357	16	8	of	of	ADP
dpc-2357	16	9	subjects	subject	NOUN
dpc-2357	16	10	affected	affect	VERB
dpc-2357	16	11	by	by	ADP
dpc-2357	16	12	different	different	ADJ
dpc-2357	16	13	degrees	degree	NOUN
dpc-2357	16	14	of	of	ADP
dpc-2357	16	15	papulopustular	papulopustular	ADJ
dpc-2357	16	16	rosacea	rosacea	NOUN
dpc-2357	16	17	.	.	PUNCT
dpc-2357	17	1	patients	patient	NOUN
dpc-2357	17	2	that	that	PRON
dpc-2357	17	3	achieved	achieve	VERB
dpc-2357	17	4	a	a	DET
dpc-2357	17	5	complete	complete	ADJ
dpc-2357	17	6	response	response	NOUN
dpc-2357	17	7	after	after	SCONJ
dpc-2357	17	8	treatment	treatment	NOUN
dpc-2357	17	9	were	be	AUX
dpc-2357	17	10	monitored	monitor	VERB
dpc-2357	17	11	every	every	DET
dpc-2357	17	12	4	4	NUM
dpc-2357	17	13	weeks	week	NOUN
dpc-2357	17	14	and	and	CCONJ
dpc-2357	17	15	up	up	ADP
dpc-2357	17	16	to	to	PART
dpc-2357	17	17	32	32	NUM
dpc-2357	17	18	additional	additional	ADJ
dpc-2357	17	19	weeks	week	NOUN
dpc-2357	17	20	.	.	PUNCT
dpc-2357	18	1	for	for	ADP
dpc-2357	18	2	each	each	DET
dpc-2357	18	3	patient	patient	NOUN
dpc-2357	18	4	,	,	PUNCT
dpc-2357	18	5	we	we	PRON
dpc-2357	18	6	evaluated	evaluate	VERB
dpc-2357	18	7	recording	record	VERB
dpc-2357	18	8	the	the	DET
dpc-2357	18	9	time	time	NOUN
dpc-2357	18	10	to	to	PART
dpc-2357	18	11	first	first	ADJ
dpc-2357	18	12	relapse	relapse	VERB
dpc-2357	18	13	and	and	CCONJ
dpc-2357	18	14	relapse	relapse	NOUN
dpc-2357	18	15	rate	rate	NOUN
dpc-2357	18	16	of	of	ADP
dpc-2357	18	17	demodex	demodex	NOUN
dpc-2357	18	18	mite	mite	NOUN
dpc-2357	18	19	infestation	infestation	NOUN
dpc-2357	18	20	and	and	CCONJ
dpc-2357	18	21	rosacea	rosacea	NOUN
dpc-2357	18	22	.	.	PUNCT
dpc-2357	19	1	results	result	VERB
dpc-2357	19	2	:	:	PUNCT
dpc-2357	19	3	the	the	DET
dpc-2357	19	4	overall	overall	ADJ
dpc-2357	19	5	success	success	NOUN
dpc-2357	19	6	rate	rate	NOUN
dpc-2357	19	7	on	on	ADP
dpc-2357	19	8	demodex	demodex	NOUN
dpc-2357	19	9	infestation	infestation	NOUN
dpc-2357	19	10	was	be	AUX
dpc-2357	19	11	87.5	87.5	NUM
dpc-2357	19	12	%	%	NOUN
dpc-2357	19	13	only	only	ADV
dpc-2357	19	14	12.5	12.5	NUM
dpc-2357	19	15	%	%	NOUN
dpc-2357	19	16	relapse	relapse	NOUN
dpc-2357	19	17	.	.	PUNCT
dpc-2357	20	1	ivermectin	ivermectin	NOUN
dpc-2357	20	2	leads	lead	VERB
dpc-2357	20	3	to	to	ADP
dpc-2357	20	4	complete	complete	ADJ
dpc-2357	20	5	response	response	NOUN
dpc-2357	20	6	in	in	ADP
dpc-2357	20	7	70	70	NUM
dpc-2357	20	8	%	%	NOUN
dpc-2357	20	9	of	of	ADP
dpc-2357	20	10	patients	patient	NOUN
dpc-2357	20	11	.	.	PUNCT
dpc-2357	21	1	median	median	ADJ
dpc-2357	21	2	time	time	NOUN
dpc-2357	21	3	to	to	PART
dpc-2357	21	4	relapse	relapse	VERB
dpc-2357	21	5	was	be	AUX
dpc-2357	21	6	140	140	NUM
dpc-2357	21	7	days	day	NOUN
dpc-2357	21	8	,	,	PUNCT
dpc-2357	21	9	the	the	DET
dpc-2357	21	10	mean	mean	ADJ
dpc-2357	21	11	time	time	NOUN
dpc-2357	21	12	was	be	AUX
dpc-2357	21	13	152	152	NUM
dpc-2357	21	14	days	day	NOUN
dpc-2357	21	15	.	.	PUNCT
dpc-2357	22	1	the	the	DET
dpc-2357	22	2	global	global	ADJ
dpc-2357	22	3	success	success	NOUN
dpc-2357	22	4	rate	rate	NOUN
dpc-2357	22	5	was	be	AUX
dpc-2357	22	6	54.76	54.76	NUM
dpc-2357	22	7	%	%	NOUN
dpc-2357	22	8	.	.	PUNCT
dpc-2357	23	1	conclusions	conclusion	NOUN
dpc-2357	23	2	:	:	PUNCT
dpc-2357	23	3	topical	topical	ADJ
dpc-2357	23	4	ivermectin	ivermectin	NOUN
dpc-2357	23	5	keeps	keep	VERB
dpc-2357	23	6	a	a	DET
dpc-2357	23	7	remission	remission	NOUN
dpc-2357	23	8	of	of	ADP
dpc-2357	23	9	demodex	demodex	NOUN
dpc-2357	23	10	infestation	infestation	NOUN
dpc-2357	23	11	and	and	CCONJ
dpc-2357	23	12	clinical	clinical	ADJ
dpc-2357	23	13	remission	remission	NOUN
dpc-2357	23	14	for	for	ADP
dpc-2357	23	15	long	long	ADJ
dpc-2357	23	16	time	time	NOUN
dpc-2357	23	17	.	.	PUNCT
dpc-2357	24	1	we	we	PRON
dpc-2357	24	2	proposed	propose	VERB
dpc-2357	24	3	a	a	DET
dpc-2357	24	4	twice	twice	ADJ
dpc-2357	24	5	weekly	weekly	ADJ
dpc-2357	24	6	ivermectin	ivermectin	NOUN
dpc-2357	24	7	maintenance	maintenance	NOUN
dpc-2357	24	8	therapy	therapy	NOUN
dpc-2357	24	9	to	to	PART
dpc-2357	24	10	reduce	reduce	VERB
dpc-2357	24	11	recurrences	recurrence	NOUN
dpc-2357	24	12	.	.	PUNCT
dpc-2357	25	1	abstract	abstract	ADJ
dpc-2357	25	2	2	2	NUM
dpc-2357	25	3	original	original	ADJ
dpc-2357	25	4	article	article	NOUN
dpc-2357	25	5	|	|	ADV
dpc-2357	25	6	dermatol	dermatol	ADJ
dpc-2357	25	7	pract	pract	NOUN
dpc-2357	25	8	concept	concept	NOUN
dpc-2357	25	9	.	.	PUNCT
dpc-2357	26	1	2022;12(4):e2022201	2022;12(4):e2022201	NUM
dpc-2357	26	2	introduction	introduction	NOUN
dpc-2357	26	3	rosacea	rosacea	NOUN
dpc-2357	26	4	is	be	AUX
dpc-2357	26	5	a	a	DET
dpc-2357	26	6	chronic	chronic	NOUN
dpc-2357	26	7	,	,	PUNCT
dpc-2357	26	8	inflammatory	inflammatory	ADJ
dpc-2357	26	9	skin	skin	NOUN
dpc-2357	26	10	disease	disease	NOUN
dpc-2357	26	11	that	that	PRON
dpc-2357	26	12	starts	start	VERB
dpc-2357	26	13	between	between	ADP
dpc-2357	26	14	30	30	NUM
dpc-2357	26	15	-	-	SYM
dpc-2357	26	16	50	50	NUM
dpc-2357	26	17	years	year	NOUN
dpc-2357	26	18	of	of	ADP
dpc-2357	26	19	age	age	NOUN
dpc-2357	26	20	with	with	ADP
dpc-2357	26	21	a	a	DET
dpc-2357	26	22	large	large	ADJ
dpc-2357	26	23	prevalence	prevalence	NOUN
dpc-2357	26	24	in	in	ADP
dpc-2357	26	25	the	the	DET
dpc-2357	26	26	general	general	ADJ
dpc-2357	26	27	population	population	NOUN
dpc-2357	27	1	[	[	X
dpc-2357	27	2	1	1	NUM
dpc-2357	27	3	]	]	PUNCT
dpc-2357	27	4	.	.	PUNCT
dpc-2357	28	1	papulopustular	papulopustular	ADJ
dpc-2357	28	2	rosacea	rosacea	NOUN
dpc-2357	28	3	(	(	PUNCT
dpc-2357	28	4	ppr	ppr	NOUN
dpc-2357	28	5	)	)	PUNCT
dpc-2357	28	6	is	be	AUX
dpc-2357	28	7	characterized	characterize	VERB
dpc-2357	28	8	by	by	ADP
dpc-2357	28	9	multiple	multiple	ADJ
dpc-2357	28	10	small	small	ADJ
dpc-2357	28	11	dome	dome	NOUN
dpc-2357	28	12	-	-	PUNCT
dpc-2357	28	13	shaped	shape	VERB
dpc-2357	28	14	erythematous	erythematous	ADJ
dpc-2357	28	15	papules	papule	NOUN
dpc-2357	28	16	and	and	CCONJ
dpc-2357	28	17	pustules	pustule	NOUN
dpc-2357	28	18	arising	arise	VERB
dpc-2357	28	19	on	on	ADP
dpc-2357	28	20	erythema	erythema	NOUN
dpc-2357	28	21	in	in	ADP
dpc-2357	28	22	a	a	DET
dpc-2357	28	23	centrofacial	centrofacial	ADJ
dpc-2357	28	24	distribution	distribution	NOUN
dpc-2357	28	25	[	[	X
dpc-2357	28	26	2	2	NUM
dpc-2357	28	27	]	]	PUNCT
dpc-2357	28	28	.	.	PUNCT
dpc-2357	29	1	topical	topical	ADJ
dpc-2357	29	2	ivermectin	ivermectin	NOUN
dpc-2357	29	3	cream	cream	NOUN
dpc-2357	29	4	1	1	NUM
dpc-2357	29	5	%	%	NOUN
dpc-2357	29	6	(	(	PUNCT
dpc-2357	29	7	ivm	ivm	PROPN
dpc-2357	29	8	)	)	PUNCT
dpc-2357	29	9	is	be	AUX
dpc-2357	29	10	a	a	DET
dpc-2357	29	11	drug	drug	NOUN
dpc-2357	29	12	characterized	characterize	VERB
dpc-2357	29	13	by	by	ADP
dpc-2357	29	14	both	both	CCONJ
dpc-2357	29	15	antiparasitic	antiparasitic	ADJ
dpc-2357	29	16	and	and	CCONJ
dpc-2357	29	17	anti	anti	ADJ
dpc-2357	29	18	-	-	ADJ
dpc-2357	29	19	inflammatory	inflammatory	ADJ
dpc-2357	29	20	effects	effect	NOUN
dpc-2357	29	21	[	[	X
dpc-2357	29	22	3	3	NUM
dpc-2357	29	23	-	-	SYM
dpc-2357	29	24	7	7	NUM
dpc-2357	29	25	]	]	PUNCT
dpc-2357	29	26	,	,	PUNCT
dpc-2357	29	27	which	which	PRON
dpc-2357	29	28	gained	gain	VERB
dpc-2357	29	29	the	the	DET
dpc-2357	29	30	food	food	NOUN
dpc-2357	29	31	and	and	CCONJ
dpc-2357	29	32	drug	drug	PROPN
dpc-2357	29	33	administration	administration	PROPN
dpc-2357	29	34	(	(	PUNCT
dpc-2357	29	35	fda	fda	PROPN
dpc-2357	29	36	)	)	PUNCT
dpc-2357	29	37	approval	approval	NOUN
dpc-2357	29	38	for	for	ADP
dpc-2357	29	39	the	the	DET
dpc-2357	29	40	treatment	treatment	NOUN
dpc-2357	29	41	of	of	ADP
dpc-2357	29	42	ppr	ppr	NOUN
dpc-2357	29	43	in	in	ADP
dpc-2357	29	44	december	december	PROPN
dpc-2357	29	45	2014	2014	NUM
dpc-2357	29	46	,	,	PUNCT
dpc-2357	29	47	and	and	CCONJ
dpc-2357	29	48	by	by	ADP
dpc-2357	29	49	european	european	ADJ
dpc-2357	29	50	medicines	medicine	NOUN
dpc-2357	29	51	agency	agency	NOUN
dpc-2357	29	52	(	(	PUNCT
dpc-2357	29	53	ema	ema	PROPN
dpc-2357	29	54	)	)	PUNCT
dpc-2357	29	55	in	in	ADP
dpc-2357	29	56	march	march	PROPN
dpc-2357	29	57	2015	2015	NUM
dpc-2357	29	58	[	[	X
dpc-2357	29	59	5	5	NUM
dpc-2357	29	60	]	]	PUNCT
dpc-2357	29	61	.	.	PUNCT
dpc-2357	30	1	demodex	demodex	NOUN
dpc-2357	30	2	mites	mite	NOUN
dpc-2357	30	3	are	be	AUX
dpc-2357	30	4	standing	stand	VERB
dpc-2357	30	5	human	human	ADJ
dpc-2357	30	6	ectoparasites	ectoparasite	NOUN
dpc-2357	30	7	that	that	PRON
dpc-2357	30	8	have	have	VERB
dpc-2357	30	9	a	a	DET
dpc-2357	30	10	higher	high	ADJ
dpc-2357	30	11	concentration	concentration	NOUN
dpc-2357	30	12	in	in	ADP
dpc-2357	30	13	ppr	ppr	NOUN
dpc-2357	30	14	(	(	PUNCT
dpc-2357	30	15	a	a	DET
dpc-2357	30	16	mean	mean	NOUN
dpc-2357	30	17	of	of	ADP
dpc-2357	30	18	12.8	12.8	NUM
dpc-2357	30	19	d	d	NOUN
dpc-2357	30	20	/	/	SYM
dpc-2357	30	21	cm2	cm2	NOUN
dpc-2357	30	22	)	)	PUNCT
dpc-2357	31	1	[	[	X
dpc-2357	31	2	8	8	NUM
dpc-2357	31	3	]	]	PUNCT
dpc-2357	31	4	than	than	ADP
dpc-2357	31	5	other	other	ADJ
dpc-2357	31	6	people	people	NOUN
dpc-2357	31	7	.	.	PUNCT
dpc-2357	32	1	demodicosis	demodicosis	NOUN
dpc-2357	32	2	in	in	ADP
dpc-2357	32	3	humans	human	NOUN
dpc-2357	32	4	is	be	AUX
dpc-2357	32	5	associated	associate	VERB
dpc-2357	32	6	with	with	ADP
dpc-2357	32	7	the	the	DET
dpc-2357	32	8	common	common	ADJ
dpc-2357	32	9	inflammatory	inflammatory	ADJ
dpc-2357	32	10	skin	skin	NOUN
dpc-2357	32	11	condition	condition	NOUN
dpc-2357	32	12	rosacea	rosacea	NOUN
dpc-2357	32	13	but	but	CCONJ
dpc-2357	32	14	also	also	ADV
dpc-2357	32	15	with	with	ADP
dpc-2357	32	16	pityriasis	pityriasis	NOUN
dpc-2357	32	17	folliculorum	folliculorum	NOUN
dpc-2357	32	18	,	,	PUNCT
dpc-2357	32	19	where	where	SCONJ
dpc-2357	32	20	it	it	PRON
dpc-2357	32	21	is	be	AUX
dpc-2357	32	22	not	not	PART
dpc-2357	32	23	accompanied	accompany	VERB
dpc-2357	32	24	by	by	ADP
dpc-2357	32	25	inflammation	inflammation	NOUN
dpc-2357	32	26	,	,	PUNCT
dpc-2357	32	27	and	and	CCONJ
dpc-2357	32	28	with	with	ADP
dpc-2357	32	29	other	other	ADJ
dpc-2357	32	30	rarer	rare	ADJ
dpc-2357	32	31	clinical	clinical	ADJ
dpc-2357	32	32	settings	setting	NOUN
dpc-2357	32	33	,	,	PUNCT
dpc-2357	32	34	including	include	VERB
dpc-2357	32	35	patients	patient	NOUN
dpc-2357	32	36	with	with	ADP
dpc-2357	32	37	symptoms	symptom	NOUN
dpc-2357	32	38	of	of	ADP
dpc-2357	32	39	perioral	perioral	ADJ
dpc-2357	32	40	dermatitis	dermatitis	NOUN
dpc-2357	32	41	[	[	X
dpc-2357	32	42	9,10	9,10	X
dpc-2357	32	43	]	]	X
dpc-2357	32	44	and	and	CCONJ
dpc-2357	32	45	granulomatous	granulomatous	ADJ
dpc-2357	32	46	rosacea	rosacea	NOUN
dpc-2357	33	1	[	[	X
dpc-2357	33	2	11	11	NUM
dpc-2357	33	3	]	]	PUNCT
dpc-2357	33	4	.	.	PUNCT
dpc-2357	34	1	although	although	SCONJ
dpc-2357	34	2	is	be	AUX
dpc-2357	34	3	well	well	ADV
dpc-2357	34	4	know	know	VERB
dpc-2357	34	5	the	the	DET
dpc-2357	34	6	anti	anti	ADJ
dpc-2357	34	7	-	-	ADJ
dpc-2357	34	8	parasitic	parasitic	ADJ
dpc-2357	34	9	effect	effect	NOUN
dpc-2357	34	10	of	of	ADP
dpc-2357	34	11	ivermectin	ivermectin	NOUN
dpc-2357	34	12	,	,	PUNCT
dpc-2357	34	13	up	up	ADP
dpc-2357	34	14	to	to	ADP
dpc-2357	34	15	now	now	ADV
dpc-2357	34	16	,	,	PUNCT
dpc-2357	34	17	there	there	PRON
dpc-2357	34	18	are	be	VERB
dpc-2357	34	19	not	not	PART
dpc-2357	34	20	studies	study	NOUN
dpc-2357	34	21	that	that	PRON
dpc-2357	34	22	consider	consider	VERB
dpc-2357	34	23	the	the	DET
dpc-2357	34	24	time	time	NOUN
dpc-2357	34	25	of	of	ADP
dpc-2357	34	26	relapse	relapse	NOUN
dpc-2357	34	27	and	and	CCONJ
dpc-2357	34	28	relapse	relapse	NOUN
dpc-2357	34	29	rates	rate	NOUN
dpc-2357	34	30	of	of	ADP
dpc-2357	34	31	demodex	demodex	NOUN
dpc-2357	34	32	mite	mite	NOUN
dpc-2357	34	33	infestation	infestation	NOUN
dpc-2357	34	34	in	in	ADP
dpc-2357	34	35	patients	patient	NOUN
dpc-2357	34	36	affected	affect	VERB
dpc-2357	34	37	by	by	ADP
dpc-2357	34	38	rosacea	rosacea	NOUN
dpc-2357	34	39	and	and	CCONJ
dpc-2357	34	40	treated	treat	VERB
dpc-2357	34	41	with	with	ADP
dpc-2357	34	42	ivermectin	ivermectin	NOUN
dpc-2357	34	43	.	.	PUNCT
dpc-2357	35	1	following	follow	VERB
dpc-2357	35	2	the	the	DET
dpc-2357	35	3	onset	onset	NOUN
dpc-2357	35	4	of	of	ADP
dpc-2357	35	5	the	the	DET
dpc-2357	35	6	disease	disease	NOUN
dpc-2357	35	7	,	,	PUNCT
dpc-2357	35	8	patients	patient	NOUN
dpc-2357	35	9	with	with	ADP
dpc-2357	35	10	rosacea	rosacea	NOUN
dpc-2357	35	11	will	will	AUX
dpc-2357	35	12	experience	experience	VERB
dpc-2357	35	13	cycles	cycle	NOUN
dpc-2357	35	14	of	of	ADP
dpc-2357	35	15	relapse	relapse	NOUN
dpc-2357	35	16	and	and	CCONJ
dpc-2357	35	17	remission	remission	NOUN
dpc-2357	35	18	of	of	ADP
dpc-2357	35	19	symptoms	symptom	NOUN
dpc-2357	35	20	through	through	ADP
dpc-2357	35	21	their	their	PRON
dpc-2357	35	22	lives	life	NOUN
dpc-2357	35	23	[	[	X
dpc-2357	35	24	3	3	NUM
dpc-2357	35	25	]	]	PUNCT
dpc-2357	35	26	.	.	PUNCT
dpc-2357	36	1	there	there	PRON
dpc-2357	36	2	are	be	VERB
dpc-2357	36	3	only	only	ADV
dpc-2357	36	4	very	very	ADV
dpc-2357	36	5	few	few	ADJ
dpc-2357	36	6	studies	study	NOUN
dpc-2357	36	7	that	that	PRON
dpc-2357	36	8	have	have	AUX
dpc-2357	36	9	analyzed	analyze	VERB
dpc-2357	36	10	patterns	pattern	NOUN
dpc-2357	36	11	of	of	ADP
dpc-2357	36	12	relapse	relapse	NOUN
dpc-2357	36	13	in	in	ADP
dpc-2357	36	14	moderate	moderate	ADJ
dpc-2357	36	15	-	-	PUNCT
dpc-2357	36	16	to	to	ADP
dpc-2357	36	17	-	-	PUNCT
dpc-2357	36	18	severe	severe	ADJ
dpc-2357	36	19	and	and	CCONJ
dpc-2357	36	20	mild	mild	ADJ
dpc-2357	36	21	-	-	PUNCT
dpc-2357	36	22	to	to	ADP
dpc-2357	36	23	-	-	PUNCT
dpc-2357	36	24	moderate	moderate	ADJ
dpc-2357	36	25	ppr	ppr	NOUN
dpc-2357	36	26	treated	treat	VERB
dpc-2357	36	27	with	with	ADP
dpc-2357	36	28	ivermectin	ivermectin	NOUN
dpc-2357	36	29	[	[	X
dpc-2357	36	30	3,12	3,12	NUM
dpc-2357	36	31	]	]	PUNCT
dpc-2357	36	32	.	.	PUNCT
dpc-2357	37	1	objectives	objective	VERB
dpc-2357	37	2	the	the	DET
dpc-2357	37	3	main	main	ADJ
dpc-2357	37	4	aim	aim	NOUN
dpc-2357	37	5	of	of	ADP
dpc-2357	37	6	this	this	DET
dpc-2357	37	7	study	study	NOUN
dpc-2357	37	8	was	be	AUX
dpc-2357	37	9	to	to	PART
dpc-2357	37	10	assess	assess	VERB
dpc-2357	37	11	the	the	DET
dpc-2357	37	12	time	time	NOUN
dpc-2357	37	13	of	of	ADP
dpc-2357	37	14	first	first	ADJ
dpc-2357	37	15	relapse	relapse	NOUN
dpc-2357	37	16	and	and	CCONJ
dpc-2357	37	17	relapse	relapse	NOUN
dpc-2357	37	18	rates	rate	NOUN
dpc-2357	37	19	of	of	ADP
dpc-2357	37	20	demodex	demodex	NOUN
dpc-2357	37	21	mite	mite	NOUN
dpc-2357	37	22	proliferation	proliferation	NOUN
dpc-2357	37	23	after	after	ADP
dpc-2357	37	24	interruption	interruption	NOUN
dpc-2357	37	25	of	of	ADP
dpc-2357	37	26	ivermectin	ivermectin	NOUN
dpc-2357	37	27	therapy	therapy	NOUN
dpc-2357	38	1	[	[	X
dpc-2357	38	2	13	13	NUM
dpc-2357	38	3	]	]	PUNCT
dpc-2357	38	4	.	.	PUNCT
dpc-2357	39	1	the	the	DET
dpc-2357	39	2	secondary	secondary	ADJ
dpc-2357	39	3	goal	goal	NOUN
dpc-2357	39	4	was	be	AUX
dpc-2357	39	5	to	to	PART
dpc-2357	39	6	study	study	VERB
dpc-2357	39	7	the	the	DET
dpc-2357	39	8	time	time	NOUN
dpc-2357	39	9	to	to	ADP
dpc-2357	39	10	first	first	ADJ
dpc-2357	39	11	clinical	clinical	ADJ
dpc-2357	39	12	relapse	relapse	NOUN
dpc-2357	39	13	and	and	CCONJ
dpc-2357	39	14	relapse	relapse	NOUN
dpc-2357	39	15	rates	rate	NOUN
dpc-2357	39	16	in	in	ADP
dpc-2357	39	17	patients	patient	NOUN
dpc-2357	39	18	affected	affect	VERB
dpc-2357	39	19	by	by	ADP
dpc-2357	39	20	almost	almost	ADV
dpc-2357	39	21	clear	clear	ADJ
dpc-2357	39	22	,	,	PUNCT
dpc-2357	39	23	mild	mild	ADJ
dpc-2357	39	24	and	and	CCONJ
dpc-2357	39	25	moderate	moderate	ADJ
dpc-2357	39	26	ppr	ppr	NOUN
dpc-2357	39	27	.	.	PUNCT
dpc-2357	40	1	methods	method	NOUN
dpc-2357	40	2	the	the	DET
dpc-2357	40	3	prospective	prospective	ADJ
dpc-2357	40	4	study	study	NOUN
dpc-2357	40	5	was	be	AUX
dpc-2357	40	6	conducted	conduct	VERB
dpc-2357	40	7	at	at	ADP
dpc-2357	40	8	the	the	DET
dpc-2357	40	9	dermatology	dermatology	NOUN
dpc-2357	40	10	centre	centre	NOUN
dpc-2357	40	11	of	of	ADP
dpc-2357	40	12	ospedale	ospedale	PROPN
dpc-2357	40	13	policlinico	policlinico	PROPN
dpc-2357	40	14	san	san	PROPN
dpc-2357	40	15	martino	martino	PROPN
dpc-2357	40	16	irccs	irccs	PROPN
dpc-2357	40	17	in	in	ADP
dpc-2357	40	18	genoa	genoa	PROPN
dpc-2357	40	19	(	(	PUNCT
dpc-2357	40	20	italy	italy	PROPN
dpc-2357	40	21	)	)	PUNCT
dpc-2357	40	22	from	from	ADP
dpc-2357	40	23	may	may	PROPN
dpc-2357	40	24	1st	1st	NOUN
dpc-2357	40	25	,	,	PUNCT
dpc-2357	40	26	2020	2020	NUM
dpc-2357	40	27	to	to	ADP
dpc-2357	40	28	may	may	PROPN
dpc-2357	40	29	31st	31st	NOUN
dpc-2357	40	30	,	,	PUNCT
dpc-2357	40	31	2021	2021	NUM
dpc-2357	40	32	on	on	ADP
dpc-2357	40	33	subjects	subject	NOUN
dpc-2357	40	34	suffering	suffer	VERB
dpc-2357	40	35	from	from	ADP
dpc-2357	40	36	papulopustular	papulopustular	ADJ
dpc-2357	40	37	rosacea	rosacea	NOUN
dpc-2357	40	38	.	.	PUNCT
dpc-2357	41	1	diagnosis	diagnosis	NOUN
dpc-2357	41	2	of	of	ADP
dpc-2357	41	3	rosacea	rosacea	NOUN
dpc-2357	41	4	was	be	AUX
dpc-2357	41	5	made	make	VERB
dpc-2357	41	6	by	by	ADP
dpc-2357	41	7	an	an	DET
dpc-2357	41	8	experienced	experienced	ADJ
dpc-2357	41	9	dermatologist	dermatologist	NOUN
dpc-2357	41	10	and	and	CCONJ
dpc-2357	41	11	based	base	VERB
dpc-2357	41	12	on	on	ADP
dpc-2357	41	13	the	the	DET
dpc-2357	41	14	following	follow	VERB
dpc-2357	41	15	national	national	PROPN
dpc-2357	41	16	rosacea	rosacea	PROPN
dpc-2357	41	17	society	society	PROPN
dpc-2357	41	18	(	(	PUNCT
dpc-2357	41	19	nrs	nrs	PROPN
dpc-2357	41	20	)	)	PUNCT
dpc-2357	41	21	expert	expert	NOUN
dpc-2357	41	22	panel	panel	NOUN
dpc-2357	41	23	criteria	criterion	NOUN
dpc-2357	42	1	[	[	X
dpc-2357	42	2	1	1	NUM
dpc-2357	42	3	]	]	SYM
dpc-2357	42	4	:	:	PUNCT
dpc-2357	42	5	1	1	X
dpc-2357	42	6	.	.	PUNCT
dpc-2357	42	7	fixed	fix	VERB
dpc-2357	42	8	centrofacial	centrofacial	ADJ
dpc-2357	42	9	erythema	erythema	ADV
dpc-2357	42	10	in	in	ADP
dpc-2357	42	11	a	a	DET
dpc-2357	42	12	characteristic	characteristic	ADJ
dpc-2357	42	13	pattern	pattern	NOUN
dpc-2357	42	14	that	that	PRON
dpc-2357	42	15	may	may	AUX
dpc-2357	42	16	periodically	periodically	ADV
dpc-2357	42	17	intensify	intensify	VERB
dpc-2357	42	18	2	2	NUM
dpc-2357	42	19	.	.	PUNCT
dpc-2357	42	20	papules	papule	NOUN
dpc-2357	42	21	and	and	CCONJ
dpc-2357	42	22	pustules	pustule	NOUN
dpc-2357	42	23	(	(	PUNCT
dpc-2357	42	24	with	with	ADP
dpc-2357	42	25	or	or	CCONJ
dpc-2357	42	26	without	without	ADP
dpc-2357	42	27	telangiectasias	telangiectasia	NOUN
dpc-2357	42	28	,	,	PUNCT
dpc-2357	42	29	flushing	flush	VERB
dpc-2357	42	30	and	and	CCONJ
dpc-2357	42	31	ocular	ocular	ADJ
dpc-2357	42	32	manifestations	manifestation	NOUN
dpc-2357	42	33	)	)	PUNCT
dpc-2357	43	1	[	[	X
dpc-2357	43	2	14	14	NUM
dpc-2357	43	3	]	]	PUNCT
dpc-2357	43	4	subjects	subject	NOUN
dpc-2357	43	5	that	that	PRON
dpc-2357	43	6	had	have	AUX
dpc-2357	43	7	been	be	AUX
dpc-2357	43	8	treated	treat	VERB
dpc-2357	43	9	with	with	ADP
dpc-2357	43	10	topical	topical	ADJ
dpc-2357	43	11	and	and	CCONJ
dpc-2357	43	12	systemic	systemic	ADJ
dpc-2357	43	13	therapies	therapy	NOUN
dpc-2357	43	14	during	during	ADP
dpc-2357	43	15	the	the	DET
dpc-2357	43	16	previous	previous	ADJ
dpc-2357	43	17	year	year	NOUN
dpc-2357	43	18	were	be	AUX
dpc-2357	43	19	not	not	PART
dpc-2357	43	20	included	include	VERB
dpc-2357	43	21	in	in	ADP
dpc-2357	43	22	the	the	DET
dpc-2357	43	23	study	study	NOUN
dpc-2357	43	24	.	.	PUNCT
dpc-2357	44	1	for	for	ADP
dpc-2357	44	2	each	each	DET
dpc-2357	44	3	patient	patient	NOUN
dpc-2357	44	4	,	,	PUNCT
dpc-2357	44	5	disease	disease	NOUN
dpc-2357	44	6	severity	severity	NOUN
dpc-2357	44	7	was	be	AUX
dpc-2357	44	8	assessed	assess	VERB
dpc-2357	44	9	by	by	ADP
dpc-2357	44	10	investigator	investigator	NOUN
dpc-2357	44	11	global	global	ADJ
dpc-2357	44	12	assessment	assessment	NOUN
dpc-2357	44	13	score	score	NOUN
dpc-2357	44	14	(	(	PUNCT
dpc-2357	44	15	iga	iga	PROPN
dpc-2357	44	16	score	score	NOUN
dpc-2357	44	17	)	)	PUNCT
dpc-2357	45	1	[	[	X
dpc-2357	45	2	11	11	NUM
dpc-2357	45	3	]	]	PUNCT
dpc-2357	45	4	.	.	PUNCT
dpc-2357	46	1	iga	iga	PROPN
dpc-2357	46	2	score	score	NOUN
dpc-2357	46	3	defines	define	NOUN
dpc-2357	46	4	disease	disease	NOUN
dpc-2357	46	5	severity	severity	NOUN
dpc-2357	46	6	from	from	ADP
dpc-2357	46	7	0	0	NUM
dpc-2357	46	8	to	to	PART
dpc-2357	46	9	4	4	NUM
dpc-2357	46	10	:	:	PUNCT
dpc-2357	46	11	iga	iga	PROPN
dpc-2357	46	12	0	0	PUNCT
dpc-2357	47	1	=	=	PUNCT
dpc-2357	47	2	no	no	DET
dpc-2357	47	3	inflammatory	inflammatory	ADJ
dpc-2357	47	4	lesions	lesion	NOUN
dpc-2357	47	5	,	,	PUNCT
dpc-2357	47	6	no	no	DET
dpc-2357	47	7	erythema	erythema	ADV
dpc-2357	47	8	;	;	PUNCT
dpc-2357	47	9	iga	iga	PROPN
dpc-2357	47	10	1	1	NUM
dpc-2357	47	11	=	=	PUNCT
dpc-2357	47	12	very	very	ADV
dpc-2357	47	13	few	few	ADJ
dpc-2357	47	14	small	small	ADJ
dpc-2357	47	15	papules	papule	NOUN
dpc-2357	47	16	/	/	SYM
dpc-2357	47	17	pustules	pustule	NOUN
dpc-2357	47	18	,	,	PUNCT
dpc-2357	47	19	very	very	ADV
dpc-2357	47	20	mild	mild	ADJ
dpc-2357	47	21	erythema	erythema	NOUN
dpc-2357	47	22	;	;	PUNCT
dpc-2357	47	23	iga	iga	PROPN
dpc-2357	47	24	2	2	NUM
dpc-2357	47	25	=	=	SYM
dpc-2357	47	26	few	few	ADJ
dpc-2357	47	27	small	small	ADJ
dpc-2357	47	28	papules	papule	NOUN
dpc-2357	47	29	/	/	SYM
dpc-2357	47	30	pustules	pustule	NOUN
dpc-2357	47	31	,	,	PUNCT
dpc-2357	47	32	mild	mild	ADJ
dpc-2357	47	33	erythema	erythema	NOUN
dpc-2357	47	34	;	;	PUNCT
dpc-2357	47	35	iga	iga	PROPN
dpc-2357	47	36	3	3	NUM
dpc-2357	47	37	=	=	SYM
dpc-2357	47	38	several	several	ADJ
dpc-2357	47	39	small	small	ADJ
dpc-2357	47	40	or	or	CCONJ
dpc-2357	47	41	large	large	ADJ
dpc-2357	47	42	papules	papule	NOUN
dpc-2357	47	43	/	/	SYM
dpc-2357	47	44	pustules	pustule	NOUN
dpc-2357	47	45	,	,	PUNCT
dpc-2357	47	46	moderate	moderate	ADJ
dpc-2357	47	47	erythema	erythema	NOUN
dpc-2357	47	48	;	;	PUNCT
dpc-2357	47	49	iga	iga	PROPN
dpc-2357	47	50	4	4	NUM
dpc-2357	47	51	=	=	SYM
dpc-2357	47	52	numerous	numerous	ADJ
dpc-2357	47	53	small	small	ADJ
dpc-2357	47	54	or	or	CCONJ
dpc-2357	47	55	large	large	ADJ
dpc-2357	47	56	papules	papule	NOUN
dpc-2357	47	57	/	/	SYM
dpc-2357	47	58	pustules	pustule	NOUN
dpc-2357	47	59	,	,	PUNCT
dpc-2357	47	60	severe	severe	ADJ
dpc-2357	47	61	erythema	erythema	NOUN
dpc-2357	48	1	[	[	X
dpc-2357	48	2	15	15	NUM
dpc-2357	48	3	]	]	PUNCT
dpc-2357	48	4	.	.	PUNCT
dpc-2357	49	1	in	in	ADP
dpc-2357	49	2	order	order	NOUN
dpc-2357	49	3	to	to	PART
dpc-2357	49	4	study	study	VERB
dpc-2357	49	5	demodex	demodex	NOUN
dpc-2357	49	6	mites	mite	NOUN
dpc-2357	49	7	count	count	NOUN
dpc-2357	49	8	,	,	PUNCT
dpc-2357	49	9	a	a	DET
dpc-2357	49	10	standardized	standardized	ADJ
dpc-2357	49	11	skin	skin	NOUN
dpc-2357	49	12	surface	surface	NOUN
dpc-2357	49	13	biopsy	biopsy	NOUN
dpc-2357	49	14	(	(	PUNCT
dpc-2357	49	15	sssb	sssb	PROPN
dpc-2357	49	16	)	)	PUNCT
dpc-2357	49	17	was	be	AUX
dpc-2357	49	18	performed	perform	VERB
dpc-2357	49	19	by	by	ADP
dpc-2357	49	20	a	a	DET
dpc-2357	49	21	trained	train	VERB
dpc-2357	49	22	dermatologist	dermatologist	NOUN
dpc-2357	49	23	on	on	ADP
dpc-2357	49	24	the	the	DET
dpc-2357	49	25	target	target	NOUN
dpc-2357	49	26	area	area	NOUN
dpc-2357	49	27	[	[	X
dpc-2357	49	28	8	8	NUM
dpc-2357	49	29	]	]	PUNCT
dpc-2357	49	30	.	.	PUNCT
dpc-2357	50	1	sssb	sssb	PROPN
dpc-2357	50	2	is	be	AUX
dpc-2357	50	3	a	a	DET
dpc-2357	50	4	sampling	sampling	NOUN
dpc-2357	50	5	method	method	NOUN
dpc-2357	50	6	in	in	ADP
dpc-2357	50	7	which	which	PRON
dpc-2357	50	8	1	1	NUM
dpc-2357	50	9	cm2	cm2	NOUN
dpc-2357	50	10	of	of	ADP
dpc-2357	50	11	the	the	DET
dpc-2357	50	12	superficial	superficial	ADJ
dpc-2357	50	13	layer	layer	NOUN
dpc-2357	50	14	of	of	ADP
dpc-2357	50	15	the	the	DET
dpc-2357	50	16	stratum	stratum	NOUN
dpc-2357	50	17	corneum	corneum	NOUN
dpc-2357	50	18	and	and	CCONJ
dpc-2357	50	19	its	its	PRON
dpc-2357	50	20	follicular	follicular	ADJ
dpc-2357	50	21	content	content	NOUN
dpc-2357	50	22	is	be	AUX
dpc-2357	50	23	recovered	recover	VERB
dpc-2357	50	24	for	for	ADP
dpc-2357	50	25	analysis	analysis	NOUN
dpc-2357	50	26	[	[	X
dpc-2357	50	27	8	8	NUM
dpc-2357	50	28	]	]	PUNCT
dpc-2357	50	29	.	.	PUNCT
dpc-2357	51	1	samples	sample	NOUN
dpc-2357	51	2	obtained	obtain	VERB
dpc-2357	51	3	by	by	ADP
dpc-2357	51	4	sssb	sssb	NOUN
dpc-2357	51	5	were	be	AUX
dpc-2357	51	6	examined	examine	VERB
dpc-2357	51	7	with	with	ADP
dpc-2357	51	8	an	an	DET
dpc-2357	51	9	optical	optical	ADJ
dpc-2357	51	10	microscope	microscope	NOUN
dpc-2357	51	11	at	at	ADP
dpc-2357	51	12	×	×	PROPN
dpc-2357	51	13	10	10	NUM
dpc-2357	51	14	and	and	CCONJ
dpc-2357	51	15	×	×	NOUN
dpc-2357	51	16	40	40	NUM
dpc-2357	51	17	magnifications	magnification	NOUN
dpc-2357	51	18	.	.	PUNCT
dpc-2357	52	1	samples	sample	NOUN
dpc-2357	52	2	with	with	ADP
dpc-2357	52	3	≥5	≥5	NUM
dpc-2357	52	4	demodex	demodex	NOUN
dpc-2357	52	5	/	/	SYM
dpc-2357	52	6	cm2	cm2	NOUN
dpc-2357	52	7	(	(	PUNCT
dpc-2357	52	8	d	d	PROPN
dpc-2357	52	9	/	/	SYM
dpc-2357	52	10	cm2	cm2	NOUN
dpc-2357	52	11	)	)	PUNCT
dpc-2357	52	12	was	be	AUX
dpc-2357	52	13	considered	consider	VERB
dpc-2357	52	14	positive	positive	ADJ
dpc-2357	52	15	(	(	PUNCT
dpc-2357	52	16	d+	d+	NOUN
dpc-2357	52	17	)	)	PUNCT
dpc-2357	53	1	[	[	X
dpc-2357	53	2	8	8	NUM
dpc-2357	53	3	]	]	PUNCT
dpc-2357	53	4	.	.	PUNCT
dpc-2357	54	1	antiparasitic	antiparasitic	ADJ
dpc-2357	54	2	efficacy	efficacy	NOUN
dpc-2357	54	3	assessments	assessment	NOUN
dpc-2357	54	4	were	be	AUX
dpc-2357	54	5	time	time	NOUN
dpc-2357	54	6	to	to	PART
dpc-2357	54	7	first	first	ADJ
dpc-2357	54	8	relapse	relapse	VERB
dpc-2357	54	9	and	and	CCONJ
dpc-2357	54	10	relapse	relapse	NOUN
dpc-2357	54	11	rate	rate	NOUN
dpc-2357	54	12	of	of	ADP
dpc-2357	54	13	positive	positive	ADJ
dpc-2357	54	14	sssb	sssb	NOUN
dpc-2357	54	15	test	test	VERB
dpc-2357	54	16	.	.	PUNCT
dpc-2357	55	1	we	we	PRON
dpc-2357	55	2	defined	define	VERB
dpc-2357	55	3	a	a	DET
dpc-2357	55	4	successful	successful	ADJ
dpc-2357	55	5	therapeutic	therapeutic	ADJ
dpc-2357	55	6	intervention	intervention	NOUN
dpc-2357	55	7	when	when	SCONJ
dpc-2357	55	8	patients	patient	NOUN
dpc-2357	55	9	affected	affect	VERB
dpc-2357	55	10	by	by	ADP
dpc-2357	55	11	iga	iga	PROPN
dpc-2357	55	12	1	1	NUM
dpc-2357	55	13	,	,	PUNCT
dpc-2357	55	14	2	2	NUM
dpc-2357	55	15	and	and	CCONJ
dpc-2357	55	16	3	3	NUM
dpc-2357	55	17	rosacea	rosacea	NOUN
dpc-2357	55	18	at	at	ADP
dpc-2357	55	19	baseline	baseline	PROPN
dpc-2357	55	20	achieved	achieve	VERB
dpc-2357	55	21	iga=	iga=	PROPN
dpc-2357	55	22	0	0	NUM
dpc-2357	55	23	after	after	ADP
dpc-2357	55	24	16	16	NUM
dpc-2357	55	25	weeks	week	NOUN
dpc-2357	55	26	of	of	ADP
dpc-2357	55	27	therapy	therapy	NOUN
dpc-2357	55	28	.	.	PUNCT
dpc-2357	56	1	after	after	ADP
dpc-2357	56	2	this	this	DET
dpc-2357	56	3	treatment	treatment	NOUN
dpc-2357	56	4	period	period	NOUN
dpc-2357	56	5	,	,	PUNCT
dpc-2357	56	6	patients	patient	NOUN
dpc-2357	56	7	that	that	PRON
dpc-2357	56	8	achieved	achieve	VERB
dpc-2357	56	9	iga=0	iga=0	NOUN
dpc-2357	56	10	were	be	AUX
dpc-2357	56	11	followed	follow	VERB
dpc-2357	56	12	every	every	DET
dpc-2357	56	13	4	4	NUM
dpc-2357	56	14	weeks	week	NOUN
dpc-2357	56	15	for	for	ADP
dpc-2357	56	16	up	up	ADP
dpc-2357	56	17	to	to	PART
dpc-2357	56	18	32	32	NUM
dpc-2357	56	19	additional	additional	ADJ
dpc-2357	56	20	weeks	week	NOUN
dpc-2357	56	21	(	(	PUNCT
dpc-2357	56	22	weeks	week	NOUN
dpc-2357	56	23	16	16	NUM
dpc-2357	56	24	-	-	SYM
dpc-2357	56	25	48	48	NUM
dpc-2357	56	26	)	)	PUNCT
dpc-2357	57	1	[	[	X
dpc-2357	57	2	3	3	NUM
dpc-2357	57	3	]	]	PUNCT
dpc-2357	57	4	.	.	PUNCT
dpc-2357	58	1	efficacy	efficacy	NOUN
dpc-2357	58	2	assessments	assessment	NOUN
dpc-2357	58	3	were	be	AUX
dpc-2357	58	4	the	the	DET
dpc-2357	58	5	time	time	NOUN
dpc-2357	58	6	to	to	PART
dpc-2357	58	7	first	first	ADJ
dpc-2357	58	8	relapse	relapse	VERB
dpc-2357	58	9	and	and	CCONJ
dpc-2357	58	10	relapse	relapse	NOUN
dpc-2357	58	11	rate	rate	NOUN
dpc-2357	58	12	[	[	X
dpc-2357	58	13	3	3	NUM
dpc-2357	58	14	]	]	PUNCT
dpc-2357	58	15	.	.	PUNCT
dpc-2357	59	1	time	time	NOUN
dpc-2357	59	2	to	to	PART
dpc-2357	59	3	first	first	ADJ
dpc-2357	59	4	relapse	relapse	NOUN
dpc-2357	59	5	was	be	AUX
dpc-2357	59	6	defined	define	VERB
dpc-2357	59	7	as	as	ADP
dpc-2357	59	8	the	the	DET
dpc-2357	59	9	time	time	NOUN
dpc-2357	59	10	relapse	relapse	NOUN
dpc-2357	59	11	between	between	ADP
dpc-2357	59	12	week	week	NOUN
dpc-2357	59	13	16	16	NUM
dpc-2357	59	14	(	(	PUNCT
dpc-2357	59	15	end	end	NOUN
dpc-2357	59	16	of	of	ADP
dpc-2357	59	17	treatment	treatment	NOUN
dpc-2357	59	18	)	)	PUNCT
dpc-2357	59	19	and	and	CCONJ
dpc-2357	59	20	the	the	DET
dpc-2357	59	21	first	first	ADJ
dpc-2357	59	22	relapse	relapse	NOUN
dpc-2357	59	23	(	(	PUNCT
dpc-2357	59	24	iga	iga	PROPN
dpc-2357	59	25	≥	≥	PROPN
dpc-2357	59	26	1	1	NUM
dpc-2357	59	27	)	)	PUNCT
dpc-2357	59	28	during	during	ADP
dpc-2357	59	29	follow	follow	VERB
dpc-2357	59	30	up	up	ADP
dpc-2357	59	31	.	.	PUNCT
dpc-2357	60	1	relapse	relapse	NOUN
dpc-2357	60	2	rate	rate	NOUN
dpc-2357	60	3	was	be	AUX
dpc-2357	60	4	defined	define	VERB
dpc-2357	60	5	as	as	ADP
dpc-2357	60	6	the	the	DET
dpc-2357	60	7	percentage	percentage	NOUN
dpc-2357	60	8	of	of	ADP
dpc-2357	60	9	patients	patient	NOUN
dpc-2357	60	10	who	who	PRON
dpc-2357	60	11	relapsed	relapse	VERB
dpc-2357	60	12	within	within	ADP
dpc-2357	60	13	the	the	DET
dpc-2357	60	14	course	course	NOUN
dpc-2357	60	15	of	of	ADP
dpc-2357	60	16	the	the	DET
dpc-2357	60	17	32	32	NUM
dpc-2357	60	18	weeks	week	NOUN
dpc-2357	60	19	.	.	PUNCT
dpc-2357	61	1	descriptive	descriptive	ADJ
dpc-2357	61	2	statistical	statistical	ADJ
dpc-2357	61	3	analyses	analysis	NOUN
dpc-2357	61	4	were	be	AUX
dpc-2357	61	5	performed	perform	VERB
dpc-2357	61	6	,	,	PUNCT
dpc-2357	61	7	and	and	CCONJ
dpc-2357	61	8	data	datum	NOUN
dpc-2357	61	9	were	be	AUX
dpc-2357	61	10	shown	show	VERB
dpc-2357	61	11	as	as	ADP
dpc-2357	61	12	median	median	NOUN
dpc-2357	61	13	(	(	PUNCT
dpc-2357	61	14	range	range	NOUN
dpc-2357	61	15	)	)	PUNCT
dpc-2357	61	16	,	,	PUNCT
dpc-2357	61	17	mean	mean	INTJ
dpc-2357	61	18	(	(	PUNCT
dpc-2357	61	19	sd	sd	NOUN
dpc-2357	61	20	)	)	PUNCT
dpc-2357	61	21	,	,	PUNCT
dpc-2357	61	22	or	or	CCONJ
dpc-2357	61	23	number	number	NOUN
dpc-2357	61	24	(	(	PUNCT
dpc-2357	61	25	percentage	percentage	NOUN
dpc-2357	61	26	)	)	PUNCT
dpc-2357	61	27	.	.	PUNCT
dpc-2357	62	1	relapse	relapse	NOUN
dpc-2357	62	2	rates	rate	NOUN
dpc-2357	62	3	and	and	CCONJ
dpc-2357	62	4	time	time	NOUN
dpc-2357	62	5	to	to	PART
dpc-2357	62	6	relapse	relapse	VERB
dpc-2357	62	7	were	be	AUX
dpc-2357	62	8	evaluated	evaluate	VERB
dpc-2357	62	9	for	for	ADP
dpc-2357	62	10	patients	patient	NOUN
dpc-2357	62	11	divided	divide	VERB
dpc-2357	62	12	for	for	ADP
dpc-2357	62	13	iga	iga	PROPN
dpc-2357	62	14	score	score	NOUN
dpc-2357	62	15	and	and	CCONJ
dpc-2357	62	16	analyzed	analyze	VERB
dpc-2357	62	17	using	use	VERB
dpc-2357	62	18	the	the	DET
dpc-2357	62	19	kaplan	kaplan	PROPN
dpc-2357	62	20	-	-	PUNCT
dpc-2357	62	21	meier	meier	PROPN
dpc-2357	62	22	method	method	NOUN
dpc-2357	62	23	and	and	CCONJ
dpc-2357	62	24	log	log	NOUN
dpc-2357	62	25	-	-	PUNCT
dpc-2357	62	26	rank	rank	NOUN
dpc-2357	62	27	test	test	NOUN
dpc-2357	62	28	.	.	PUNCT
dpc-2357	63	1	patients	patient	NOUN
dpc-2357	63	2	who	who	PRON
dpc-2357	63	3	relapsed	relapse	VERB
dpc-2357	63	4	were	be	AUX
dpc-2357	63	5	considered	consider	VERB
dpc-2357	63	6	censored	censor	VERB
dpc-2357	63	7	in	in	ADP
dpc-2357	63	8	the	the	DET
dpc-2357	63	9	analysis	analysis	NOUN
dpc-2357	63	10	.	.	PUNCT
dpc-2357	64	1	for	for	ADP
dpc-2357	64	2	categorical	categorical	ADJ
dpc-2357	64	3	variables	variable	NOUN
dpc-2357	64	4	,	,	PUNCT
dpc-2357	64	5	data	datum	NOUN
dpc-2357	64	6	were	be	AUX
dpc-2357	64	7	analyzed	analyze	VERB
dpc-2357	64	8	using	use	VERB
dpc-2357	64	9	the	the	DET
dpc-2357	64	10	χ2	χ2	PROPN
dpc-2357	64	11	test	test	NOUN
dpc-2357	64	12	and	and	CCONJ
dpc-2357	64	13	fisher	fisher	PROPN
dpc-2357	64	14	exact	exact	ADJ
dpc-2357	64	15	test	test	NOUN
dpc-2357	64	16	.	.	PUNCT
dpc-2357	65	1	the	the	DET
dpc-2357	65	2	study	study	NOUN
dpc-2357	65	3	was	be	AUX
dpc-2357	65	4	approved	approve	VERB
dpc-2357	65	5	by	by	ADP
dpc-2357	65	6	the	the	DET
dpc-2357	65	7	local	local	ADJ
dpc-2357	65	8	ethical	ethical	PROPN
dpc-2357	65	9	review	review	NOUN
dpc-2357	65	10	board	board	NOUN
dpc-2357	65	11	(	(	PUNCT
dpc-2357	65	12	comitato	comitato	PROPN
dpc-2357	65	13	etico	etico	PROPN
dpc-2357	65	14	regione	regione	PROPN
dpc-2357	65	15	liguria	liguria	PROPN
dpc-2357	65	16	.	.	PUNCT
dpc-2357	66	1	n.	n.	PROPN
dpc-2357	66	2	registro	registro	PROPN
dpc-2357	66	3	cer	cer	PROPN
dpc-2357	66	4	liguria	liguria	PROPN
dpc-2357	66	5	:	:	PUNCT
dpc-2357	66	6	467/2021	467/2021	NUM
dpc-2357	66	7	–	–	PUNCT
dpc-2357	66	8	db	db	VERB
dpc-2357	66	9	i	i	PROPN
dpc-2357	66	10	d	d	PROPN
dpc-2357	66	11	11726	11726	NUM
dpc-2357	66	12	)	)	PUNCT
dpc-2357	66	13	results	result	NOUN
dpc-2357	66	14	we	we	PRON
dpc-2357	66	15	recruited	recruit	VERB
dpc-2357	66	16	60	60	NUM
dpc-2357	66	17	caucasian	caucasian	ADJ
dpc-2357	66	18	patients	patient	NOUN
dpc-2357	66	19	,	,	PUNCT
dpc-2357	66	20	including	include	VERB
dpc-2357	66	21	45	45	NUM
dpc-2357	66	22	women	woman	NOUN
dpc-2357	66	23	(	(	PUNCT
dpc-2357	66	24	75	75	NUM
dpc-2357	66	25	%	%	NOUN
dpc-2357	66	26	)	)	PUNCT
dpc-2357	66	27	and	and	CCONJ
dpc-2357	66	28	15	15	NUM
dpc-2357	66	29	men	man	NOUN
dpc-2357	66	30	(	(	PUNCT
dpc-2357	66	31	25	25	NUM
dpc-2357	66	32	%	%	NOUN
dpc-2357	66	33	)	)	PUNCT
dpc-2357	66	34	with	with	ADP
dpc-2357	66	35	a	a	DET
dpc-2357	66	36	mean	mean	ADJ
dpc-2357	66	37	age	age	NOUN
dpc-2357	66	38	of	of	ADP
dpc-2357	66	39	57	57	NUM
dpc-2357	66	40	years	year	NOUN
dpc-2357	66	41	(	(	PUNCT
dpc-2357	66	42	sd	sd	NOUN
dpc-2357	66	43	11.2	11.2	NUM
dpc-2357	66	44	,	,	PUNCT
dpc-2357	66	45	range	range	VERB
dpc-2357	66	46	30	30	NUM
dpc-2357	66	47	-	-	SYM
dpc-2357	66	48	81	81	NUM
dpc-2357	66	49	years	year	NOUN
dpc-2357	66	50	)	)	PUNCT
dpc-2357	66	51	.	.	PUNCT
dpc-2357	67	1	demographic	demographic	ADJ
dpc-2357	67	2	and	and	CCONJ
dpc-2357	67	3	clinical	clinical	ADJ
dpc-2357	67	4	data	datum	NOUN
dpc-2357	67	5	are	be	AUX
dpc-2357	67	6	summarized	summarize	VERB
dpc-2357	67	7	in	in	ADP
dpc-2357	67	8	table	table	NOUN
dpc-2357	67	9	1	1	NUM
dpc-2357	67	10	.	.	X
dpc-2357	67	11	thirty	thirty	NUM
dpc-2357	67	12	-	-	PUNCT
dpc-2357	67	13	one/60	one/60	ADJ
dpc-2357	67	14	patients	patient	NOUN
dpc-2357	67	15	(	(	PUNCT
dpc-2357	67	16	51.67	51.67	NUM
dpc-2357	67	17	%	%	NOUN
dpc-2357	67	18	)	)	PUNCT
dpc-2357	67	19	had	have	VERB
dpc-2357	67	20	an	an	DET
dpc-2357	67	21	iga	iga	PROPN
dpc-2357	67	22	score	score	NOUN
dpc-2357	67	23	1	1	NUM
dpc-2357	67	24	,	,	PUNCT
dpc-2357	67	25	16/60	16/60	NUM
dpc-2357	67	26	patients	patient	NOUN
dpc-2357	67	27	(	(	PUNCT
dpc-2357	67	28	26.67	26.67	NUM
dpc-2357	67	29	%	%	NOUN
dpc-2357	67	30	)	)	PUNCT
dpc-2357	67	31	had	have	VERB
dpc-2357	67	32	an	an	DET
dpc-2357	67	33	iga	iga	PROPN
dpc-2357	67	34	score	score	NOUN
dpc-2357	67	35	2	2	NUM
dpc-2357	67	36	and	and	CCONJ
dpc-2357	67	37	13/60	13/60	NUM
dpc-2357	67	38	(	(	PUNCT
dpc-2357	67	39	21.66	21.66	NUM
dpc-2357	67	40	%	%	NOUN
dpc-2357	67	41	)	)	PUNCT
dpc-2357	67	42	had	have	VERB
dpc-2357	67	43	an	an	DET
dpc-2357	67	44	iga	iga	PROPN
dpc-2357	67	45	score	score	NOUN
dpc-2357	67	46	3	3	X
dpc-2357	67	47	.	.	PUNCT
dpc-2357	67	48	original	original	ADJ
dpc-2357	67	49	article	article	NOUN
dpc-2357	68	1	|	|	ADV
dpc-2357	68	2	dermatol	dermatol	ADJ
dpc-2357	68	3	pract	pract	NOUN
dpc-2357	68	4	concept	concept	NOUN
dpc-2357	68	5	.	.	PUNCT
dpc-2357	69	1	2022;12(4):e2022201	2022;12(4):e2022201	NUM
dpc-2357	69	2	3	3	NUM
dpc-2357	69	3	demodex	demodex	NOUN
dpc-2357	69	4	mite	mite	NOUN
dpc-2357	69	5	density	density	NOUN
dpc-2357	69	6	using	use	VERB
dpc-2357	69	7	sssb	sssb	NOUN
dpc-2357	69	8	,	,	PUNCT
dpc-2357	69	9	demodex	demodex	NOUN
dpc-2357	69	10	mites	mite	NOUN
dpc-2357	69	11	were	be	AUX
dpc-2357	69	12	found	find	VERB
dpc-2357	69	13	(	(	PUNCT
dpc-2357	69	14	d+	d+	X
dpc-2357	69	15	)	)	PUNCT
dpc-2357	69	16	in	in	ADP
dpc-2357	69	17	20/60	20/60	NUM
dpc-2357	69	18	(	(	PUNCT
dpc-2357	69	19	33.33	33.33	NUM
dpc-2357	69	20	%	%	NOUN
dpc-2357	69	21	)	)	PUNCT
dpc-2357	69	22	patients	patient	NOUN
dpc-2357	69	23	of	of	ADP
dpc-2357	69	24	whom	whom	PRON
dpc-2357	69	25	7	7	NUM
dpc-2357	69	26	had	have	VERB
dpc-2357	69	27	iga	iga	PROPN
dpc-2357	69	28	1	1	NUM
dpc-2357	69	29	,	,	PUNCT
dpc-2357	69	30	7	7	NUM
dpc-2357	69	31	had	have	VERB
dpc-2357	69	32	iga	iga	PROPN
dpc-2357	69	33	2	2	NUM
dpc-2357	69	34	and	and	CCONJ
dpc-2357	69	35	6	6	NUM
dpc-2357	69	36	had	have	VERB
dpc-2357	69	37	iga3	iga3	NOUN
dpc-2357	69	38	.	.	PUNCT
dpc-2357	70	1	after	after	ADP
dpc-2357	70	2	16	16	NUM
dpc-2357	70	3	weeks	week	NOUN
dpc-2357	70	4	of	of	ADP
dpc-2357	70	5	therapy	therapy	NOUN
dpc-2357	70	6	,	,	PUNCT
dpc-2357	70	7	sssb	sssb	PROPN
dpc-2357	70	8	resulted	result	VERB
dpc-2357	70	9	negative	negative	ADJ
dpc-2357	70	10	(	(	PUNCT
dpc-2357	70	11	d-	d-	X
dpc-2357	70	12	)	)	PUNCT
dpc-2357	70	13	in	in	ADP
dpc-2357	70	14	16/20	16/20	NUM
dpc-2357	70	15	(	(	PUNCT
dpc-2357	70	16	80	80	NUM
dpc-2357	70	17	%	%	NOUN
dpc-2357	70	18	)	)	PUNCT
dpc-2357	70	19	of	of	ADP
dpc-2357	70	20	whom	whom	PRON
dpc-2357	70	21	5/7	5/7	NUM
dpc-2357	70	22	(	(	PUNCT
dpc-2357	70	23	71.43	71.43	NUM
dpc-2357	70	24	%	%	NOUN
dpc-2357	70	25	)	)	PUNCT
dpc-2357	70	26	had	have	VERB
dpc-2357	70	27	iga	iga	PROPN
dpc-2357	70	28	1	1	NUM
dpc-2357	70	29	,	,	PUNCT
dpc-2357	70	30	6/7	6/7	NUM
dpc-2357	70	31	(	(	PUNCT
dpc-2357	70	32	85.71	85.71	NUM
dpc-2357	70	33	%	%	NOUN
dpc-2357	70	34	)	)	PUNCT
dpc-2357	70	35	had	have	VERB
dpc-2357	70	36	iga2	iga2	ADJ
dpc-2357	70	37	and	and	CCONJ
dpc-2357	70	38	5/6	5/6	NUM
dpc-2357	70	39	(	(	PUNCT
dpc-2357	70	40	83.33	83.33	NUM
dpc-2357	70	41	%	%	NOUN
dpc-2357	70	42	)	)	PUNCT
dpc-2357	70	43	had	have	VERB
dpc-2357	70	44	iga3	iga3	NOUN
dpc-2357	70	45	.	.	PUNCT
dpc-2357	71	1	there	there	PRON
dpc-2357	71	2	are	be	VERB
dpc-2357	71	3	not	not	PART
dpc-2357	71	4	statistical	statistical	ADJ
dpc-2357	71	5	differences	difference	NOUN
dpc-2357	71	6	to	to	PART
dpc-2357	71	7	become	become	VERB
dpc-2357	71	8	d(p	d(p	PROPN
dpc-2357	71	9	>	>	ADP
dpc-2357	71	10	0.999	0.999	NUM
dpc-2357	71	11	,	,	PUNCT
dpc-2357	71	12	p	p	X
dpc-2357	71	13	>	>	X
dpc-2357	71	14	0.999	0.999	NUM
dpc-2357	71	15	,	,	PUNCT
dpc-2357	71	16	p	p	X
dpc-2357	71	17	>	>	X
dpc-2357	71	18	0.999	0.999	NUM
dpc-2357	71	19	)	)	PUNCT
dpc-2357	71	20	after	after	ADP
dpc-2357	71	21	16	16	NUM
dpc-2357	71	22	weeks	week	NOUN
dpc-2357	71	23	of	of	ADP
dpc-2357	71	24	therapy	therapy	NOUN
dpc-2357	71	25	.	.	PUNCT
dpc-2357	72	1	relapse	relapse	NOUN
dpc-2357	72	2	evaluation	evaluation	NOUN
dpc-2357	72	3	and	and	CCONJ
dpc-2357	72	4	demodex	demodex	NOUN
dpc-2357	72	5	mite	mite	NOUN
dpc-2357	72	6	infestation	infestation	NOUN
dpc-2357	72	7	only	only	ADV
dpc-2357	72	8	2/16	2/16	NUM
dpc-2357	72	9	(	(	PUNCT
dpc-2357	72	10	12.5	12.5	NUM
dpc-2357	72	11	%	%	NOUN
dpc-2357	72	12	)	)	PUNCT
dpc-2357	72	13	iga	iga	PROPN
dpc-2357	72	14	2	2	NUM
dpc-2357	72	15	ppr	ppr	NOUN
dpc-2357	72	16	drelapsed	drelapse	VERB
dpc-2357	72	17	after	after	ADP
dpc-2357	72	18	224	224	NUM
dpc-2357	72	19	days	day	NOUN
dpc-2357	72	20	.	.	PUNCT
dpc-2357	73	1	the	the	DET
dpc-2357	73	2	global	global	ADJ
dpc-2357	73	3	success	success	NOUN
dpc-2357	73	4	rate	rate	NOUN
dpc-2357	73	5	of	of	ADP
dpc-2357	73	6	demodex	demodex	NOUN
dpc-2357	73	7	infestation	infestation	NOUN
dpc-2357	73	8	was	be	AUX
dpc-2357	73	9	87.5	87.5	NUM
dpc-2357	73	10	%	%	NOUN
dpc-2357	73	11	.	.	PUNCT
dpc-2357	74	1	regarding	regard	VERB
dpc-2357	74	2	4	4	NUM
dpc-2357	74	3	d+	d+	NOUN
dpc-2357	74	4	patients	patient	NOUN
dpc-2357	74	5	positive	positive	ADJ
dpc-2357	74	6	after	after	ADP
dpc-2357	74	7	16	16	NUM
dpc-2357	74	8	weeks	week	NOUN
dpc-2357	74	9	of	of	ADP
dpc-2357	74	10	therapy	therapy	NOUN
dpc-2357	74	11	,	,	PUNCT
dpc-2357	74	12	2/4	2/4	NUM
dpc-2357	74	13	achieved	achieve	VERB
dpc-2357	74	14	dat	dat	ADJ
dpc-2357	74	15	day	day	NOUN
dpc-2357	74	16	150	150	NUM
dpc-2357	74	17	,	,	PUNCT
dpc-2357	74	18	¼	¼	NOUN
dpc-2357	74	19	at	at	ADP
dpc-2357	74	20	day	day	NOUN
dpc-2357	74	21	224	224	NUM
dpc-2357	74	22	while	while	SCONJ
dpc-2357	74	23	¼	¼	NOUN
dpc-2357	74	24	remained	remain	VERB
dpc-2357	74	25	d+	d+	PUNCT
dpc-2357	74	26	.	.	PUNCT
dpc-2357	75	1	iga	iga	PROPN
dpc-2357	75	2	score	score	NOUN
dpc-2357	75	3	and	and	CCONJ
dpc-2357	75	4	effectiveness	effectiveness	NOUN
dpc-2357	75	5	patients	patient	NOUN
dpc-2357	75	6	that	that	PRON
dpc-2357	75	7	reached	reach	VERB
dpc-2357	75	8	iga=0	iga=0	NOUN
dpc-2357	75	9	after	after	ADP
dpc-2357	75	10	16	16	NUM
dpc-2357	75	11	weeks	week	NOUN
dpc-2357	75	12	of	of	ADP
dpc-2357	75	13	treatment	treatment	NOUN
dpc-2357	75	14	are	be	AUX
dpc-2357	75	15	summarized	summarize	VERB
dpc-2357	75	16	in	in	ADP
dpc-2357	75	17	table	table	NOUN
dpc-2357	75	18	1	1	NUM
dpc-2357	75	19	.	.	PUNCT
dpc-2357	76	1	there	there	PRON
dpc-2357	76	2	are	be	VERB
dpc-2357	76	3	not	not	PART
dpc-2357	76	4	statistical	statistical	ADJ
dpc-2357	76	5	significative	significative	ADJ
dpc-2357	76	6	differences	difference	NOUN
dpc-2357	76	7	to	to	PART
dpc-2357	76	8	achieve	achieve	VERB
dpc-2357	76	9	iga	iga	PROPN
dpc-2357	76	10	=	=	PUNCT
dpc-2357	76	11	0	0	NUM
dpc-2357	76	12	among	among	ADP
dpc-2357	76	13	iga1	iga1	NOUN
dpc-2357	76	14	-	-	PUNCT
dpc-2357	76	15	2	2	NUM
dpc-2357	76	16	-	-	SYM
dpc-2357	76	17	3	3	NUM
dpc-2357	76	18	at	at	ADP
dpc-2357	76	19	baseline	baseline	NOUN
dpc-2357	76	20	(	(	PUNCT
dpc-2357	76	21	p	p	X
dpc-2357	76	22	=	=	NOUN
dpc-2357	76	23	0.725	0.725	NUM
dpc-2357	76	24	,	,	PUNCT
dpc-2357	76	25	p	p	X
dpc-2357	76	26	=	=	PROPN
dpc-2357	76	27	0.1552	0.1552	NUM
dpc-2357	76	28	,	,	PUNCT
dpc-2357	76	29	p	p	NOUN
dpc-2357	76	30	=	=	PROPN
dpc-2357	76	31	0.47	0.47	NUM
dpc-2357	76	32	,	,	PUNCT
dpc-2357	76	33	respectively	respectively	ADV
dpc-2357	76	34	)	)	PUNCT
dpc-2357	76	35	.	.	PUNCT
dpc-2357	77	1	relapse	relapse	NOUN
dpc-2357	77	2	evaluation	evaluation	NOUN
dpc-2357	77	3	kaplan	kaplan	PROPN
dpc-2357	77	4	-	-	PUNCT
dpc-2357	77	5	meier	meier	PROPN
dpc-2357	77	6	curves	curve	NOUN
dpc-2357	77	7	show	show	VERB
dpc-2357	77	8	no	no	DET
dpc-2357	77	9	different	different	ADJ
dpc-2357	77	10	median	median	ADJ
dpc-2357	77	11	time	time	NOUN
dpc-2357	77	12	of	of	ADP
dpc-2357	77	13	first	first	ADJ
dpc-2357	77	14	relapse	relapse	NOUN
dpc-2357	77	15	(	(	PUNCT
dpc-2357	77	16	iga	iga	PROPN
dpc-2357	77	17	≥	≥	PROPN
dpc-2357	77	18	1	1	NUM
dpc-2357	77	19	)	)	PUNCT
dpc-2357	77	20	among	among	ADP
dpc-2357	77	21	iga	iga	PROPN
dpc-2357	77	22	1	1	NUM
dpc-2357	77	23	-	-	SYM
dpc-2357	77	24	2	2	NUM
dpc-2357	77	25	-	-	SYM
dpc-2357	77	26	3	3	NUM
dpc-2357	77	27	(	(	PUNCT
dpc-2357	77	28	p	p	NOUN
dpc-2357	77	29	log	log	PROPN
dpc-2357	77	30	rank	rank	NOUN
dpc-2357	77	31	test	test	NOUN
dpc-2357	77	32	=	=	SYM
dpc-2357	77	33	0.551	0.551	NUM
dpc-2357	77	34	)	)	PUNCT
dpc-2357	77	35	(	(	PUNCT
dpc-2357	77	36	figure	figure	NOUN
dpc-2357	77	37	1	1	NUM
dpc-2357	77	38	)	)	PUNCT
dpc-2357	77	39	.	.	PUNCT
dpc-2357	78	1	at	at	ADP
dpc-2357	78	2	week	week	NOUN
dpc-2357	78	3	48	48	NUM
dpc-2357	78	4	,	,	PUNCT
dpc-2357	78	5	the	the	DET
dpc-2357	78	6	percentages	percentage	NOUN
dpc-2357	78	7	of	of	ADP
dpc-2357	78	8	patients	patient	NOUN
dpc-2357	78	9	who	who	PRON
dpc-2357	78	10	experienced	experience	VERB
dpc-2357	78	11	a	a	DET
dpc-2357	78	12	relapse	relapse	NOUN
dpc-2357	78	13	(	(	PUNCT
dpc-2357	78	14	iga	iga	PROPN
dpc-2357	78	15	≥	≥	NUM
dpc-2357	78	16	1	1	NUM
dpc-2357	78	17	)	)	PUNCT
dpc-2357	78	18	after	after	ADP
dpc-2357	78	19	discontinuation	discontinuation	NOUN
dpc-2357	78	20	of	of	ADP
dpc-2357	78	21	ivermectin	ivermectin	NOUN
dpc-2357	78	22	treatment	treatment	NOUN
dpc-2357	78	23	(	(	PUNCT
dpc-2357	78	24	relapse	relapse	NOUN
dpc-2357	78	25	rate	rate	NOUN
dpc-2357	78	26	)	)	PUNCT
dpc-2357	78	27	was	be	AUX
dpc-2357	78	28	45.24	45.24	NUM
dpc-2357	78	29	%	%	NOUN
dpc-2357	78	30	,	,	PUNCT
dpc-2357	78	31	and	and	CCONJ
dpc-2357	78	32	in	in	ADP
dpc-2357	78	33	particular	particular	ADJ
dpc-2357	78	34	,	,	PUNCT
dpc-2357	78	35	they	they	PRON
dpc-2357	78	36	were	be	AUX
dpc-2357	78	37	45.83	45.83	NUM
dpc-2357	78	38	%	%	NOUN
dpc-2357	78	39	for	for	ADP
dpc-2357	78	40	iga1	iga1	NOUN
dpc-2357	78	41	,	,	PUNCT
dpc-2357	78	42	45.45	45.45	NUM
dpc-2357	78	43	%	%	NOUN
dpc-2357	78	44	for	for	ADP
dpc-2357	78	45	iga	iga	PROPN
dpc-2357	78	46	2	2	NUM
dpc-2357	78	47	e	e	NOUN
dpc-2357	78	48	28.57	28.57	NUM
dpc-2357	78	49	%	%	NOUN
dpc-2357	78	50	for	for	ADP
dpc-2357	78	51	iga	iga	PROPN
dpc-2357	78	52	3	3	NUM
dpc-2357	78	53	.	.	PUNCT
dpc-2357	79	1	the	the	DET
dpc-2357	79	2	global	global	ADJ
dpc-2357	79	3	success	success	NOUN
dpc-2357	79	4	rate	rate	NOUN
dpc-2357	79	5	(	(	PUNCT
dpc-2357	79	6	percentage	percentage	NOUN
dpc-2357	79	7	of	of	ADP
dpc-2357	79	8	patients	patient	NOUN
dpc-2357	79	9	who	who	PRON
dpc-2357	79	10	reached	reach	VERB
dpc-2357	79	11	0	0	NUM
dpc-2357	79	12	at	at	ADP
dpc-2357	79	13	the	the	DET
dpc-2357	79	14	end	end	NOUN
dpc-2357	79	15	of	of	ADP
dpc-2357	79	16	treatment	treatment	NOUN
dpc-2357	79	17	and	and	CCONJ
dpc-2357	79	18	had	have	VERB
dpc-2357	79	19	no	no	DET
dpc-2357	79	20	relapse	relapse	NOUN
dpc-2357	79	21	in	in	ADP
dpc-2357	79	22	follow	follow	NOUN
dpc-2357	79	23	up	up	ADP
dpc-2357	79	24	)	)	PUNCT
dpc-2357	79	25	was	be	AUX
dpc-2357	79	26	54.76	54.76	NUM
dpc-2357	79	27	%	%	NOUN
dpc-2357	79	28	and	and	CCONJ
dpc-2357	79	29	in	in	ADP
dpc-2357	79	30	particular	particular	ADJ
dpc-2357	79	31	,	,	PUNCT
dpc-2357	79	32	they	they	PRON
dpc-2357	79	33	were	be	AUX
dpc-2357	79	34	54.17	54.17	NUM
dpc-2357	79	35	%	%	NOUN
dpc-2357	79	36	for	for	ADP
dpc-2357	79	37	iga1	iga1	NOUN
dpc-2357	79	38	,	,	PUNCT
dpc-2357	79	39	54.54	54.54	NUM
dpc-2357	79	40	%	%	NOUN
dpc-2357	79	41	for	for	ADP
dpc-2357	79	42	iga	iga	PROPN
dpc-2357	79	43	2	2	NUM
dpc-2357	79	44	and	and	CCONJ
dpc-2357	79	45	71.43	71.43	NUM
dpc-2357	79	46	%	%	NOUN
dpc-2357	79	47	for	for	ADP
dpc-2357	79	48	iga3	iga3	NOUN
dpc-2357	79	49	.	.	PUNCT
dpc-2357	80	1	median	median	ADJ
dpc-2357	80	2	time	time	NOUN
dpc-2357	80	3	to	to	PART
dpc-2357	80	4	relapse	relapse	VERB
dpc-2357	80	5	was	be	AUX
dpc-2357	80	6	140	140	NUM
dpc-2357	80	7	days	day	NOUN
dpc-2357	80	8	(	(	PUNCT
dpc-2357	80	9	84	84	NUM
dpc-2357	80	10	-	-	SYM
dpc-2357	80	11	224	224	NUM
dpc-2357	80	12	days	day	NOUN
dpc-2357	80	13	)	)	PUNCT
dpc-2357	80	14	,	,	PUNCT
dpc-2357	80	15	in	in	ADP
dpc-2357	80	16	particular	particular	ADJ
dpc-2357	80	17	,	,	PUNCT
dpc-2357	80	18	154	154	NUM
dpc-2357	80	19	days	day	NOUN
dpc-2357	80	20	(	(	PUNCT
dpc-2357	80	21	range	range	NOUN
dpc-2357	80	22	:	:	PUNCT
dpc-2357	80	23	84	84	NUM
dpc-2357	80	24	-	-	SYM
dpc-2357	80	25	224	224	NUM
dpc-2357	80	26	)	)	PUNCT
dpc-2357	80	27	for	for	ADP
dpc-2357	80	28	iga	iga	PROPN
dpc-2357	80	29	1	1	NUM
dpc-2357	80	30	,	,	PUNCT
dpc-2357	80	31	196	196	NUM
dpc-2357	80	32	days	day	NOUN
dpc-2357	80	33	(	(	PUNCT
dpc-2357	80	34	range	range	NOUN
dpc-2357	80	35	:	:	PUNCT
dpc-2357	80	36	98	98	NUM
dpc-2357	80	37	-	-	SYM
dpc-2357	80	38	224	224	NUM
dpc-2357	80	39	)	)	PUNCT
dpc-2357	80	40	for	for	ADP
dpc-2357	80	41	iga	iga	PROPN
dpc-2357	80	42	2	2	NUM
dpc-2357	80	43	,	,	PUNCT
dpc-2357	80	44	105	105	NUM
dpc-2357	80	45	days	day	NOUN
dpc-2357	80	46	(	(	PUNCT
dpc-2357	80	47	range	range	NOUN
dpc-2357	80	48	:	:	PUNCT
dpc-2357	80	49	98	98	NUM
dpc-2357	80	50	-	-	SYM
dpc-2357	80	51	112	112	NUM
dpc-2357	80	52	)	)	PUNCT
dpc-2357	80	53	for	for	ADP
dpc-2357	80	54	iga	iga	PROPN
dpc-2357	80	55	3	3	NUM
dpc-2357	80	56	.	.	PUNCT
dpc-2357	81	1	the	the	DET
dpc-2357	81	2	mean	mean	ADJ
dpc-2357	81	3	time	time	NOUN
dpc-2357	81	4	to	to	PART
dpc-2357	81	5	relapse	relapse	VERB
dpc-2357	81	6	was	be	AUX
dpc-2357	81	7	152.44	152.44	NUM
dpc-2357	81	8	±	±	NUM
dpc-2357	81	9	51.47	51.47	NUM
dpc-2357	81	10	days	day	NOUN
dpc-2357	81	11	,	,	PUNCT
dpc-2357	81	12	in	in	ADP
dpc-2357	81	13	particular	particular	ADJ
dpc-2357	81	14	,	,	PUNCT
dpc-2357	81	15	154	154	NUM
dpc-2357	81	16	±	±	NOUN
dpc-2357	81	17	50.47	50.47	NUM
dpc-2357	81	18	days	day	NOUN
dpc-2357	81	19	for	for	ADP
dpc-2357	81	20	iga	iga	PROPN
dpc-2357	81	21	1	1	NUM
dpc-2357	81	22	,	,	PUNCT
dpc-2357	81	23	168	168	NUM
dpc-2357	81	24	±	±	NOUN
dpc-2357	81	25	58.57	58.57	NUM
dpc-2357	81	26	days	day	NOUN
dpc-2357	81	27	for	for	ADP
dpc-2357	81	28	iga	iga	PROPN
dpc-2357	81	29	2	2	NUM
dpc-2357	81	30	and	and	CCONJ
dpc-2357	81	31	105	105	NUM
dpc-2357	81	32	days	day	NOUN
dpc-2357	81	33	±	±	NUM
dpc-2357	81	34	9.90	9.90	NUM
dpc-2357	81	35	days	day	NOUN
dpc-2357	81	36	for	for	ADP
dpc-2357	81	37	iga	iga	PROPN
dpc-2357	81	38	3	3	NUM
dpc-2357	81	39	.	.	PUNCT
dpc-2357	81	40	table	table	NOUN
dpc-2357	81	41	1	1	NUM
dpc-2357	81	42	.	.	PUNCT
dpc-2357	81	43	demographic	demographic	ADJ
dpc-2357	81	44	and	and	CCONJ
dpc-2357	81	45	clinical	clinical	ADJ
dpc-2357	81	46	data	datum	NOUN
dpc-2357	81	47	of	of	ADP
dpc-2357	81	48	patients	patient	NOUN
dpc-2357	81	49	divided	divide	VERB
dpc-2357	81	50	by	by	ADP
dpc-2357	81	51	iga	iga	PROPN
dpc-2357	81	52	score	score	NOUN
dpc-2357	81	53	.	.	PUNCT
dpc-2357	82	1	iga	iga	PROPN
dpc-2357	82	2	1	1	NUM
dpc-2357	82	3	(	(	PUNCT
dpc-2357	82	4	31	31	NUM
dpc-2357	82	5	)	)	PUNCT
dpc-2357	82	6	iga	iga	PROPN
dpc-2357	82	7	2	2	NUM
dpc-2357	82	8	(	(	PUNCT
dpc-2357	82	9	16	16	NUM
dpc-2357	82	10	)	)	PUNCT
dpc-2357	82	11	iga	iga	PROPN
dpc-2357	82	12	3	3	NUM
dpc-2357	82	13	(	(	PUNCT
dpc-2357	82	14	13	13	NUM
dpc-2357	82	15	)	)	PUNCT
dpc-2357	82	16	total	total	NOUN
dpc-2357	82	17	(	(	PUNCT
dpc-2357	82	18	60	60	NUM
dpc-2357	82	19	)	)	PUNCT
dpc-2357	82	20	age	age	NOUN
dpc-2357	82	21	,	,	PUNCT
dpc-2357	82	22	years	year	NOUN
dpc-2357	82	23	,	,	PUNCT
dpc-2357	82	24	mean	mean	INTJ
dpc-2357	82	25	(	(	PUNCT
dpc-2357	82	26	sd	sd	NOUN
dpc-2357	82	27	)	)	PUNCT
dpc-2357	82	28	58	58	NUM
dpc-2357	82	29	(	(	PUNCT
dpc-2357	82	30	10.1	10.1	NUM
dpc-2357	82	31	)	)	PUNCT
dpc-2357	82	32	56	56	NUM
dpc-2357	82	33	(	(	PUNCT
dpc-2357	82	34	14,0	14,0	NUM
dpc-2357	82	35	)	)	PUNCT
dpc-2357	82	36	57	57	NUM
dpc-2357	82	37	(	(	PUNCT
dpc-2357	82	38	9.5	9.5	NUM
dpc-2357	82	39	)	)	PUNCT
dpc-2357	82	40	57	57	NUM
dpc-2357	82	41	(	(	PUNCT
dpc-2357	82	42	11.2	11.2	NUM
dpc-2357	82	43	)	)	PUNCT
dpc-2357	82	44	gender	gender	NOUN
dpc-2357	82	45	female	female	NOUN
dpc-2357	82	46	,	,	PUNCT
dpc-2357	82	47	n	n	CCONJ
dpc-2357	82	48	(	(	PUNCT
dpc-2357	82	49	%	%	INTJ
dpc-2357	82	50	)	)	PUNCT
dpc-2357	82	51	20	20	NUM
dpc-2357	82	52	(	(	PUNCT
dpc-2357	82	53	64.52	64.52	NUM
dpc-2357	82	54	)	)	PUNCT
dpc-2357	82	55	13	13	NUM
dpc-2357	82	56	(	(	PUNCT
dpc-2357	82	57	81.25	81.25	NUM
dpc-2357	82	58	)	)	PUNCT
dpc-2357	82	59	12	12	NUM
dpc-2357	82	60	(	(	PUNCT
dpc-2357	82	61	92.31	92.31	NUM
dpc-2357	82	62	)	)	PUNCT
dpc-2357	82	63	45	45	NUM
dpc-2357	82	64	(	(	PUNCT
dpc-2357	82	65	75	75	NUM
dpc-2357	82	66	)	)	PUNCT
dpc-2357	82	67	male	male	NOUN
dpc-2357	82	68	,	,	PUNCT
dpc-2357	82	69	n	n	CCONJ
dpc-2357	82	70	(	(	PUNCT
dpc-2357	82	71	%	%	INTJ
dpc-2357	82	72	)	)	PUNCT
dpc-2357	82	73	11	11	NUM
dpc-2357	82	74	(	(	PUNCT
dpc-2357	82	75	35.48	35.48	NUM
dpc-2357	82	76	)	)	PUNCT
dpc-2357	82	77	3	3	NUM
dpc-2357	82	78	(	(	PUNCT
dpc-2357	82	79	18.75	18.75	NUM
dpc-2357	82	80	)	)	PUNCT
dpc-2357	82	81	1	1	NUM
dpc-2357	82	82	(	(	PUNCT
dpc-2357	82	83	7.69	7.69	NUM
dpc-2357	82	84	)	)	PUNCT
dpc-2357	82	85	15	15	NUM
dpc-2357	82	86	(	(	PUNCT
dpc-2357	82	87	25	25	NUM
dpc-2357	82	88	)	)	PUNCT
dpc-2357	82	89	patients	patient	NOUN
dpc-2357	82	90	reaching	reach	VERB
dpc-2357	82	91	iga=	iga=	NOUN
dpc-2357	82	92	0	0	NUM
dpc-2357	82	93	at	at	ADP
dpc-2357	82	94	16	16	NUM
dpc-2357	82	95	weeks	week	NOUN
dpc-2357	82	96	,	,	PUNCT
dpc-2357	82	97	n	n	CCONJ
dpc-2357	82	98	(	(	PUNCT
dpc-2357	82	99	%	%	INTJ
dpc-2357	82	100	)	)	PUNCT
dpc-2357	82	101	24	24	NUM
dpc-2357	82	102	(	(	PUNCT
dpc-2357	82	103	77.42	77.42	NUM
dpc-2357	82	104	)	)	PUNCT
dpc-2357	82	105	11	11	NUM
dpc-2357	82	106	(	(	PUNCT
dpc-2357	82	107	68.75	68.75	NUM
dpc-2357	82	108	)	)	PUNCT
dpc-2357	82	109	7	7	NUM
dpc-2357	82	110	(	(	PUNCT
dpc-2357	82	111	53.85	53.85	NUM
dpc-2357	82	112	)	)	PUNCT
dpc-2357	82	113	42	42	NUM
dpc-2357	82	114	(	(	PUNCT
dpc-2357	82	115	70	70	NUM
dpc-2357	82	116	)	)	PUNCT
dpc-2357	82	117	patients	patient	NOUN
dpc-2357	82	118	positive	positive	ADJ
dpc-2357	82	119	for	for	ADP
dpc-2357	82	120	demodex	demodex	NOUN
dpc-2357	82	121	at	at	ADP
dpc-2357	82	122	baseline	baseline	NOUN
dpc-2357	82	123	,	,	PUNCT
dpc-2357	82	124	n	n	CCONJ
dpc-2357	82	125	(	(	PUNCT
dpc-2357	82	126	%	%	INTJ
dpc-2357	82	127	)	)	PUNCT
dpc-2357	82	128	7	7	NUM
dpc-2357	82	129	(	(	PUNCT
dpc-2357	82	130	22.58	22.58	NUM
dpc-2357	82	131	)	)	PUNCT
dpc-2357	82	132	7	7	NUM
dpc-2357	82	133	(	(	PUNCT
dpc-2357	82	134	43.75	43.75	NUM
dpc-2357	82	135	)	)	PUNCT
dpc-2357	82	136	6	6	NUM
dpc-2357	82	137	(	(	PUNCT
dpc-2357	82	138	46.15	46.15	NUM
dpc-2357	82	139	)	)	PUNCT
dpc-2357	82	140	20	20	NUM
dpc-2357	82	141	(	(	PUNCT
dpc-2357	82	142	33.33	33.33	NUM
dpc-2357	82	143	)	)	PUNCT
dpc-2357	82	144	patients	patient	NOUN
dpc-2357	82	145	negative	negative	ADJ
dpc-2357	82	146	for	for	ADP
dpc-2357	82	147	demodex	demodex	NOUN
dpc-2357	82	148	at	at	ADP
dpc-2357	82	149	16	16	NUM
dpc-2357	82	150	weeks	week	NOUN
dpc-2357	82	151	,	,	PUNCT
dpc-2357	82	152	n	n	CCONJ
dpc-2357	82	153	(	(	PUNCT
dpc-2357	82	154	%	%	INTJ
dpc-2357	82	155	)	)	PUNCT
dpc-2357	82	156	5	5	NUM
dpc-2357	82	157	(	(	PUNCT
dpc-2357	82	158	16.13	16.13	NUM
dpc-2357	82	159	)	)	PUNCT
dpc-2357	82	160	6	6	NUM
dpc-2357	82	161	(	(	PUNCT
dpc-2357	82	162	37.5	37.5	NUM
dpc-2357	82	163	)	)	SYM
dpc-2357	82	164	5	5	NUM
dpc-2357	82	165	(	(	PUNCT
dpc-2357	82	166	38.46	38.46	NUM
dpc-2357	82	167	)	)	PUNCT
dpc-2357	82	168	16	16	NUM
dpc-2357	82	169	(	(	PUNCT
dpc-2357	82	170	26.67	26.67	NUM
dpc-2357	82	171	)	)	PUNCT
dpc-2357	82	172	iga=	iga=	PROPN
dpc-2357	82	173	investigal	investigal	ADJ
dpc-2357	82	174	global	global	ADJ
dpc-2357	82	175	assessment	assessment	NOUN
dpc-2357	82	176	;	;	PUNCT
dpc-2357	82	177	sd	sd	NOUN
dpc-2357	82	178	=	=	SYM
dpc-2357	82	179	standard	standard	ADJ
dpc-2357	82	180	deviation	deviation	NOUN
dpc-2357	82	181	.	.	PUNCT
dpc-2357	83	1	100	100	NUM
dpc-2357	83	2	pe	pe	NUM
dpc-2357	83	3	rc	rc	PROPN
dpc-2357	83	4	en	en	X
dpc-2357	83	5	ta	ta	X
dpc-2357	83	6	ge	ge	PROPN
dpc-2357	84	1	o	o	PROPN
dpc-2357	85	1	f	f	X
dpc-2357	85	2	p	p	NOUN
dpc-2357	85	3	at	at	ADP
dpc-2357	85	4	ie	ie	X
dpc-2357	85	5	nt	not	PART
dpc-2357	85	6	s	s	PART
dpc-2357	85	7	re	re	VERB
dpc-2357	85	8	m	m	PROPN
dpc-2357	85	9	ai	ai	VERB
dpc-2357	85	10	ni	ni	PROPN
dpc-2357	85	11	ng	ng	PROPN
dpc-2357	85	12	w	w	PROPN
dpc-2357	85	13	it	it	PRON
dpc-2357	85	14	ho	ho	PROPN
dpc-2357	85	15	ut	ut	PROPN
dpc-2357	85	16	re	re	X
dpc-2357	85	17	la	la	PROPN
dpc-2357	85	18	ps	ps	PROPN
dpc-2357	85	19	e	e	X
dpc-2357	85	20	(	(	PUNCT
dpc-2357	85	21	%	%	INTJ
dpc-2357	85	22	)	)	PUNCT
dpc-2357	85	23	iga	iga	PROPN
dpc-2357	85	24	1	1	NUM
dpc-2357	85	25	iga	iga	PROPN
dpc-2357	85	26	2	2	NUM
dpc-2357	85	27	iga	iga	PROPN
dpc-2357	85	28	3	3	NUM
dpc-2357	85	29	50	50	NUM
dpc-2357	85	30	0	0	NUM
dpc-2357	85	31	0	0	NUM
dpc-2357	85	32	14	14	NUM
dpc-2357	85	33	28	28	NUM
dpc-2357	85	34	42	42	NUM
dpc-2357	85	35	56	56	NUM
dpc-2357	85	36	70	70	NUM
dpc-2357	85	37	time	time	NOUN
dpc-2357	85	38	from	from	ADP
dpc-2357	85	39	end	end	NOUN
dpc-2357	85	40	of	of	ADP
dpc-2357	85	41	ivermectin	ivermectin	NOUN
dpc-2357	85	42	treatment	treatment	NOUN
dpc-2357	85	43	(	(	PUNCT
dpc-2357	85	44	days	day	NOUN
dpc-2357	85	45	)	)	PUNCT
dpc-2357	85	46	84	84	NUM
dpc-2357	85	47	98	98	NUM
dpc-2357	85	48	112	112	NUM
dpc-2357	85	49	126	126	NUM
dpc-2357	85	50	140	140	NUM
dpc-2357	85	51	154	154	NUM
dpc-2357	85	52	168	168	NUM
dpc-2357	85	53	182	182	NUM
dpc-2357	85	54	196	196	NUM
dpc-2357	85	55	210	210	NUM
dpc-2357	85	56	224	224	NUM
dpc-2357	85	57	figure	figure	NOUN
dpc-2357	85	58	1	1	NUM
dpc-2357	85	59	.	.	NOUN
dpc-2357	85	60	time	time	NOUN
dpc-2357	85	61	to	to	PART
dpc-2357	85	62	first	first	ADJ
dpc-2357	85	63	relapse	relapse	NOUN
dpc-2357	85	64	of	of	ADP
dpc-2357	85	65	patients	patient	NOUN
dpc-2357	85	66	in	in	ADP
dpc-2357	85	67	ivermectin	ivermectin	NOUN
dpc-2357	85	68	1	1	NUM
dpc-2357	85	69	%	%	NOUN
dpc-2357	85	70	cream	cream	NOUN
dpc-2357	85	71	.	.	PUNCT
dpc-2357	86	1	kaplan	kaplan	PROPN
dpc-2357	86	2	-	-	PUNCT
dpc-2357	86	3	meier	meier	PROPN
dpc-2357	86	4	plot	plot	NOUN
dpc-2357	86	5	demonstrates	demonstrate	VERB
dpc-2357	86	6	that	that	SCONJ
dpc-2357	86	7	there	there	PRON
dpc-2357	86	8	are	be	VERB
dpc-2357	86	9	not	not	PART
dpc-2357	86	10	differences	difference	NOUN
dpc-2357	86	11	among	among	ADP
dpc-2357	86	12	patients	patient	NOUN
dpc-2357	86	13	treated	treat	VERB
dpc-2357	86	14	with	with	ADP
dpc-2357	86	15	ivermectin	ivermectin	NOUN
dpc-2357	86	16	divided	divide	VERB
dpc-2357	86	17	to	to	ADP
dpc-2357	86	18	iga	iga	PROPN
dpc-2357	86	19	score	score	NOUN
dpc-2357	86	20	(	(	PUNCT
dpc-2357	86	21	p	p	X
dpc-2357	86	22	=	=	NOUN
dpc-2357	86	23	0.551	0.551	NUM
dpc-2357	86	24	)	)	PUNCT
dpc-2357	86	25	.	.	PUNCT
dpc-2357	87	1	4	4	NUM
dpc-2357	87	2	original	original	ADJ
dpc-2357	87	3	article	article	NOUN
dpc-2357	87	4	|	|	ADV
dpc-2357	87	5	dermatol	dermatol	ADJ
dpc-2357	87	6	pract	pract	NOUN
dpc-2357	87	7	concept	concept	NOUN
dpc-2357	87	8	.	.	PUNCT
dpc-2357	88	1	2022;12(4):e2022201	2022;12(4):e2022201	NUM
dpc-2357	88	2	versus	versus	ADP
dpc-2357	88	3	85	85	NUM
dpc-2357	88	4	days	day	NOUN
dpc-2357	88	5	)	)	PUNCT
dpc-2357	89	1	[	[	X
dpc-2357	89	2	3	3	NUM
dpc-2357	89	3	]	]	PUNCT
dpc-2357	89	4	.	.	PUNCT
dpc-2357	90	1	in	in	ADP
dpc-2357	90	2	addition	addition	NOUN
dpc-2357	90	3	,	,	PUNCT
dpc-2357	90	4	relapse	relapse	NOUN
dpc-2357	90	5	rate	rate	NOUN
dpc-2357	90	6	was	be	AUX
dpc-2357	90	7	lower	low	ADJ
dpc-2357	90	8	for	for	ADP
dpc-2357	90	9	patients	patient	NOUN
dpc-2357	90	10	previously	previously	ADV
dpc-2357	90	11	treated	treat	VERB
dpc-2357	90	12	with	with	ADP
dpc-2357	90	13	ivermectin	ivermectin	NOUN
dpc-2357	90	14	1	1	NUM
dpc-2357	90	15	%	%	NOUN
dpc-2357	90	16	compared	compare	VERB
dpc-2357	90	17	with	with	ADP
dpc-2357	90	18	metronidazole	metronidazole	NOUN
dpc-2357	90	19	0.75	0.75	NUM
dpc-2357	90	20	%	%	NOUN
dpc-2357	90	21	(	(	PUNCT
dpc-2357	90	22	62.7	62.7	NUM
dpc-2357	90	23	%	%	NOUN
dpc-2357	90	24	versus	versus	ADP
dpc-2357	90	25	68.4	68.4	NUM
dpc-2357	90	26	%	%	NOUN
dpc-2357	90	27	)	)	PUNCT
dpc-2357	91	1	[	[	X
dpc-2357	91	2	3	3	NUM
dpc-2357	91	3	]	]	PUNCT
dpc-2357	91	4	.	.	PUNCT
dpc-2357	92	1	dall’oglio	dall’oglio	NOUN
dpc-2357	92	2	found	find	VERB
dpc-2357	92	3	only	only	ADV
dpc-2357	92	4	2/20	2/20	NUM
dpc-2357	92	5	mild	mild	ADJ
dpc-2357	92	6	and	and	CCONJ
dpc-2357	92	7	moderate	moderate	ADJ
dpc-2357	92	8	ppr	ppr	NOUN
dpc-2357	92	9	patients	patient	NOUN
dpc-2357	92	10	that	that	PRON
dpc-2357	92	11	relapsed	relapse	VERB
dpc-2357	92	12	[	[	X
dpc-2357	92	13	12	12	NUM
dpc-2357	92	14	]	]	PUNCT
dpc-2357	92	15	.	.	PUNCT
dpc-2357	93	1	in	in	ADP
dpc-2357	93	2	our	our	PRON
dpc-2357	93	3	study	study	NOUN
dpc-2357	93	4	,	,	PUNCT
dpc-2357	93	5	we	we	PRON
dpc-2357	93	6	found	find	VERB
dpc-2357	93	7	a	a	DET
dpc-2357	93	8	longer	long	ADV
dpc-2357	93	9	median	median	ADJ
dpc-2357	93	10	time	time	NOUN
dpc-2357	93	11	of	of	ADP
dpc-2357	93	12	first	first	ADJ
dpc-2357	93	13	relapse	relapse	NOUN
dpc-2357	93	14	(	(	PUNCT
dpc-2357	93	15	140	140	NUM
dpc-2357	93	16	days	day	NOUN
dpc-2357	93	17	)	)	PUNCT
dpc-2357	93	18	with	with	ADP
dpc-2357	93	19	a	a	DET
dpc-2357	93	20	lower	low	ADJ
dpc-2357	93	21	relapse	relapse	NOUN
dpc-2357	93	22	rate	rate	NOUN
dpc-2357	93	23	(	(	PUNCT
dpc-2357	93	24	45.24	45.24	NUM
dpc-2357	93	25	%	%	NOUN
dpc-2357	93	26	)	)	PUNCT
dpc-2357	93	27	than	than	ADP
dpc-2357	93	28	studies	study	NOUN
dpc-2357	93	29	in	in	ADP
dpc-2357	93	30	the	the	DET
dpc-2357	93	31	literature	literature	NOUN
dpc-2357	93	32	.	.	PUNCT
dpc-2357	94	1	as	as	SCONJ
dpc-2357	94	2	we	we	PRON
dpc-2357	94	3	have	have	AUX
dpc-2357	94	4	just	just	ADV
dpc-2357	94	5	shown	show	VERB
dpc-2357	94	6	,	,	PUNCT
dpc-2357	94	7	relapse	relapse	NOUN
dpc-2357	94	8	rates	rate	NOUN
dpc-2357	94	9	are	be	AUX
dpc-2357	94	10	difficult	difficult	ADJ
dpc-2357	94	11	to	to	PART
dpc-2357	94	12	compare	compare	VERB
dpc-2357	94	13	between	between	ADP
dpc-2357	94	14	different	different	ADJ
dpc-2357	94	15	studies	study	NOUN
dpc-2357	94	16	.	.	PUNCT
dpc-2357	95	1	we	we	PRON
dpc-2357	95	2	suppose	suppose	VERB
dpc-2357	95	3	that	that	SCONJ
dpc-2357	95	4	our	our	PRON
dpc-2357	95	5	results	result	NOUN
dpc-2357	95	6	are	be	AUX
dpc-2357	95	7	better	well	ADJ
dpc-2357	95	8	than	than	ADP
dpc-2357	95	9	those	those	PRON
dpc-2357	95	10	of	of	ADP
dpc-2357	95	11	shaub	shaub	NOUN
dpc-2357	95	12	et	et	NOUN
dpc-2357	95	13	al	al	PROPN
dpc-2357	95	14	because	because	SCONJ
dpc-2357	95	15	we	we	PRON
dpc-2357	95	16	considered	consider	VERB
dpc-2357	95	17	mild	mild	ADJ
dpc-2357	95	18	forms	form	NOUN
dpc-2357	95	19	instead	instead	ADV
dpc-2357	95	20	of	of	ADP
dpc-2357	95	21	moderate	moderate	ADJ
dpc-2357	95	22	-	-	PUNCT
dpc-2357	95	23	severe	severe	ADJ
dpc-2357	95	24	forms	form	NOUN
dpc-2357	95	25	of	of	ADP
dpc-2357	95	26	rosacea	rosacea	PROPN
dpc-2357	95	27	baseline	baseline	PROPN
dpc-2357	96	1	[	[	X
dpc-2357	96	2	3	3	NUM
dpc-2357	96	3	]	]	PUNCT
dpc-2357	96	4	.	.	PUNCT
dpc-2357	97	1	in	in	ADP
dpc-2357	97	2	fact	fact	NOUN
dpc-2357	97	3	,	,	PUNCT
dpc-2357	97	4	patients	patient	NOUN
dpc-2357	97	5	with	with	ADP
dpc-2357	97	6	iga	iga	PROPN
dpc-2357	97	7	3	3	NUM
dpc-2357	97	8	-	-	SYM
dpc-2357	97	9	4	4	NUM
dpc-2357	97	10	rosacea	rosacea	NOUN
dpc-2357	97	11	had	have	VERB
dpc-2357	97	12	higher	high	ADJ
dpc-2357	97	13	number	number	NOUN
dpc-2357	97	14	of	of	ADP
dpc-2357	97	15	inflammatory	inflammatory	ADJ
dpc-2357	97	16	lesions	lesion	NOUN
dpc-2357	97	17	than	than	ADP
dpc-2357	97	18	patients	patient	NOUN
dpc-2357	97	19	with	with	ADP
dpc-2357	97	20	iga	iga	PROPN
dpc-2357	97	21	1	1	NUM
dpc-2357	97	22	-	-	SYM
dpc-2357	97	23	2	2	NUM
dpc-2357	97	24	rosacea	rosacea	NOUN
dpc-2357	97	25	that	that	PRON
dpc-2357	97	26	keep	keep	VERB
dpc-2357	97	27	clinical	clinical	ADJ
dpc-2357	97	28	remission	remission	NOUN
dpc-2357	97	29	for	for	ADP
dpc-2357	97	30	longer	long	ADJ
dpc-2357	97	31	days	day	NOUN
dpc-2357	97	32	.	.	PUNCT
dpc-2357	98	1	moreover	moreover	ADV
dpc-2357	98	2	,	,	PUNCT
dpc-2357	98	3	differences	difference	NOUN
dpc-2357	98	4	among	among	ADP
dpc-2357	98	5	studies	study	NOUN
dpc-2357	98	6	could	could	AUX
dpc-2357	98	7	be	be	AUX
dpc-2357	98	8	justified	justify	VERB
dpc-2357	98	9	by	by	ADP
dpc-2357	98	10	a	a	DET
dpc-2357	98	11	different	different	ADJ
dpc-2357	98	12	definition	definition	NOUN
dpc-2357	98	13	of	of	ADP
dpc-2357	98	14	relapse	relapse	NOUN
dpc-2357	98	15	;	;	PUNCT
dpc-2357	98	16	while	while	SCONJ
dpc-2357	98	17	shaub	shaub	NOUN
dpc-2357	98	18	et	et	NOUN
dpc-2357	98	19	al	al	PROPN
dpc-2357	98	20	considered	consider	VERB
dpc-2357	98	21	a	a	DET
dpc-2357	98	22	relapse	relapse	NOUN
dpc-2357	98	23	as	as	ADP
dpc-2357	98	24	iga	iga	PROPN
dpc-2357	98	25	≥	≥	NUM
dpc-2357	98	26	2	2	NUM
dpc-2357	98	27	we	we	PRON
dpc-2357	98	28	regarded	regard	VERB
dpc-2357	98	29	as	as	ADP
dpc-2357	98	30	iga	iga	PROPN
dpc-2357	98	31	≥	≥	PROPN
dpc-2357	98	32	1	1	NUM
dpc-2357	98	33	ppr	ppr	NOUN
dpc-2357	99	1	[	[	X
dpc-2357	99	2	3	3	NUM
dpc-2357	99	3	]	]	PUNCT
dpc-2357	99	4	.	.	PUNCT
dpc-2357	100	1	this	this	PRON
dpc-2357	100	2	is	be	AUX
dpc-2357	100	3	because	because	SCONJ
dpc-2357	100	4	we	we	PRON
dpc-2357	100	5	take	take	VERB
dpc-2357	100	6	on	on	ADP
dpc-2357	100	7	iga	iga	PROPN
dpc-2357	100	8	=	=	PUNCT
dpc-2357	100	9	0	0	PUNCT
dpc-2357	101	1	as	as	ADP
dpc-2357	101	2	desirable	desirable	ADJ
dpc-2357	101	3	ideal	ideal	ADJ
dpc-2357	101	4	goal	goal	NOUN
dpc-2357	101	5	of	of	ADP
dpc-2357	101	6	maintenance	maintenance	NOUN
dpc-2357	101	7	,	,	PUNCT
dpc-2357	101	8	crucial	crucial	ADJ
dpc-2357	101	9	for	for	ADP
dpc-2357	101	10	patient	patient	NOUN
dpc-2357	101	11	’s	’s	PART
dpc-2357	101	12	outcome	outcome	NOUN
dpc-2357	101	13	and	and	CCONJ
dpc-2357	101	14	for	for	ADP
dpc-2357	101	15	an	an	DET
dpc-2357	101	16	effective	effective	ADJ
dpc-2357	101	17	improvement	improvement	NOUN
dpc-2357	101	18	of	of	ADP
dpc-2357	101	19	his	his	PRON
dpc-2357	101	20	quality	quality	NOUN
dpc-2357	101	21	of	of	ADP
dpc-2357	101	22	life	life	NOUN
dpc-2357	101	23	.	.	PUNCT
dpc-2357	102	1	however	however	ADV
dpc-2357	102	2	,	,	PUNCT
dpc-2357	102	3	patients	patient	NOUN
dpc-2357	102	4	that	that	PRON
dpc-2357	102	5	relapsed	relapse	VERB
dpc-2357	102	6	in	in	ADP
dpc-2357	102	7	our	our	PRON
dpc-2357	102	8	study	study	NOUN
dpc-2357	102	9	showed	show	VERB
dpc-2357	102	10	mainly	mainly	ADV
dpc-2357	102	11	iga	iga	PROPN
dpc-2357	102	12	=	=	SYM
dpc-2357	102	13	1	1	NUM
dpc-2357	102	14	ppr	ppr	NOUN
dpc-2357	102	15	(	(	PUNCT
dpc-2357	102	16	22/27	22/27	NUM
dpc-2357	102	17	)	)	PUNCT
dpc-2357	102	18	without	without	ADP
dpc-2357	102	19	serious	serious	ADJ
dpc-2357	102	20	cases	case	NOUN
dpc-2357	102	21	after	after	ADP
dpc-2357	102	22	suspension	suspension	NOUN
dpc-2357	102	23	of	of	ADP
dpc-2357	102	24	therapy	therapy	NOUN
dpc-2357	102	25	.	.	PUNCT
dpc-2357	103	1	finally	finally	ADV
dpc-2357	103	2	,	,	PUNCT
dpc-2357	103	3	the	the	DET
dpc-2357	103	4	difficulties	difficulty	NOUN
dpc-2357	103	5	may	may	AUX
dpc-2357	103	6	also	also	ADV
dpc-2357	103	7	be	be	AUX
dpc-2357	103	8	due	due	ADJ
dpc-2357	103	9	to	to	ADP
dpc-2357	103	10	the	the	DET
dpc-2357	103	11	different	different	ADJ
dpc-2357	103	12	follow	follow	NOUN
dpc-2357	103	13	-	-	PUNCT
dpc-2357	103	14	up	up	ADP
dpc-2357	103	15	periods	period	NOUN
dpc-2357	103	16	.	.	PUNCT
dpc-2357	104	1	in	in	ADP
dpc-2357	104	2	fact	fact	NOUN
dpc-2357	104	3	,	,	PUNCT
dpc-2357	104	4	while	while	SCONJ
dpc-2357	104	5	we	we	PRON
dpc-2357	104	6	tracked	track	VERB
dpc-2357	104	7	our	our	PRON
dpc-2357	104	8	patients	patient	NOUN
dpc-2357	104	9	for	for	ADP
dpc-2357	104	10	32	32	NUM
dpc-2357	104	11	weeks	week	NOUN
dpc-2357	104	12	,	,	PUNCT
dpc-2357	104	13	shaub	shaub	NOUN
dpc-2357	104	14	et	et	NOUN
dpc-2357	104	15	al	al	PROPN
dpc-2357	104	16	followed	follow	VERB
dpc-2357	104	17	them	they	PRON
dpc-2357	104	18	for	for	ADP
dpc-2357	104	19	36	36	NUM
dpc-2357	104	20	weeks	week	NOUN
dpc-2357	104	21	and	and	CCONJ
dpc-2357	104	22	dall’oglio	dall’oglio	VERB
dpc-2357	104	23	]	]	PUNCT
dpc-2357	104	24	for	for	ADP
dpc-2357	104	25	12	12	NUM
dpc-2357	104	26	-	-	PUNCT
dpc-2357	104	27	to-24	to-24	NOUN
dpc-2357	104	28	weeks	week	NOUN
dpc-2357	104	29	after	after	ADP
dpc-2357	104	30	treatment	treatment	NOUN
dpc-2357	104	31	:	:	PUNCT
dpc-2357	104	32	a	a	DET
dpc-2357	104	33	longer	long	ADV
dpc-2357	104	34	follow	follow	VERB
dpc-2357	104	35	-	-	PUNCT
dpc-2357	104	36	up	up	ADP
dpc-2357	104	37	periods	period	NOUN
dpc-2357	104	38	correspond	correspond	VERB
dpc-2357	104	39	to	to	ADP
dpc-2357	104	40	higher	high	ADJ
dpc-2357	104	41	probability	probability	NOUN
dpc-2357	104	42	of	of	ADP
dpc-2357	104	43	relapse	relapse	NOUN
dpc-2357	105	1	[	[	X
dpc-2357	105	2	3,12	3,12	NUM
dpc-2357	105	3	]	]	PUNCT
dpc-2357	105	4	.	.	PUNCT
dpc-2357	106	1	since	since	SCONJ
dpc-2357	106	2	our	our	PRON
dpc-2357	106	3	results	result	NOUN
dpc-2357	106	4	,	,	PUNCT
dpc-2357	106	5	ivermectin	ivermectin	NOUN
dpc-2357	106	6	work	work	VERB
dpc-2357	106	7	with	with	ADP
dpc-2357	106	8	an	an	DET
dpc-2357	106	9	anti	anti	ADJ
dpc-2357	106	10	-	-	ADJ
dpc-2357	106	11	parasitic	parasitic	ADJ
dpc-2357	106	12	effect	effect	NOUN
dpc-2357	106	13	in	in	ADP
dpc-2357	106	14	demodex	demodex	NOUN
dpc-2357	106	15	positive	positive	ADJ
dpc-2357	106	16	pprs	pprs	ADJ
dpc-2357	106	17	eliminating	eliminating	NOUN
dpc-2357	106	18	mites	mite	NOUN
dpc-2357	106	19	as	as	ADP
dpc-2357	106	20	cause	cause	NOUN
dpc-2357	106	21	of	of	ADP
dpc-2357	106	22	inflammation	inflammation	NOUN
dpc-2357	106	23	and	and	CCONJ
dpc-2357	106	24	enabling	enable	VERB
dpc-2357	106	25	a	a	DET
dpc-2357	106	26	long	long	ADJ
dpc-2357	106	27	remission	remission	NOUN
dpc-2357	106	28	of	of	ADP
dpc-2357	106	29	ppr	ppr	NOUN
dpc-2357	106	30	with	with	ADP
dpc-2357	106	31	a	a	DET
dpc-2357	106	32	low	low	ADJ
dpc-2357	106	33	conclusions	conclusion	NOUN
dpc-2357	106	34	similarly	similarly	ADV
dpc-2357	106	35	,	,	PUNCT
dpc-2357	106	36	to	to	ADP
dpc-2357	106	37	previous	previous	ADJ
dpc-2357	106	38	study	study	NOUN
dpc-2357	106	39	,	,	PUNCT
dpc-2357	106	40	we	we	PRON
dpc-2357	106	41	found	find	VERB
dpc-2357	106	42	33	33	NUM
dpc-2357	106	43	%	%	NOUN
dpc-2357	106	44	of	of	ADP
dpc-2357	106	45	demodex	demodex	NOUN
dpc-2357	106	46	positive	positive	ADJ
dpc-2357	106	47	samples	sample	NOUN
dpc-2357	106	48	at	at	ADP
dpc-2357	106	49	baseline	baseline	NOUN
dpc-2357	106	50	[	[	X
dpc-2357	106	51	7	7	NUM
dpc-2357	106	52	]	]	PUNCT
dpc-2357	106	53	.	.	PUNCT
dpc-2357	107	1	the	the	DET
dpc-2357	107	2	great	great	ADJ
dpc-2357	107	3	anti	anti	ADJ
dpc-2357	107	4	-	-	ADJ
dpc-2357	107	5	parasitic	parasitic	ADJ
dpc-2357	107	6	effect	effect	NOUN
dpc-2357	107	7	of	of	ADP
dpc-2357	107	8	ivermectin	ivermectin	NOUN
dpc-2357	107	9	was	be	AUX
dpc-2357	107	10	confirmed	confirm	VERB
dpc-2357	107	11	by	by	ADP
dpc-2357	107	12	the	the	DET
dpc-2357	107	13	overall	overall	ADJ
dpc-2357	107	14	success	success	NOUN
dpc-2357	107	15	rate	rate	NOUN
dpc-2357	107	16	of	of	ADP
dpc-2357	107	17	demodex	demodex	NOUN
dpc-2357	107	18	infestation	infestation	NOUN
dpc-2357	107	19	(	(	PUNCT
dpc-2357	107	20	87.5	87.5	NUM
dpc-2357	107	21	%	%	NOUN
dpc-2357	107	22	)	)	PUNCT
dpc-2357	107	23	.	.	PUNCT
dpc-2357	108	1	in	in	ADP
dpc-2357	108	2	the	the	DET
dpc-2357	108	3	literature	literature	NOUN
dpc-2357	108	4	,	,	PUNCT
dpc-2357	108	5	there	there	PRON
dpc-2357	108	6	are	be	VERB
dpc-2357	108	7	not	not	PART
dpc-2357	108	8	studies	study	NOUN
dpc-2357	108	9	that	that	PRON
dpc-2357	108	10	consider	consider	VERB
dpc-2357	108	11	the	the	DET
dpc-2357	108	12	time	time	NOUN
dpc-2357	108	13	of	of	ADP
dpc-2357	108	14	relapse	relapse	NOUN
dpc-2357	108	15	and	and	CCONJ
dpc-2357	108	16	relapse	relapse	NOUN
dpc-2357	108	17	rates	rate	NOUN
dpc-2357	108	18	of	of	ADP
dpc-2357	108	19	demodex	demodex	NOUN
dpc-2357	108	20	mite	mite	NOUN
dpc-2357	108	21	infestation	infestation	NOUN
dpc-2357	108	22	in	in	ADP
dpc-2357	108	23	patients	patient	NOUN
dpc-2357	108	24	affected	affect	VERB
dpc-2357	108	25	by	by	ADP
dpc-2357	108	26	rosacea	rosacea	NOUN
dpc-2357	108	27	and	and	CCONJ
dpc-2357	108	28	treated	treat	VERB
dpc-2357	108	29	with	with	ADP
dpc-2357	108	30	ivermectin	ivermectin	NOUN
dpc-2357	108	31	.	.	PUNCT
dpc-2357	109	1	in	in	ADP
dpc-2357	109	2	our	our	PRON
dpc-2357	109	3	study	study	NOUN
dpc-2357	109	4	,	,	PUNCT
dpc-2357	109	5	we	we	PRON
dpc-2357	109	6	observed	observe	VERB
dpc-2357	109	7	a	a	DET
dpc-2357	109	8	low	low	ADJ
dpc-2357	109	9	relapse	relapse	NOUN
dpc-2357	109	10	rate	rate	NOUN
dpc-2357	109	11	of	of	ADP
dpc-2357	109	12	demodex	demodex	NOUN
dpc-2357	109	13	mite	mite	NOUN
dpc-2357	109	14	infestation	infestation	NOUN
dpc-2357	109	15	(	(	PUNCT
dpc-2357	109	16	12.5	12.5	NUM
dpc-2357	109	17	%	%	NOUN
dpc-2357	109	18	)	)	PUNCT
dpc-2357	109	19	in	in	ADP
dpc-2357	109	20	ppr	ppr	NOUN
dpc-2357	109	21	showing	show	VERB
dpc-2357	109	22	as	as	SCONJ
dpc-2357	109	23	ivermectin	ivermectin	NOUN
dpc-2357	109	24	has	have	VERB
dpc-2357	109	25	an	an	DET
dpc-2357	109	26	excellent	excellent	ADJ
dpc-2357	109	27	antiparasitic	antiparasitic	ADJ
dpc-2357	109	28	effect	effect	NOUN
dpc-2357	109	29	that	that	PRON
dpc-2357	109	30	last	last	ADJ
dpc-2357	109	31	over	over	ADP
dpc-2357	109	32	time	time	NOUN
dpc-2357	109	33	.	.	PUNCT
dpc-2357	110	1	it	it	PRON
dpc-2357	110	2	acts	act	VERB
dpc-2357	110	3	by	by	ADP
dpc-2357	110	4	blocking	block	VERB
dpc-2357	110	5	ligand	ligand	NOUN
dpc-2357	110	6	-	-	PUNCT
dpc-2357	110	7	gated	gate	VERB
dpc-2357	110	8	chloride	chloride	NOUN
dpc-2357	110	9	channels	channel	NOUN
dpc-2357	110	10	,	,	PUNCT
dpc-2357	110	11	especially	especially	ADV
dpc-2357	110	12	glutamate	glutamate	NOUN
dpc-2357	110	13	-	-	PUNCT
dpc-2357	110	14	gated	gate	VERB
dpc-2357	110	15	anion	anion	NOUN
dpc-2357	110	16	channels	channel	NOUN
dpc-2357	110	17	in	in	ADP
dpc-2357	110	18	the	the	DET
dpc-2357	110	19	peripheral	peripheral	ADJ
dpc-2357	110	20	nervous	nervous	ADJ
dpc-2357	110	21	system	system	NOUN
dpc-2357	110	22	of	of	ADP
dpc-2357	110	23	demodex	demodex	NOUN
dpc-2357	110	24	mites	mite	NOUN
dpc-2357	110	25	causing	cause	VERB
dpc-2357	110	26	their	their	PRON
dpc-2357	110	27	paralysis	paralysis	NOUN
dpc-2357	110	28	and	and	CCONJ
dpc-2357	110	29	death	death	NOUN
dpc-2357	111	1	[	[	X
dpc-2357	111	2	16	16	NUM
dpc-2357	111	3	]	]	PUNCT
dpc-2357	111	4	.	.	PUNCT
dpc-2357	112	1	the	the	DET
dpc-2357	112	2	two	two	NUM
dpc-2357	112	3	patients	patient	NOUN
dpc-2357	112	4	that	that	PRON
dpc-2357	112	5	showed	show	VERB
dpc-2357	112	6	a	a	DET
dpc-2357	112	7	relapse	relapse	NOUN
dpc-2357	112	8	of	of	ADP
dpc-2357	112	9	demodex	demodex	NOUN
dpc-2357	112	10	mite	mite	PROPN
dpc-2357	112	11	infestation	infestation	NOUN
dpc-2357	112	12	presented	present	VERB
dpc-2357	112	13	an	an	DET
dpc-2357	112	14	erythemato	erythemato	NOUN
dpc-2357	112	15	-	-	PUNCT
dpc-2357	112	16	telangiectatic	telangiectatic	ADJ
dpc-2357	112	17	rosacea	rosacea	NOUN
dpc-2357	112	18	(	(	PUNCT
dpc-2357	112	19	etr	etr	PROPN
dpc-2357	112	20	)	)	PUNCT
dpc-2357	112	21	with	with	ADP
dpc-2357	112	22	few	few	ADJ
dpc-2357	112	23	papules	papule	NOUN
dpc-2357	112	24	(	(	PUNCT
dpc-2357	112	25	figure	figure	NOUN
dpc-2357	112	26	2	2	NUM
dpc-2357	112	27	)	)	PUNCT
dpc-2357	112	28	.	.	PUNCT
dpc-2357	113	1	this	this	DET
dpc-2357	113	2	result	result	NOUN
dpc-2357	113	3	is	be	AUX
dpc-2357	113	4	according	accord	VERB
dpc-2357	113	5	to	to	ADP
dpc-2357	113	6	the	the	DET
dpc-2357	113	7	hypothesis	hypothesis	NOUN
dpc-2357	113	8	that	that	PRON
dpc-2357	113	9	etr	etr	PROPN
dpc-2357	113	10	may	may	AUX
dpc-2357	113	11	be	be	AUX
dpc-2357	113	12	associated	associate	VERB
dpc-2357	113	13	with	with	ADP
dpc-2357	113	14	non	non	ADJ
dpc-2357	113	15	-	-	ADJ
dpc-2357	113	16	visible	visible	ADJ
dpc-2357	113	17	demodex	demodex	NOUN
dpc-2357	113	18	proliferation	proliferation	NOUN
dpc-2357	113	19	,	,	PUNCT
dpc-2357	113	20	possibly	possibly	ADV
dpc-2357	113	21	corresponding	correspond	VERB
dpc-2357	113	22	to	to	ADP
dpc-2357	113	23	a	a	DET
dpc-2357	113	24	subclinical	subclinical	ADJ
dpc-2357	113	25	stage	stage	NOUN
dpc-2357	113	26	of	of	ADP
dpc-2357	113	27	demodicosis	demodicosis	NOUN
dpc-2357	113	28	[	[	X
dpc-2357	113	29	17	17	NUM
dpc-2357	113	30	-	-	SYM
dpc-2357	113	31	19	19	NUM
dpc-2357	113	32	]	]	PUNCT
dpc-2357	113	33	.	.	PUNCT
dpc-2357	114	1	few	few	ADJ
dpc-2357	114	2	papules	papule	NOUN
dpc-2357	114	3	may	may	AUX
dpc-2357	114	4	be	be	AUX
dpc-2357	114	5	an	an	DET
dpc-2357	114	6	early	early	ADJ
dpc-2357	114	7	sign	sign	NOUN
dpc-2357	114	8	of	of	ADP
dpc-2357	114	9	relapsed	relapse	VERB
dpc-2357	114	10	demodex	demodex	NOUN
dpc-2357	114	11	mite	mite	NOUN
dpc-2357	114	12	proliferation	proliferation	NOUN
dpc-2357	114	13	[	[	X
dpc-2357	114	14	20	20	NUM
dpc-2357	114	15	]	]	PUNCT
dpc-2357	114	16	.	.	PUNCT
dpc-2357	115	1	our	our	PRON
dpc-2357	115	2	study	study	NOUN
dpc-2357	115	3	confirms	confirm	VERB
dpc-2357	115	4	the	the	DET
dpc-2357	115	5	efficacy	efficacy	NOUN
dpc-2357	115	6	of	of	ADP
dpc-2357	115	7	ivermectin	ivermectin	NOUN
dpc-2357	115	8	1	1	NUM
dpc-2357	115	9	%	%	NOUN
dpc-2357	115	10	cream	cream	NOUN
dpc-2357	115	11	leading	lead	VERB
dpc-2357	115	12	to	to	ADP
dpc-2357	115	13	complete	complete	ADJ
dpc-2357	115	14	response	response	NOUN
dpc-2357	115	15	in	in	ADP
dpc-2357	115	16	70	70	NUM
dpc-2357	115	17	%	%	NOUN
dpc-2357	115	18	of	of	ADP
dpc-2357	115	19	almost	almost	ADV
dpc-2357	115	20	clear	clear	ADJ
dpc-2357	115	21	,	,	PUNCT
dpc-2357	115	22	mild	mild	ADJ
dpc-2357	115	23	and	and	CCONJ
dpc-2357	115	24	moderate	moderate	ADJ
dpc-2357	115	25	ppr	ppr	NOUN
dpc-2357	115	26	after	after	ADP
dpc-2357	115	27	16	16	NUM
dpc-2357	115	28	weeks	week	NOUN
dpc-2357	115	29	of	of	ADP
dpc-2357	115	30	therapy	therapy	NOUN
dpc-2357	115	31	.	.	PUNCT
dpc-2357	116	1	regarding	regard	VERB
dpc-2357	116	2	relapses	relapse	NOUN
dpc-2357	116	3	in	in	ADP
dpc-2357	116	4	patients	patient	NOUN
dpc-2357	116	5	with	with	ADP
dpc-2357	116	6	rosacea	rosacea	NOUN
dpc-2357	116	7	,	,	PUNCT
dpc-2357	116	8	a	a	DET
dpc-2357	116	9	study	study	NOUN
dpc-2357	116	10	from	from	ADP
dpc-2357	116	11	2016	2016	NUM
dpc-2357	116	12	showing	show	VERB
dpc-2357	116	13	that	that	SCONJ
dpc-2357	116	14	patients	patient	NOUN
dpc-2357	116	15	affected	affect	VERB
dpc-2357	116	16	by	by	ADP
dpc-2357	116	17	moderate	moderate	ADJ
dpc-2357	116	18	-	-	PUNCT
dpc-2357	116	19	severe	severe	ADJ
dpc-2357	116	20	rosacea	rosacea	NOUN
dpc-2357	116	21	and	and	CCONJ
dpc-2357	116	22	treated	treat	VERB
dpc-2357	116	23	with	with	ADP
dpc-2357	116	24	ivermectin	ivermectin	NOUN
dpc-2357	116	25	had	have	VERB
dpc-2357	116	26	median	median	ADJ
dpc-2357	116	27	times	time	NOUN
dpc-2357	116	28	of	of	ADP
dpc-2357	116	29	first	first	ADJ
dpc-2357	116	30	relapse	relapse	NOUN
dpc-2357	116	31	significantly	significantly	ADV
dpc-2357	116	32	longer	long	ADV
dpc-2357	116	33	than	than	ADP
dpc-2357	116	34	those	those	PRON
dpc-2357	116	35	treated	treat	VERB
dpc-2357	116	36	with	with	ADP
dpc-2357	116	37	metronidazole	metronidazole	NOUN
dpc-2357	116	38	0.75	0.75	NUM
dpc-2357	116	39	%	%	NOUN
dpc-2357	116	40	cream	cream	NOUN
dpc-2357	116	41	(	(	PUNCT
dpc-2357	116	42	115	115	NUM
dpc-2357	116	43	days	day	NOUN
dpc-2357	116	44	figure	figure	NOUN
dpc-2357	116	45	2	2	NUM
dpc-2357	116	46	.	.	PUNCT
dpc-2357	116	47	relapse	relapse	NOUN
dpc-2357	116	48	of	of	ADP
dpc-2357	116	49	erythemato	erythemato	NOUN
dpc-2357	116	50	-	-	PUNCT
dpc-2357	116	51	telangiectatic	telangiectatic	ADJ
dpc-2357	116	52	after	after	ADP
dpc-2357	116	53	224	224	NUM
dpc-2357	116	54	days	day	NOUN
dpc-2357	116	55	of	of	ADP
dpc-2357	116	56	suspension	suspension	NOUN
dpc-2357	116	57	of	of	ADP
dpc-2357	116	58	therapy	therapy	NOUN
dpc-2357	116	59	.	.	PUNCT
dpc-2357	117	1	original	original	ADJ
dpc-2357	117	2	article	article	NOUN
dpc-2357	117	3	|	|	ADV
dpc-2357	117	4	dermatol	dermatol	ADJ
dpc-2357	117	5	pract	pract	NOUN
dpc-2357	117	6	concept	concept	NOUN
dpc-2357	117	7	.	.	PUNCT
dpc-2357	118	1	2022;12(4):e2022201	2022;12(4):e2022201	NUM
dpc-2357	118	2	5	5	NUM
dpc-2357	118	3	risk	risk	NOUN
dpc-2357	118	4	of	of	ADP
dpc-2357	118	5	relapse	relapse	NOUN
dpc-2357	118	6	.	.	PUNCT
dpc-2357	119	1	in	in	ADP
dpc-2357	119	2	addition	addition	NOUN
dpc-2357	119	3	,	,	PUNCT
dpc-2357	119	4	ivermectin	ivermectin	NOUN
dpc-2357	119	5	acts	act	VERB
dpc-2357	119	6	as	as	ADP
dpc-2357	119	7	anti	anti	ADJ
dpc-2357	119	8	-	-	ADJ
dpc-2357	119	9	inflammatory	inflammatory	ADJ
dpc-2357	119	10	drug	drug	NOUN
dpc-2357	119	11	inducing	induce	VERB
dpc-2357	119	12	a	a	DET
dpc-2357	119	13	downregulation	downregulation	NOUN
dpc-2357	119	14	of	of	ADP
dpc-2357	119	15	the	the	DET
dpc-2357	119	16	pro	pro	ADJ
dpc-2357	119	17	-	-	ADJ
dpc-2357	119	18	inflammatory	inflammatory	ADJ
dpc-2357	119	19	genes	gene	NOUN
dpc-2357	119	20	il-8	il-8	VERB
dpc-2357	119	21	,	,	PUNCT
dpc-2357	119	22	human	human	ADJ
dpc-2357	119	23	ß	ß	X
dpc-2357	119	24	-	-	PROPN
dpc-2357	119	25	defensin-3	defensin-3	PROPN
dpc-2357	119	26	(	(	PUNCT
dpc-2357	119	27	hbd3	hbd3	PROPN
dpc-2357	119	28	)	)	PUNCT
dpc-2357	119	29	,	,	PUNCT
dpc-2357	119	30	toll	toll	NOUN
dpc-2357	119	31	-	-	PUNCT
dpc-2357	119	32	like	like	ADJ
dpc-2357	119	33	receptor-4	receptor-4	PROPN
dpc-2357	119	34	(	(	PUNCT
dpc-2357	119	35	tlr4	tlr4	NOUN
dpc-2357	119	36	)	)	PUNCT
dpc-2357	119	37	,	,	PUNCT
dpc-2357	119	38	and	and	CCONJ
dpc-2357	119	39	tumor	tumor	NOUN
dpc-2357	119	40	necrotic	necrotic	ADJ
dpc-2357	119	41	factor	factor	NOUN
dpc-2357	119	42	-	-	PUNCT
dpc-2357	119	43	alpha	alpha	NOUN
dpc-2357	119	44	(	(	PUNCT
dpc-2357	119	45	tnf	tnf	PROPN
dpc-2357	119	46	-	-	PUNCT
dpc-2357	119	47	α	α	NOUN
dpc-2357	119	48	)	)	PUNCT
dpc-2357	120	1	[	[	X
dpc-2357	120	2	21	21	NUM
dpc-2357	120	3	]	]	PUNCT
dpc-2357	120	4	,	,	PUNCT
dpc-2357	120	5	and	and	CCONJ
dpc-2357	120	6	by	by	ADP
dpc-2357	120	7	an	an	DET
dpc-2357	120	8	inhibition	inhibition	NOUN
dpc-2357	120	9	of	of	ADP
dpc-2357	120	10	cathelicidin	cathelicidin	VERB
dpc-2357	120	11	innate	innate	ADJ
dpc-2357	120	12	immune	immune	ADJ
dpc-2357	120	13	mediators	mediator	NOUN
dpc-2357	120	14	,	,	PUNCT
dpc-2357	120	15	ll-3720	ll-3720	NOUN
dpc-2357	120	16	21	21	NUM
dpc-2357	120	17	and	and	CCONJ
dpc-2357	120	18	kallikrein-5	kallikrein-5	PROPN
dpc-2357	120	19	(	(	PUNCT
dpc-2357	120	20	klk5	klk5	PROPN
dpc-2357	120	21	)	)	PUNCT
dpc-2357	120	22	in	in	ADP
dpc-2357	120	23	demodex	demodex	NOUN
dpc-2357	120	24	positive	positive	ADJ
dpc-2357	120	25	and	and	CCONJ
dpc-2357	120	26	negative	negative	ADJ
dpc-2357	120	27	pprs	pprs	ADJ
dpc-2357	121	1	[	[	X
dpc-2357	121	2	21,22	21,22	NOUN
dpc-2357	121	3	]	]	X
dpc-2357	121	4	.	.	PUNCT
dpc-2357	122	1	we	we	PRON
dpc-2357	122	2	propose	propose	VERB
dpc-2357	122	3	to	to	PART
dpc-2357	122	4	keep	keep	VERB
dpc-2357	122	5	a	a	DET
dpc-2357	122	6	twice	twice	ADJ
dpc-2357	122	7	-	-	PUNCT
dpc-2357	122	8	weekly	weekly	ADJ
dpc-2357	122	9	ivermectin	ivermectin	NOUN
dpc-2357	122	10	maintenance	maintenance	NOUN
dpc-2357	122	11	therapy	therapy	NOUN
dpc-2357	122	12	to	to	PART
dpc-2357	122	13	reduce	reduce	VERB
dpc-2357	122	14	relapses	relapse	NOUN
dpc-2357	122	15	,	,	PUNCT
dpc-2357	122	16	especially	especially	ADV
dpc-2357	122	17	in	in	ADP
dpc-2357	122	18	demodex	demodex	NOUN
dpc-2357	122	19	negative	negative	ADJ
dpc-2357	122	20	rosacea	rosacea	NOUN
dpc-2357	122	21	where	where	SCONJ
dpc-2357	122	22	ivermectin	ivermectin	NOUN
dpc-2357	122	23	only	only	ADV
dpc-2357	122	24	holds	hold	VERB
dpc-2357	122	25	an	an	DET
dpc-2357	122	26	anti	anti	ADJ
dpc-2357	122	27	-	-	ADJ
dpc-2357	122	28	inflammatory	inflammatory	ADJ
dpc-2357	122	29	effect	effect	NOUN
dpc-2357	122	30	.	.	PUNCT
dpc-2357	123	1	however	however	ADV
dpc-2357	123	2	,	,	PUNCT
dpc-2357	123	3	further	further	ADJ
dpc-2357	123	4	studies	study	NOUN
dpc-2357	123	5	are	be	AUX
dpc-2357	123	6	needed	need	VERB
dpc-2357	123	7	to	to	PART
dpc-2357	123	8	evaluate	evaluate	VERB
dpc-2357	123	9	the	the	DET
dpc-2357	123	10	efficacy	efficacy	NOUN
dpc-2357	123	11	of	of	ADP
dpc-2357	123	12	maintenance	maintenance	NOUN
dpc-2357	123	13	therapy	therapy	NOUN
dpc-2357	123	14	in	in	ADP
dpc-2357	123	15	patients	patient	NOUN
dpc-2357	123	16	treated	treat	VERB
dpc-2357	123	17	with	with	ADP
dpc-2357	123	18	ivermectin	ivermectin	NOUN
dpc-2357	123	19	.	.	PUNCT
dpc-2357	124	1	our	our	PRON
dpc-2357	124	2	study	study	NOUN
dpc-2357	124	3	has	have	VERB
dpc-2357	124	4	different	different	ADJ
dpc-2357	124	5	limitations	limitation	NOUN
dpc-2357	124	6	:	:	PUNCT
dpc-2357	124	7	we	we	PRON
dpc-2357	124	8	did	do	AUX
dpc-2357	124	9	not	not	PART
dpc-2357	124	10	have	have	VERB
dpc-2357	124	11	patients	patient	NOUN
dpc-2357	124	12	with	with	ADP
dpc-2357	124	13	severe	severe	ADJ
dpc-2357	124	14	rosacea	rosacea	NOUN
dpc-2357	124	15	and	and	CCONJ
dpc-2357	124	16	we	we	PRON
dpc-2357	124	17	did	do	AUX
dpc-2357	124	18	not	not	PART
dpc-2357	124	19	evaluated	evaluate	VERB
dpc-2357	124	20	patients	patient	NOUN
dpc-2357	124	21	with	with	ADP
dpc-2357	124	22	object	object	NOUN
dpc-2357	124	23	instruments	instrument	NOUN
dpc-2357	124	24	like	like	ADP
dpc-2357	124	25	erythema	erythema	ADV
dpc-2357	124	26	-	-	PUNCT
dpc-2357	124	27	directed	direct	VERB
dpc-2357	124	28	digital	digital	ADJ
dpc-2357	124	29	photography	photography	NOUN
dpc-2357	124	30	.	.	PUNCT
dpc-2357	125	1	in	in	ADP
dpc-2357	125	2	conclusion	conclusion	NOUN
dpc-2357	125	3	,	,	PUNCT
dpc-2357	125	4	we	we	PRON
dpc-2357	125	5	confirm	confirm	VERB
dpc-2357	125	6	the	the	DET
dpc-2357	125	7	anti	anti	ADJ
dpc-2357	125	8	-	-	ADJ
dpc-2357	125	9	parasitic	parasitic	ADJ
dpc-2357	125	10	effect	effect	NOUN
dpc-2357	125	11	over	over	ADP
dpc-2357	125	12	time	time	NOUN
dpc-2357	125	13	of	of	ADP
dpc-2357	125	14	ivermectin	ivermectin	NOUN
dpc-2357	125	15	in	in	ADP
dpc-2357	125	16	ppr	ppr	NOUN
dpc-2357	125	17	after	after	ADP
dpc-2357	125	18	cessation	cessation	NOUN
dpc-2357	125	19	of	of	ADP
dpc-2357	125	20	the	the	DET
dpc-2357	125	21	treatment	treatment	NOUN
dpc-2357	125	22	.	.	PUNCT
dpc-2357	126	1	in	in	ADP
dpc-2357	126	2	addition	addition	NOUN
dpc-2357	126	3	,	,	PUNCT
dpc-2357	126	4	we	we	PRON
dpc-2357	126	5	demonstrate	demonstrate	VERB
dpc-2357	126	6	an	an	DET
dpc-2357	126	7	extended	extended	ADJ
dpc-2357	126	8	clinical	clinical	ADJ
dpc-2357	126	9	remission	remission	NOUN
dpc-2357	126	10	of	of	ADP
dpc-2357	126	11	ppr	ppr	NOUN
dpc-2357	126	12	and	and	CCONJ
dpc-2357	126	13	we	we	PRON
dpc-2357	126	14	propose	propose	VERB
dpc-2357	126	15	a	a	DET
dpc-2357	126	16	twice	twice	ADJ
dpc-2357	126	17	-	-	PUNCT
dpc-2357	126	18	weekly	weekly	ADJ
dpc-2357	126	19	ivermectin	ivermectin	NOUN
dpc-2357	126	20	maintenance	maintenance	NOUN
dpc-2357	126	21	therapy	therapy	NOUN
dpc-2357	126	22	to	to	PART
dpc-2357	126	23	reduce	reduce	VERB
dpc-2357	126	24	clinical	clinical	ADJ
dpc-2357	126	25	recurrences	recurrence	NOUN
dpc-2357	126	26	.	.	PUNCT
dpc-2357	127	1	references	reference	NOUN
dpc-2357	127	2	1	1	NUM
dpc-2357	127	3	.	.	PUNCT
dpc-2357	128	1	van	van	PROPN
dpc-2357	128	2	zuuren	zuuren	PROPN
dpc-2357	128	3	ej	ej	PROPN
dpc-2357	128	4	.	.	PROPN
dpc-2357	128	5	rosacea	rosacea	PROPN
dpc-2357	128	6	.	.	PUNCT
dpc-2357	129	1	n	n	PROPN
dpc-2357	129	2	engl	engl	PROPN
dpc-2357	129	3	j	j	PROPN
dpc-2357	129	4	med	med	PROPN
dpc-2357	129	5	.	.	PUNCT
dpc-2357	130	1	2017;377(18):17541764	2017;377(18):17541764	X
dpc-2357	130	2	.	.	PUNCT
dpc-2357	131	1	doi	doi	NOUN
dpc-2357	131	2	:	:	PUNCT
dpc-2357	131	3	10.1056	10.1056	NUM
dpc-2357	131	4	/	/	SYM
dpc-2357	131	5	nejmcp1506630	nejmcp1506630	PROPN
dpc-2357	131	6	.	.	PUNCT
dpc-2357	132	1	pmid	pmid	NOUN
dpc-2357	132	2	:	:	PUNCT
dpc-2357	132	3	29091565	29091565	NUM
dpc-2357	132	4	.	.	PUNCT
dpc-2357	133	1	2	2	X
dpc-2357	133	2	.	.	X
dpc-2357	133	3	wilkin	wilkin	PROPN
dpc-2357	133	4	j	j	PROPN
dpc-2357	133	5	,	,	PUNCT
dpc-2357	133	6	dahl	dahl	PROPN
dpc-2357	133	7	m	m	PROPN
dpc-2357	133	8	,	,	PUNCT
dpc-2357	133	9	detmar	detmar	PROPN
dpc-2357	133	10	m	m	PROPN
dpc-2357	133	11	,	,	PUNCT
dpc-2357	133	12	et	et	PROPN
dpc-2357	133	13	al	al	PROPN
dpc-2357	133	14	.	.	PROPN
dpc-2357	133	15	standard	standard	ADJ
dpc-2357	133	16	classification	classification	NOUN
dpc-2357	133	17	of	of	ADP
dpc-2357	133	18	rosacea	rosacea	NOUN
dpc-2357	133	19	:	:	PUNCT
dpc-2357	133	20	report	report	NOUN
dpc-2357	133	21	of	of	ADP
dpc-2357	133	22	the	the	DET
dpc-2357	133	23	national	national	PROPN
dpc-2357	133	24	rosacea	rosacea	PROPN
dpc-2357	133	25	society	society	PROPN
dpc-2357	133	26	expert	expert	PROPN
dpc-2357	133	27	committee	committee	PROPN
dpc-2357	133	28	on	on	ADP
dpc-2357	133	29	the	the	DET
dpc-2357	133	30	classification	classification	NOUN
dpc-2357	133	31	and	and	CCONJ
dpc-2357	133	32	staging	staging	NOUN
dpc-2357	133	33	of	of	ADP
dpc-2357	133	34	rosacea	rosacea	NOUN
dpc-2357	133	35	.	.	PUNCT
dpc-2357	134	1	j	j	PROPN
dpc-2357	134	2	am	be	AUX
dpc-2357	134	3	acad	acad	ADJ
dpc-2357	134	4	dermatol	dermatol	NOUN
dpc-2357	134	5	.	.	PUNCT
dpc-2357	135	1	2002;46(4):584	2002;46(4):584	NUM
dpc-2357	135	2	-	-	SYM
dpc-2357	135	3	587	587	NUM
dpc-2357	135	4	.	.	PUNCT
dpc-2357	136	1	doi	doi	NOUN
dpc-2357	136	2	:	:	PUNCT
dpc-2357	136	3	10.1067	10.1067	NUM
dpc-2357	136	4	/	/	SYM
dpc-2357	136	5	mjd.2002.120625	mjd.2002.120625	NUM
dpc-2357	136	6	.	.	PUNCT
dpc-2357	137	1	pmid	pmid	NOUN
dpc-2357	137	2	:	:	PUNCT
dpc-2357	137	3	11907512	11907512	NUM
dpc-2357	137	4	.	.	PUNCT
dpc-2357	138	1	3	3	X
dpc-2357	138	2	.	.	X
dpc-2357	138	3	taieb	taieb	PROPN
dpc-2357	138	4	a	a	DET
dpc-2357	138	5	,	,	PUNCT
dpc-2357	138	6	khemis	khemis	PROPN
dpc-2357	138	7	a	a	X
dpc-2357	138	8	,	,	PUNCT
dpc-2357	138	9	ruzicka	ruzicka	PROPN
dpc-2357	138	10	t	t	PROPN
dpc-2357	138	11	,	,	PUNCT
dpc-2357	138	12	et	et	PROPN
dpc-2357	138	13	al	al	PROPN
dpc-2357	138	14	.	.	PUNCT
dpc-2357	138	15	ivermectin	ivermectin	PROPN
dpc-2357	138	16	phase	phase	NOUN
dpc-2357	138	17	iii	iii	NUM
dpc-2357	138	18	study	study	NOUN
dpc-2357	138	19	group	group	NOUN
dpc-2357	138	20	.	.	PUNCT
dpc-2357	139	1	maintenance	maintenance	NOUN
dpc-2357	139	2	of	of	ADP
dpc-2357	139	3	remission	remission	NOUN
dpc-2357	139	4	following	follow	VERB
dpc-2357	139	5	successful	successful	ADJ
dpc-2357	139	6	treatment	treatment	NOUN
dpc-2357	139	7	of	of	ADP
dpc-2357	139	8	papulopustular	papulopustular	ADJ
dpc-2357	139	9	rosacea	rosacea	NOUN
dpc-2357	139	10	with	with	ADP
dpc-2357	139	11	ivermectin	ivermectin	NOUN
dpc-2357	139	12	1	1	NUM
dpc-2357	139	13	%	%	NOUN
dpc-2357	139	14	cream	cream	NOUN
dpc-2357	139	15	vs.	vs.	ADP
dpc-2357	139	16	metronidazole	metronidazole	NOUN
dpc-2357	139	17	0.75	0.75	NUM
dpc-2357	139	18	%	%	NOUN
dpc-2357	139	19	cream	cream	NOUN
dpc-2357	139	20	:	:	PUNCT
dpc-2357	139	21	36	36	NUM
dpc-2357	139	22	-	-	PUNCT
dpc-2357	139	23	week	week	NOUN
dpc-2357	139	24	extension	extension	NOUN
dpc-2357	139	25	of	of	ADP
dpc-2357	139	26	the	the	DET
dpc-2357	139	27	attract	attract	NOUN
dpc-2357	139	28	randomized	randomized	ADJ
dpc-2357	139	29	study	study	NOUN
dpc-2357	139	30	.	.	PUNCT
dpc-2357	140	1	j	j	PROPN
dpc-2357	140	2	eur	eur	PROPN
dpc-2357	140	3	acad	acad	PROPN
dpc-2357	140	4	dermatol	dermatol	NOUN
dpc-2357	140	5	venereol	venereol	NOUN
dpc-2357	140	6	.	.	PUNCT
dpc-2357	141	1	2016;30(5):829	2016;30(5):829	X
dpc-2357	141	2	-	-	PUNCT
dpc-2357	141	3	836	836	NUM
dpc-2357	141	4	.	.	PUNCT
dpc-2357	141	5	  	  	SPACE
dpc-2357	141	6	doi	doi	NOUN
dpc-2357	141	7	:	:	PUNCT
dpc-2357	141	8	10.1111	10.1111	NUM
dpc-2357	141	9	/	/	SYM
dpc-2357	141	10	jdv.13537	jdv.13537	PROPN
dpc-2357	141	11	.	.	PUNCT
dpc-2357	142	1	pmid	pmid	NOUN
dpc-2357	142	2	:	:	PUNCT
dpc-2357	142	3	26691278	26691278	NUM
dpc-2357	142	4	.	.	PUNCT
dpc-2357	143	1	4	4	X
dpc-2357	143	2	.	.	X
dpc-2357	143	3	schaller	schaller	PROPN
dpc-2357	143	4	m	m	PROPN
dpc-2357	143	5	,	,	PUNCT
dpc-2357	143	6	almeida	almeida	PROPN
dpc-2357	143	7	lm	lm	PROPN
dpc-2357	143	8	,	,	PUNCT
dpc-2357	143	9	bewley	bewley	PROPN
dpc-2357	143	10	a	a	PROPN
dpc-2357	143	11	,	,	PUNCT
dpc-2357	143	12	et	et	PROPN
dpc-2357	143	13	al	al	PROPN
dpc-2357	143	14	.	.	PROPN
dpc-2357	143	15	rosacea	rosacea	PROPN
dpc-2357	143	16	treatment	treatment	NOUN
dpc-2357	143	17	update	update	NOUN
dpc-2357	143	18	:	:	PUNCT
dpc-2357	143	19	recommendations	recommendation	NOUN
dpc-2357	143	20	from	from	ADP
dpc-2357	143	21	the	the	DET
dpc-2357	143	22	global	global	ADJ
dpc-2357	143	23	rosacea	rosacea	PROPN
dpc-2357	143	24	consensus	consensus	PROPN
dpc-2357	143	25	(	(	PUNCT
dpc-2357	143	26	rosco	rosco	PROPN
dpc-2357	143	27	)	)	PUNCT
dpc-2357	143	28	panel	panel	NOUN
dpc-2357	143	29	.	.	PUNCT
dpc-2357	144	1	br	br	PROPN
dpc-2357	144	2	j	j	PROPN
dpc-2357	144	3	dermatol	dermatol	NOUN
dpc-2357	144	4	.	.	PUNCT
dpc-2357	145	1	2017;176(2):465	2017;176(2):465	NUM
dpc-2357	145	2	-	-	SYM
dpc-2357	145	3	471	471	NUM
dpc-2357	145	4	.	.	PUNCT
dpc-2357	146	1	doi	doi	NOUN
dpc-2357	146	2	:	:	PUNCT
dpc-2357	146	3	10.1111	10.1111	NUM
dpc-2357	146	4	/	/	SYM
dpc-2357	146	5	bjd.15173	bjd.15173	PROPN
dpc-2357	146	6	.	.	PUNCT
dpc-2357	147	1	pmid	pmid	NOUN
dpc-2357	147	2	:	:	PUNCT
dpc-2357	147	3	27861741	27861741	NUM
dpc-2357	147	4	.	.	PUNCT
dpc-2357	148	1	5	5	NUM
dpc-2357	148	2	.	.	NOUN
dpc-2357	148	3	steinhoff	steinhoff	PROPN
dpc-2357	148	4	m	m	PROPN
dpc-2357	148	5	,	,	PUNCT
dpc-2357	148	6	vocanson	vocanson	PROPN
dpc-2357	148	7	m	m	PROPN
dpc-2357	148	8	,	,	PUNCT
dpc-2357	148	9	voegel	voegel	PROPN
dpc-2357	148	10	jj	jj	PROPN
dpc-2357	148	11	,	,	PUNCT
dpc-2357	148	12	hacini	hacini	NOUN
dpc-2357	148	13	-	-	PUNCT
dpc-2357	148	14	rachinel	rachinel	NOUN
dpc-2357	148	15	f	f	NOUN
dpc-2357	148	16	,	,	PUNCT
dpc-2357	148	17	schäfer	schäfer	NOUN
dpc-2357	148	18	g.	g.	NOUN
dpc-2357	148	19	topical	topical	ADJ
dpc-2357	148	20	ivermectin	ivermectin	NOUN
dpc-2357	148	21	10	10	NUM
dpc-2357	148	22	  	  	SPACE
dpc-2357	148	23	mg	mg	PROPN
dpc-2357	148	24	/	/	SYM
dpc-2357	148	25	g	g	PROPN
dpc-2357	148	26	and	and	CCONJ
dpc-2357	148	27	oral	oral	ADJ
dpc-2357	148	28	doxycycline	doxycycline	NOUN
dpc-2357	148	29	40	40	NUM
dpc-2357	148	30	  	  	SPACE
dpc-2357	148	31	mg	mg	PROPN
dpc-2357	148	32	modified	modify	VERB
dpc-2357	148	33	-	-	PUNCT
dpc-2357	148	34	release	release	NOUN
dpc-2357	148	35	:	:	PUNCT
dpc-2357	148	36	current	current	ADJ
dpc-2357	148	37	evidence	evidence	NOUN
dpc-2357	148	38	on	on	ADP
dpc-2357	148	39	the	the	DET
dpc-2357	148	40	complementary	complementary	ADJ
dpc-2357	148	41	use	use	NOUN
dpc-2357	148	42	of	of	ADP
dpc-2357	148	43	anti	anti	ADJ
dpc-2357	148	44	-	-	ADJ
dpc-2357	148	45	inflammatory	inflammatory	ADJ
dpc-2357	148	46	rosacea	rosacea	NOUN
dpc-2357	148	47	treatments	treatment	NOUN
dpc-2357	148	48	.	.	PUNCT
dpc-2357	149	1	adv	adv	INTJ
dpc-2357	149	2	ther	ther	ADV
dpc-2357	149	3	.	.	PUNCT
dpc-2357	150	1	2016;33(9):1481	2016;33(9):1481	NUM
dpc-2357	150	2	-	-	SYM
dpc-2357	150	3	501	501	NUM
dpc-2357	150	4	.	.	PUNCT
dpc-2357	150	5	doi	doi	NOUN
dpc-2357	150	6	:	:	PUNCT
dpc-2357	150	7	10.1007	10.1007	NUM
dpc-2357	150	8	/	/	SYM
dpc-2357	150	9	s12325	s12325	PROPN
dpc-2357	150	10	-	-	PUNCT
dpc-2357	150	11	016	016	NUM
dpc-2357	150	12	-	-	PUNCT
dpc-2357	150	13	0380	0380	NUM
dpc-2357	150	14	-	-	PUNCT
dpc-2357	150	15	z.	z.	PROPN
dpc-2357	150	16	pmid	pmid	PROPN
dpc-2357	150	17	:	:	PUNCT
dpc-2357	150	18	27432381	27432381	NUM
dpc-2357	150	19	:	:	PUNCT
dpc-2357	150	20	pmcid	pmcid	NOUN
dpc-2357	150	21	:	:	PUNCT
dpc-2357	150	22	pmc5020118	pmc5020118	NOUN
dpc-2357	150	23	.	.	PUNCT
dpc-2357	151	1	6	6	X
dpc-2357	151	2	.	.	X
dpc-2357	151	3	mendieta	mendieta	PROPN
dpc-2357	151	4	eckert	eckert	PROPN
dpc-2357	151	5	m	m	PROPN
dpc-2357	151	6	,	,	PUNCT
dpc-2357	151	7	landa	landa	PROPN
dpc-2357	151	8	gundin	gundin	VERB
dpc-2357	151	9	n.	n.	NOUN
dpc-2357	151	10	treatment	treatment	NOUN
dpc-2357	151	11	of	of	ADP
dpc-2357	151	12	rosacea	rosacea	NOUN
dpc-2357	151	13	with	with	ADP
dpc-2357	151	14	topical	topical	ADJ
dpc-2357	151	15	ivermectin	ivermectin	NOUN
dpc-2357	151	16	cream	cream	NOUN
dpc-2357	151	17	:	:	PUNCT
dpc-2357	151	18	a	a	DET
dpc-2357	151	19	series	series	NOUN
dpc-2357	151	20	of	of	ADP
dpc-2357	151	21	34	34	NUM
dpc-2357	151	22	cases	case	NOUN
dpc-2357	151	23	.	.	PUNCT
dpc-2357	152	1	dermatol	dermatol	NOUN
dpc-2357	152	2	online	online	PROPN
dpc-2357	152	3	j.	j.	PROPN
dpc-2357	152	4	2016;22(8):13030	2016;22(8):13030	PROPN
dpc-2357	152	5	/	/	SYM
dpc-2357	152	6	qt9ks1c48n	qt9ks1c48n	PROPN
dpc-2357	152	7	.	.	PUNCT
dpc-2357	153	1	pmid	pmid	NOUN
dpc-2357	153	2	:	:	PUNCT
dpc-2357	153	3	27617938	27617938	NUM
dpc-2357	153	4	..	..	PUNCT
dpc-2357	154	1	7	7	X
dpc-2357	154	2	.	.	X
dpc-2357	154	3	trave	trave	PROPN
dpc-2357	154	4	i	i	PRON
dpc-2357	154	5	,	,	PUNCT
dpc-2357	154	6	merlo	merlo	PROPN
dpc-2357	154	7	g	g	PROPN
dpc-2357	154	8	,	,	PUNCT
dpc-2357	154	9	cozzani	cozzani	ADJ
dpc-2357	154	10	e	e	NOUN
dpc-2357	154	11	,	,	PUNCT
dpc-2357	154	12	parodi	parodi	PROPN
dpc-2357	154	13	a.	a.	NOUN
dpc-2357	154	14	real	real	ADJ
dpc-2357	154	15	-	-	PUNCT
dpc-2357	154	16	life	life	NOUN
dpc-2357	154	17	experience	experience	NOUN
dpc-2357	154	18	on	on	ADP
dpc-2357	154	19	effectiveness	effectiveness	NOUN
dpc-2357	154	20	and	and	CCONJ
dpc-2357	154	21	tolerability	tolerability	NOUN
dpc-2357	154	22	of	of	ADP
dpc-2357	154	23	topical	topical	ADJ
dpc-2357	154	24	ivermectin	ivermectin	NOUN
dpc-2357	154	25	in	in	ADP
dpc-2357	154	26	papulopustular	papulopustular	ADJ
dpc-2357	154	27	rosacea	rosacea	NOUN
dpc-2357	154	28	and	and	CCONJ
dpc-2357	154	29	antiparasitic	antiparasitic	ADJ
dpc-2357	154	30	effect	effect	NOUN
dpc-2357	154	31	on	on	ADP
dpc-2357	154	32	demodex	demodex	NOUN
dpc-2357	154	33	mites	mite	NOUN
dpc-2357	154	34	.	.	PUNCT
dpc-2357	155	1	dermatol	dermatol	NOUN
dpc-2357	155	2	ther	ther	ADV
dpc-2357	155	3	.	.	PUNCT
dpc-2357	156	1	2019;32(6):e13093	2019;32(6):e13093	NUM
dpc-2357	156	2	.	.	PUNCT
dpc-2357	156	3	doi	doi	NOUN
dpc-2357	156	4	:	:	PUNCT
dpc-2357	156	5	10.1111	10.1111	NUM
dpc-2357	156	6	/	/	SYM
dpc-2357	156	7	dth.13093	dth.13093	NUM
dpc-2357	156	8	.	.	PUNCT
dpc-2357	157	1	pmid	pmid	NOUN
dpc-2357	157	2	:	:	PUNCT
dpc-2357	157	3	31579993	31579993	NUM
dpc-2357	157	4	.	.	PUNCT
dpc-2357	158	1	8	8	X
dpc-2357	158	2	.	.	PUNCT
dpc-2357	159	1	forton	forton	PROPN
dpc-2357	159	2	f	f	PROPN
dpc-2357	159	3	,	,	PUNCT
dpc-2357	159	4	seys	seys	PROPN
dpc-2357	159	5	b.	b.	PROPN
dpc-2357	159	6	density	density	PROPN
dpc-2357	159	7	of	of	ADP
dpc-2357	159	8	demodex	demodex	NOUN
dpc-2357	159	9	folliculorum	folliculorum	NOUN
dpc-2357	159	10	in	in	ADP
dpc-2357	159	11	rosacea	rosacea	NOUN
dpc-2357	159	12	:	:	PUNCT
dpc-2357	159	13	a	a	DET
dpc-2357	159	14	case	case	NOUN
dpc-2357	159	15	-	-	PUNCT
dpc-2357	159	16	control	control	NOUN
dpc-2357	159	17	study	study	NOUN
dpc-2357	159	18	using	use	VERB
dpc-2357	159	19	standardized	standardized	ADJ
dpc-2357	159	20	skin	skin	NOUN
dpc-2357	159	21	-	-	PUNCT
dpc-2357	159	22	surface	surface	NOUN
dpc-2357	159	23	biopsy	biopsy	NOUN
dpc-2357	159	24	.	.	PUNCT
dpc-2357	160	1	br	br	PROPN
dpc-2357	160	2	j	j	PROPN
dpc-2357	160	3	dermatol	dermatol	NOUN
dpc-2357	160	4	.	.	PUNCT
dpc-2357	161	1	1993;128(6):650	1993;128(6):650	NUM
dpc-2357	161	2	-	-	SYM
dpc-2357	161	3	659	659	NUM
dpc-2357	161	4	.	.	PUNCT
dpc-2357	162	1	doi	doi	NOUN
dpc-2357	162	2	:	:	PUNCT
dpc-2357	162	3	10.1111	10.1111	NUM
dpc-2357	162	4	/	/	SYM
dpc-2357	162	5	j.13652133.1993.tb00261.x	j.13652133.1993.tb00261.x	PROPN
dpc-2357	162	6	.	.	PUNCT
dpc-2357	163	1	pmid	pmid	NOUN
dpc-2357	163	2	:	:	PUNCT
dpc-2357	163	3	8338749	8338749	NUM
dpc-2357	163	4	.	.	PUNCT
dpc-2357	164	1	9	9	X
dpc-2357	164	2	.	.	X
dpc-2357	164	3	alniemi	alniemi	PROPN
dpc-2357	164	4	dt	dt	PROPN
dpc-2357	164	5	,	,	PUNCT
dpc-2357	164	6	chen	chen	PROPN
dpc-2357	164	7	dl	dl	PROPN
dpc-2357	164	8	.	.	PROPN
dpc-2357	164	9	perioral	perioral	PROPN
dpc-2357	164	10	demodex	demodex	NOUN
dpc-2357	164	11	folliculitis	folliculitis	NOUN
dpc-2357	164	12	masquerading	masquerade	VERB
dpc-2357	164	13	as	as	ADP
dpc-2357	164	14	perioral	perioral	ADJ
dpc-2357	164	15	dermatitis	dermatitis	NOUN
dpc-2357	164	16	in	in	ADP
dpc-2357	164	17	the	the	DET
dpc-2357	164	18	peripartum	peripartum	NOUN
dpc-2357	164	19	period	period	NOUN
dpc-2357	164	20	.	.	PUNCT
dpc-2357	165	1	jaad	jaad	NOUN
dpc-2357	165	2	case	case	NOUN
dpc-2357	165	3	rep	rep	PROPN
dpc-2357	165	4	.	.	PROPN
dpc-2357	165	5	2019;5(7):639–641	2019;5(7):639–641	PROPN
dpc-2357	165	6	.	.	PUNCT
dpc-2357	165	7	doi	doi	PROPN
dpc-2357	165	8	:	:	PUNCT
dpc-2357	165	9	10.1016	10.1016	NUM
dpc-2357	165	10	/	/	SYM
dpc-2357	165	11	j.jdcr.2019.05.012	j.jdcr.2019.05.012	PROPN
dpc-2357	165	12	.	.	PUNCT
dpc-2357	166	1	pmid	pmid	NOUN
dpc-2357	166	2	:	:	PUNCT
dpc-2357	166	3	31341946	31341946	NUM
dpc-2357	166	4	.	.	PUNCT
dpc-2357	167	1	pmcid	pmcid	ADJ
dpc-2357	167	2	:	:	PUNCT
dpc-2357	167	3	pmc6630018	pmc6630018	NOUN
dpc-2357	167	4	.	.	PUNCT
dpc-2357	168	1	10	10	NUM
dpc-2357	168	2	.	.	PUNCT
dpc-2357	169	1	friedman	friedman	PROPN
dpc-2357	169	2	p	p	NOUN
dpc-2357	169	3	,	,	PUNCT
dpc-2357	169	4	sabban	sabban	NOUN
dpc-2357	169	5	ec	ec	PROPN
dpc-2357	169	6	,	,	PUNCT
dpc-2357	169	7	cabo	cabo	PROPN
dpc-2357	169	8	h.	h.	PROPN
dpc-2357	169	9	usefulness	usefulness	NOUN
dpc-2357	169	10	of	of	ADP
dpc-2357	169	11	dermoscopy	dermoscopy	NOUN
dpc-2357	169	12	in	in	ADP
dpc-2357	169	13	the	the	DET
dpc-2357	169	14	diagnosis	diagnosis	NOUN
dpc-2357	169	15	and	and	CCONJ
dpc-2357	169	16	monitoring	monitor	VERB
dpc-2357	169	17	treatment	treatment	NOUN
dpc-2357	169	18	of	of	ADP
dpc-2357	169	19	demodicidosis	demodicidosis	NOUN
dpc-2357	169	20	.	.	PUNCT
dpc-2357	170	1	dermatol	dermatol	NOUN
dpc-2357	170	2	pract	pract	PROPN
dpc-2357	170	3	concept	concept	NOUN
dpc-2357	170	4	.	.	PUNCT
dpc-2357	171	1	2017;7(1):35–38	2017;7(1):35–38	X
dpc-2357	171	2	.	.	PUNCT
dpc-2357	172	1	doi	doi	NOUN
dpc-2357	172	2	:	:	PUNCT
dpc-2357	172	3	10.5826/	10.5826/	NUM
dpc-2357	172	4	dpc.0701a06	dpc.0701a06	NOUN
dpc-2357	172	5	.	.	PUNCT
dpc-2357	173	1	pmid	pmid	NOUN
dpc-2357	173	2	:	:	PUNCT
dpc-2357	173	3	28243492	28243492	NUM
dpc-2357	173	4	.	.	PUNCT
dpc-2357	174	1	pmcid	pmcid	NOUN
dpc-2357	174	2	:	:	PUNCT
dpc-2357	174	3	pmc5315038	pmc5315038	NOUN
dpc-2357	174	4	.	.	PUNCT
dpc-2357	175	1	11	11	NUM
dpc-2357	175	2	.	.	PUNCT
dpc-2357	176	1	lee	lee	PROPN
dpc-2357	176	2	jy	jy	PROPN
dpc-2357	176	3	,	,	PUNCT
dpc-2357	176	4	hsu	hsu	PROPN
dpc-2357	176	5	ck	ck	PROPN
dpc-2357	176	6	.	.	PUNCT
dpc-2357	177	1	granulomatous	granulomatous	ADJ
dpc-2357	177	2	rosacea	rosacea	NOUN
dpc-2357	177	3	-	-	PUNCT
dpc-2357	177	4	like	like	ADJ
dpc-2357	177	5	demodicidosis	demodicidosis	NOUN
dpc-2357	177	6	.	.	PUNCT
dpc-2357	178	1	dermatol	dermatol	NOUN
dpc-2357	178	2	online	online	PROPN
dpc-2357	178	3	j.	j.	PROPN
dpc-2357	178	4	2007;13(4):9	2007;13(4):9	PROPN
dpc-2357	178	5	.	.	PUNCT
dpc-2357	179	1	pmid	pmid	NOUN
dpc-2357	179	2	:	:	PUNCT
dpc-2357	179	3	18319006	18319006	NUM
dpc-2357	179	4	.	.	PUNCT
dpc-2357	180	1	12	12	NUM
dpc-2357	180	2	.	.	PUNCT
dpc-2357	181	1	dall'oglio	dall'oglio	PROPN
dpc-2357	181	2	f	f	PROPN
dpc-2357	181	3	,	,	PUNCT
dpc-2357	181	4	lacarrubba	lacarrubba	PROPN
dpc-2357	181	5	f	f	PROPN
dpc-2357	181	6	,	,	PUNCT
dpc-2357	181	7	luca	luca	PROPN
dpc-2357	181	8	m	m	PROPN
dpc-2357	181	9	,	,	PUNCT
dpc-2357	181	10	boscaglia	boscaglia	PROPN
dpc-2357	181	11	s	s	PART
dpc-2357	181	12	,	,	PUNCT
dpc-2357	181	13	micali	micali	NOUN
dpc-2357	181	14	g.	g.	PROPN
dpc-2357	181	15	clinical	clinical	ADJ
dpc-2357	181	16	and	and	CCONJ
dpc-2357	181	17	erythema	erythema	ADV
dpc-2357	181	18	-	-	PUNCT
dpc-2357	181	19	directed	direct	VERB
dpc-2357	181	20	imaging	imaging	NOUN
dpc-2357	181	21	evaluation	evaluation	NOUN
dpc-2357	181	22	of	of	ADP
dpc-2357	181	23	papulo	papulo	NOUN
dpc-2357	181	24	-	-	PUNCT
dpc-2357	181	25	pustular	pustular	ADJ
dpc-2357	181	26	rosacea	rosacea	NOUN
dpc-2357	181	27	with	with	ADP
dpc-2357	181	28	topical	topical	ADJ
dpc-2357	181	29	ivermectin	ivermectin	NOUN
dpc-2357	181	30	:	:	PUNCT
dpc-2357	181	31	a	a	DET
dpc-2357	181	32	32	32	NUM
dpc-2357	181	33	weeks	week	NOUN
dpc-2357	181	34	duration	duration	NOUN
dpc-2357	181	35	study	study	NOUN
dpc-2357	181	36	.	.	PUNCT
dpc-2357	182	1	j	j	PROPN
dpc-2357	182	2	dermatolog	dermatolog	PROPN
dpc-2357	182	3	treat	treat	NOUN
dpc-2357	182	4	.	.	PUNCT
dpc-2357	183	1	2019;30(7):703	2019;30(7):703	NUM
dpc-2357	183	2	-	-	SYM
dpc-2357	183	3	707	707	NUM
dpc-2357	183	4	.	.	PUNCT
dpc-2357	184	1	doi	doi	NOUN
dpc-2357	184	2	:	:	PUNCT
dpc-2357	184	3	10.1080/09546634.2019.1572860	10.1080/09546634.2019.1572860	NUM
dpc-2357	184	4	.	.	PUNCT
dpc-2357	185	1	pmid	pmid	NOUN
dpc-2357	185	2	:	:	PUNCT
dpc-2357	185	3	30663445	30663445	NUM
dpc-2357	185	4	.	.	PUNCT
dpc-2357	186	1	13	13	NUM
dpc-2357	186	2	.	.	PUNCT
dpc-2357	187	1	drago	drago	PROPN
dpc-2357	187	2	f	f	PROPN
dpc-2357	187	3	,	,	PUNCT
dpc-2357	187	4	ciccarese	ciccarese	PROPN
dpc-2357	187	5	g	g	PROPN
dpc-2357	187	6	,	,	PUNCT
dpc-2357	187	7	herzum	herzum	PROPN
dpc-2357	187	8	a	a	PROPN
dpc-2357	187	9	,	,	PUNCT
dpc-2357	187	10	rebora	rebora	PROPN
dpc-2357	187	11	a	a	DET
dpc-2357	187	12	,	,	PUNCT
dpc-2357	187	13	parodi	parodi	ADJ
dpc-2357	187	14	a.	a.	NOUN
dpc-2357	187	15	rosacea	rosacea	NOUN
dpc-2357	187	16	and	and	CCONJ
dpc-2357	187	17	alcohol	alcohol	NOUN
dpc-2357	187	18	intake	intake	NOUN
dpc-2357	187	19	.	.	PUNCT
dpc-2357	188	1	j	j	PROPN
dpc-2357	188	2	am	be	AUX
dpc-2357	188	3	acad	acad	ADJ
dpc-2357	188	4	dermatol	dermatol	NOUN
dpc-2357	188	5	.	.	PUNCT
dpc-2357	189	1	2018;78(1):e25	2018;78(1):e25	NUM
dpc-2357	189	2	.	.	PUNCT
dpc-2357	190	1	doi	doi	NOUN
dpc-2357	190	2	:	:	PUNCT
dpc-2357	190	3	10.1016	10.1016	NUM
dpc-2357	190	4	/	/	SYM
dpc-2357	190	5	j.jaad.2017.08.063	j.jaad.2017.08.063	X
dpc-2357	190	6	.	.	PUNCT
dpc-2357	191	1	pmid	pmid	NOUN
dpc-2357	191	2	:	:	PUNCT
dpc-2357	191	3	29126626	29126626	NUM
dpc-2357	191	4	.	.	PUNCT
dpc-2357	192	1	14	14	NUM
dpc-2357	192	2	.	.	PUNCT
dpc-2357	192	3	gallo	gallo	PROPN
dpc-2357	192	4	rl	rl	PROPN
dpc-2357	192	5	,	,	PUNCT
dpc-2357	192	6	granstein	granstein	PROPN
dpc-2357	192	7	rd	rd	PROPN
dpc-2357	192	8	,	,	PUNCT
dpc-2357	192	9	kang	kang	PROPN
dpc-2357	192	10	s	s	PROPN
dpc-2357	192	11	,	,	PUNCT
dpc-2357	192	12	et	et	PROPN
dpc-2357	192	13	al	al	PROPN
dpc-2357	192	14	.	.	PROPN
dpc-2357	193	1	standard	standard	ADJ
dpc-2357	193	2	classification	classification	NOUN
dpc-2357	193	3	and	and	CCONJ
dpc-2357	193	4	pathophysiology	pathophysiology	NOUN
dpc-2357	193	5	of	of	ADP
dpc-2357	193	6	rosacea	rosacea	NOUN
dpc-2357	193	7	:	:	PUNCT
dpc-2357	193	8	the	the	DET
dpc-2357	193	9	2017	2017	NUM
dpc-2357	193	10	update	update	NOUN
dpc-2357	193	11	by	by	ADP
dpc-2357	193	12	the	the	DET
dpc-2357	193	13	national	national	PROPN
dpc-2357	193	14	rosacea	rosacea	PROPN
dpc-2357	193	15	society	society	PROPN
dpc-2357	193	16	expert	expert	PROPN
dpc-2357	193	17	committee	committee	PROPN
dpc-2357	193	18	.	.	PUNCT
dpc-2357	194	1	j	j	PROPN
dpc-2357	194	2	am	be	AUX
dpc-2357	194	3	acad	acad	ADJ
dpc-2357	194	4	dermatol	dermatol	NOUN
dpc-2357	194	5	2018;78(1):148	2018;78(1):148	PROPN
dpc-2357	194	6	-	-	SYM
dpc-2357	194	7	155	155	NUM
dpc-2357	194	8	.	.	PUNCT
dpc-2357	195	1	doi	doi	NOUN
dpc-2357	195	2	:	:	PUNCT
dpc-2357	195	3	10.1016	10.1016	NUM
dpc-2357	195	4	/	/	SYM
dpc-2357	195	5	j.jaad.2017.08.037	j.jaad.2017.08.037	PROPN
dpc-2357	195	6	.	.	PUNCT
dpc-2357	196	1	pmid	pmid	NOUN
dpc-2357	196	2	:	:	PUNCT
dpc-2357	196	3	29089180	29089180	NUM
dpc-2357	196	4	.	.	PUNCT
dpc-2357	197	1	15	15	NUM
dpc-2357	197	2	.	.	PUNCT
dpc-2357	198	1	hopkinson	hopkinson	PROPN
dpc-2357	198	2	d	d	PROPN
dpc-2357	198	3	,	,	PUNCT
dpc-2357	198	4	moradi	moradi	VERB
dpc-2357	198	5	tuchayi	tuchayi	NOUN
dpc-2357	198	6	s	s	PROPN
dpc-2357	198	7	,	,	PUNCT
dpc-2357	198	8	alinia	alinia	PROPN
dpc-2357	198	9	h	h	PROPN
dpc-2357	198	10	,	,	PUNCT
dpc-2357	198	11	feldman	feldman	PROPN
dpc-2357	198	12	sr	sr	PROPN
dpc-2357	198	13	.	.	PUNCT
dpc-2357	199	1	assessment	assessment	NOUN
dpc-2357	199	2	of	of	ADP
dpc-2357	199	3	rosacea	rosacea	NOUN
dpc-2357	199	4	severity	severity	PROPN
dpc-2357	199	5	:	:	PUNCT
dpc-2357	199	6	a	a	DET
dpc-2357	199	7	review	review	NOUN
dpc-2357	199	8	of	of	ADP
dpc-2357	199	9	evaluation	evaluation	NOUN
dpc-2357	199	10	methods	method	NOUN
dpc-2357	199	11	used	use	VERB
dpc-2357	199	12	in	in	ADP
dpc-2357	199	13	clinical	clinical	ADJ
dpc-2357	199	14	trials	trial	NOUN
dpc-2357	199	15	.	.	PUNCT
dpc-2357	200	1	j	j	PROPN
dpc-2357	200	2	am	be	AUX
dpc-2357	200	3	acad	acad	ADJ
dpc-2357	200	4	dermatol	dermatol	NOUN
dpc-2357	200	5	.	.	PUNCT
dpc-2357	201	1	2015;73(1):138	2015;73(1):138	PROPN
dpc-2357	201	2	-	-	PUNCT
dpc-2357	201	3	143.e4	143.e4	NUM
dpc-2357	201	4	.	.	PUNCT
dpc-2357	202	1	doi	doi	NOUN
dpc-2357	202	2	:	:	PUNCT
dpc-2357	202	3	10.1016	10.1016	NUM
dpc-2357	202	4	/	/	SYM
dpc-2357	202	5	j.jaad.2015.02.1121	j.jaad.2015.02.1121	PROPN
dpc-2357	202	6	.	.	PUNCT
dpc-2357	203	1	pmid	pmid	NOUN
dpc-2357	203	2	:	:	PUNCT
dpc-2357	203	3	25799418	25799418	NUM
dpc-2357	203	4	.	.	PUNCT
dpc-2357	204	1	16	16	NUM
dpc-2357	204	2	.	.	PUNCT
dpc-2357	205	1	laing	lae	VERB
dpc-2357	205	2	r	r	PROPN
dpc-2357	205	3	,	,	PUNCT
dpc-2357	205	4	gillan	gillan	PROPN
dpc-2357	205	5	v	v	PROPN
dpc-2357	205	6	,	,	PUNCT
dpc-2357	205	7	devaney	devaney	PROPN
dpc-2357	205	8	e.	e.	PROPN
dpc-2357	205	9	ivermectin	ivermectin	PROPN
dpc-2357	205	10	old	old	ADJ
dpc-2357	205	11	drug	drug	NOUN
dpc-2357	205	12	,	,	PUNCT
dpc-2357	205	13	new	new	ADJ
dpc-2357	205	14	tricks	trick	NOUN
dpc-2357	205	15	?	?	PUNCT
dpc-2357	206	1	trends	trend	NOUN
dpc-2357	206	2	parasitol	parasitol	NOUN
dpc-2357	206	3	.	.	PUNCT
dpc-2357	207	1	2017;33(6):463–472	2017;33(6):463–472	X
dpc-2357	207	2	.	.	X
dpc-2357	207	3	doi	doi	NOUN
dpc-2357	207	4	:	:	PUNCT
dpc-2357	207	5	10.1016	10.1016	NUM
dpc-2357	207	6	/	/	SYM
dpc-2357	207	7	j.	j.	PROPN
dpc-2357	207	8	pt.2017.02.004	pt.2017.02.004	PROPN
dpc-2357	207	9	.	.	PUNCT
dpc-2357	208	1	pmid	pmid	NOUN
dpc-2357	208	2	:	:	PUNCT
dpc-2357	208	3	28285851	28285851	NUM
dpc-2357	208	4	.	.	PUNCT
dpc-2357	209	1	pmcid	pmcid	NOUN
dpc-2357	209	2	:	:	PUNCT
dpc-2357	209	3	pmc5446326	pmc5446326	NOUN
dpc-2357	209	4	.	.	PUNCT
dpc-2357	210	1	17	17	NUM
dpc-2357	210	2	.	.	PUNCT
dpc-2357	211	1	forton	forton	PROPN
dpc-2357	211	2	f	f	PROPN
dpc-2357	211	3	,	,	PUNCT
dpc-2357	211	4	germaux	germaux	PROPN
dpc-2357	211	5	ma	ma	PROPN
dpc-2357	211	6	,	,	PUNCT
dpc-2357	211	7	brasseur	brasseur	PROPN
dpc-2357	211	8	t	t	PROPN
dpc-2357	211	9	,	,	PUNCT
dpc-2357	211	10	et	et	PROPN
dpc-2357	211	11	al	al	PROPN
dpc-2357	211	12	.	.	PROPN
dpc-2357	211	13	demodicosis	demodicosis	PROPN
dpc-2357	211	14	and	and	CCONJ
dpc-2357	211	15	rosacea	rosacea	NOUN
dpc-2357	211	16	:	:	PUNCT
dpc-2357	211	17	epidemiology	epidemiology	NOUN
dpc-2357	211	18	and	and	CCONJ
dpc-2357	211	19	significance	significance	NOUN
dpc-2357	211	20	in	in	ADP
dpc-2357	211	21	daily	daily	ADJ
dpc-2357	211	22	dermatologic	dermatologic	ADJ
dpc-2357	211	23	practice	practice	NOUN
dpc-2357	211	24	.	.	PUNCT
dpc-2357	212	1	j	j	PROPN
dpc-2357	212	2	am	be	AUX
dpc-2357	212	3	acad	acad	ADJ
dpc-2357	212	4	dermatol	dermatol	NOUN
dpc-2357	212	5	.	.	PUNCT
dpc-2357	213	1	2005;52(1):74	2005;52(1):74	PROPN
dpc-2357	213	2	-	-	PUNCT
dpc-2357	213	3	87	87	NUM
dpc-2357	213	4	.	.	PUNCT
dpc-2357	214	1	doi	doi	NOUN
dpc-2357	214	2	:	:	PUNCT
dpc-2357	214	3	10.1016	10.1016	NUM
dpc-2357	214	4	/	/	SYM
dpc-2357	214	5	j.	j.	PROPN
dpc-2357	214	6	jaad.2004.05.034	jaad.2004.05.034	PROPN
dpc-2357	214	7	.	.	PUNCT
dpc-2357	215	1	pmid	pmid	NOUN
dpc-2357	215	2	:	:	PUNCT
dpc-2357	215	3	15627084	15627084	NUM
dpc-2357	215	4	.	.	PUNCT
dpc-2357	216	1	18	18	NUM
dpc-2357	216	2	.	.	PUNCT
dpc-2357	217	1	forton	forton	PROPN
dpc-2357	217	2	f	f	PROPN
dpc-2357	217	3	,	,	PUNCT
dpc-2357	217	4	de	de	X
dpc-2357	217	5	maertelaer	maertelaer	ADJ
dpc-2357	217	6	v.	v.	ADP
dpc-2357	217	7	erythematotelangiectatic	erythematotelangiectatic	PROPN
dpc-2357	217	8	rosacea	rosacea	PROPN
dpc-2357	217	9	may	may	AUX
dpc-2357	217	10	be	be	AUX
dpc-2357	217	11	associated	associate	VERB
dpc-2357	217	12	with	with	ADP
dpc-2357	217	13	a	a	DET
dpc-2357	217	14	subclinical	subclinical	ADJ
dpc-2357	217	15	stage	stage	NOUN
dpc-2357	217	16	of	of	ADP
dpc-2357	217	17	demodicosis	demodicosis	NOUN
dpc-2357	217	18	:	:	PUNCT
dpc-2357	217	19	a	a	DET
dpc-2357	217	20	case	case	NOUN
dpc-2357	217	21	-	-	PUNCT
dpc-2357	217	22	control	control	NOUN
dpc-2357	217	23	study	study	NOUN
dpc-2357	217	24	.	.	PUNCT
dpc-2357	218	1	br	br	PROPN
dpc-2357	218	2	j	j	PROPN
dpc-2357	218	3	dermatol	dermatol	NOUN
dpc-2357	218	4	.	.	PUNCT
dpc-2357	219	1	2019;181(4):818	2019;181(4):818	NUM
dpc-2357	219	2	-	-	SYM
dpc-2357	219	3	825	825	NUM
dpc-2357	219	4	.	.	PUNCT
dpc-2357	220	1	doi	doi	NOUN
dpc-2357	220	2	:	:	PUNCT
dpc-2357	220	3	10.1111	10.1111	NUM
dpc-2357	220	4	/	/	SYM
dpc-2357	220	5	bjd.17817	bjd.17817	PROPN
dpc-2357	220	6	.	.	PUNCT
dpc-2357	221	1	pmid	pmid	NOUN
dpc-2357	221	2	:	:	PUNCT
dpc-2357	221	3	30801673	30801673	NUM
dpc-2357	221	4	.	.	PUNCT
dpc-2357	222	1	19	19	NUM
dpc-2357	222	2	.	.	PUNCT
dpc-2357	223	1	forton	forton	PROPN
dpc-2357	223	2	fmn	fmn	PROPN
dpc-2357	223	3	.	.	PUNCT
dpc-2357	224	1	the	the	DET
dpc-2357	224	2	pathogenic	pathogenic	ADJ
dpc-2357	224	3	role	role	NOUN
dpc-2357	224	4	of	of	ADP
dpc-2357	224	5	demodex	demodex	NOUN
dpc-2357	224	6	mites	mite	NOUN
dpc-2357	224	7	in	in	ADP
dpc-2357	224	8	rosacea	rosacea	NOUN
dpc-2357	224	9	:	:	PUNCT
dpc-2357	224	10	a	a	DET
dpc-2357	224	11	potential	potential	ADJ
dpc-2357	224	12	therapeutic	therapeutic	ADJ
dpc-2357	224	13	target	target	NOUN
dpc-2357	224	14	already	already	ADV
dpc-2357	224	15	in	in	ADP
dpc-2357	224	16	erythematotelangiectatic	erythematotelangiectatic	ADJ
dpc-2357	224	17	rosacea	rosacea	NOUN
dpc-2357	224	18	?	?	PUNCT
dpc-2357	225	1	dermatol	dermatol	NOUN
dpc-2357	225	2	ther	ther	ADV
dpc-2357	225	3	(	(	PUNCT
dpc-2357	225	4	heidelb	heidelb	NOUN
dpc-2357	225	5	)	)	PUNCT
dpc-2357	225	6	.	.	PUNCT
dpc-2357	226	1	2020;10(6):1229	2020;10(6):1229	NUM
dpc-2357	226	2	-	-	PUNCT
dpc-2357	226	3	1253	1253	NUM
dpc-2357	226	4	.	.	PUNCT
dpc-2357	227	1	doi	doi	NOUN
dpc-2357	227	2	:	:	PUNCT
dpc-2357	227	3	10.1007	10.1007	NUM
dpc-2357	227	4	/	/	SYM
dpc-2357	227	5	s13555	s13555	PROPN
dpc-2357	227	6	-	-	PUNCT
dpc-2357	227	7	020	020	NUM
dpc-2357	227	8	-	-	PUNCT
dpc-2357	227	9	00458	00458	NUM
dpc-2357	227	10	-	-	PUNCT
dpc-2357	227	11	9	9	NUM
dpc-2357	227	12	.	.	PUNCT
dpc-2357	228	1	pmid	pmid	NOUN
dpc-2357	228	2	:	:	PUNCT
dpc-2357	228	3	33095403	33095403	NUM
dpc-2357	228	4	.	.	PUNCT
dpc-2357	229	1	pmcid	pmcid	NOUN
dpc-2357	229	2	:	:	PUNCT
dpc-2357	229	3	pmc7649190	pmc7649190	ADJ
dpc-2357	229	4	.	.	PUNCT
dpc-2357	230	1	20	20	NUM
dpc-2357	230	2	.	.	X
dpc-2357	230	3	trave	trave	PROPN
dpc-2357	231	1	i	i	PRON
dpc-2357	231	2	,	,	PUNCT
dpc-2357	231	3	micalizzi	micalizzi	PROPN
dpc-2357	231	4	c	c	X
dpc-2357	231	5	,	,	PUNCT
dpc-2357	231	6	gasparini	gasparini	NOUN
dpc-2357	231	7	g	g	NOUN
dpc-2357	231	8	,	,	PUNCT
dpc-2357	231	9	cozzani	cozzani	ADJ
dpc-2357	231	10	e	e	NOUN
dpc-2357	231	11	,	,	PUNCT
dpc-2357	231	12	parodi	parodi	PROPN
dpc-2357	231	13	a.	a.	NOUN
dpc-2357	231	14	dermoscopy	dermoscopy	NOUN
dpc-2357	231	15	of	of	ADP
dpc-2357	231	16	papulopustular	papulopustular	ADJ
dpc-2357	231	17	rosacea	rosacea	NOUN
dpc-2357	231	18	and	and	CCONJ
dpc-2357	231	19	comparison	comparison	NOUN
dpc-2357	231	20	of	of	ADP
dpc-2357	231	21	dermoscopic	dermoscopic	NOUN
dpc-2357	231	22	features	feature	NOUN
dpc-2357	231	23	in	in	ADP
dpc-2357	231	24	patients	patient	NOUN
dpc-2357	231	25	with	with	ADP
dpc-2357	231	26	or	or	CCONJ
dpc-2357	231	27	without	without	ADP
dpc-2357	231	28	concomitant	concomitant	ADJ
dpc-2357	231	29	demodex	demodex	NOUN
dpc-2357	231	30	folliculorum	folliculorum	NOUN
dpc-2357	231	31	.	.	PUNCT
dpc-2357	232	1	clin	clin	PROPN
dpc-2357	232	2	exp	exp	NOUN
dpc-2357	232	3	dermatol	dermatol	NOUN
dpc-2357	232	4	.	.	PUNCT
dpc-2357	233	1	2021;46(8):1434	2021;46(8):1434	NUM
dpc-2357	233	2	-	-	SYM
dpc-2357	233	3	1440	1440	NUM
dpc-2357	233	4	.	.	PUNCT
dpc-2357	234	1	doi	doi	NOUN
dpc-2357	234	2	:	:	PUNCT
dpc-2357	234	3	10.1111	10.1111	NUM
dpc-2357	234	4	/	/	SYM
dpc-2357	234	5	ced.14731	ced.14731	PROPN
dpc-2357	234	6	.	.	PUNCT
dpc-2357	235	1	pmid	pmid	NOUN
dpc-2357	235	2	:	:	PUNCT
dpc-2357	235	3	33987859	33987859	NUM
dpc-2357	235	4	.	.	PUNCT
dpc-2357	236	1	21	21	NUM
dpc-2357	236	2	.	.	X
dpc-2357	236	3	schaller	schaller	PROPN
dpc-2357	236	4	m	m	PROPN
dpc-2357	236	5	,	,	PUNCT
dpc-2357	236	6	gonser	gonser	PROPN
dpc-2357	236	7	l	l	PROPN
dpc-2357	236	8	,	,	PUNCT
dpc-2357	236	9	belge	belge	PROPN
dpc-2357	236	10	k	k	PROPN
dpc-2357	236	11	,	,	PUNCT
dpc-2357	236	12	et	et	PROPN
dpc-2357	236	13	al	al	PROPN
dpc-2357	236	14	.	.	PUNCT
dpc-2357	237	1	dual	dual	ADJ
dpc-2357	237	2	anti	anti	ADJ
dpc-2357	237	3	-	-	ADJ
dpc-2357	237	4	inflammatory	inflammatory	ADJ
dpc-2357	237	5	and	and	CCONJ
dpc-2357	237	6	anti	anti	ADJ
dpc-2357	237	7	-	-	ADJ
dpc-2357	237	8	parasitic	parasitic	ADJ
dpc-2357	237	9	action	action	NOUN
dpc-2357	237	10	of	of	ADP
dpc-2357	237	11	topical	topical	ADJ
dpc-2357	237	12	ivermectin	ivermectin	NOUN
dpc-2357	237	13	1	1	NUM
dpc-2357	237	14	%	%	NOUN
dpc-2357	237	15	in	in	ADP
dpc-2357	237	16	papulopustular	papulopustular	ADJ
dpc-2357	237	17	rosacea	rosacea	NOUN
dpc-2357	237	18	.	.	PUNCT
dpc-2357	238	1	j	j	PROPN
dpc-2357	238	2	eur	eur	PROPN
dpc-2357	238	3	acad	acad	PROPN
dpc-2357	238	4	dermatol	dermatol	NOUN
dpc-2357	238	5	venereol	venereol	NOUN
dpc-2357	238	6	.	.	PUNCT
dpc-2357	239	1	2017;31(11):1907	2017;31(11):1907	NUM
dpc-2357	239	2	–	–	PUNCT
dpc-2357	239	3	1911	1911	NUM
dpc-2357	239	4	.	.	PUNCT
dpc-2357	240	1	doi	doi	NOUN
dpc-2357	240	2	:	:	PUNCT
dpc-2357	240	3	10.1111	10.1111	NUM
dpc-2357	240	4	/	/	SYM
dpc-2357	240	5	jdv.14437	jdv.14437	PROPN
dpc-2357	240	6	.	.	PUNCT
dpc-2357	241	1	pmid	pmid	NOUN
dpc-2357	241	2	:	:	PUNCT
dpc-2357	241	3	28653460	28653460	NUM
dpc-2357	241	4	.	.	PUNCT
dpc-2357	242	1	22	22	NUM
dpc-2357	242	2	.	.	PUNCT
dpc-2357	243	1	thibaut	thibaut	PROPN
dpc-2357	243	2	de	de	X
dpc-2357	243	3	ménonville	ménonville	PROPN
dpc-2357	243	4	s	s	PART
dpc-2357	243	5	,	,	PUNCT
dpc-2357	243	6	rosignoli	rosignoli	NOUN
dpc-2357	243	7	c	c	PROPN
dpc-2357	243	8	,	,	PUNCT
dpc-2357	243	9	soares	soares	PROPN
dpc-2357	243	10	e	e	PROPN
dpc-2357	243	11	,	,	PUNCT
dpc-2357	243	12	et	et	PROPN
dpc-2357	243	13	al	al	PROPN
dpc-2357	243	14	.	.	PUNCT
dpc-2357	244	1	topical	topical	ADJ
dpc-2357	244	2	treatment	treatment	NOUN
dpc-2357	244	3	of	of	ADP
dpc-2357	244	4	rosacea	rosacea	NOUN
dpc-2357	244	5	with	with	ADP
dpc-2357	244	6	ivermectin	ivermectin	NOUN
dpc-2357	244	7	inhibits	inhibit	VERB
dpc-2357	244	8	gene	gene	NOUN
dpc-2357	244	9	expression	expression	NOUN
dpc-2357	244	10	of	of	ADP
dpc-2357	244	11	cathelicidin	cathelicidin	VERB
dpc-2357	244	12	innate	innate	ADJ
dpc-2357	244	13	immune	immune	ADJ
dpc-2357	244	14	mediators	mediator	NOUN
dpc-2357	244	15	,	,	PUNCT
dpc-2357	244	16	ll-37	ll-37	NOUN
dpc-2357	244	17	and	and	CCONJ
dpc-2357	244	18	klk5	klk5	NOUN
dpc-2357	244	19	,	,	PUNCT
dpc-2357	244	20	in	in	ADP
dpc-2357	244	21	reconstructed	reconstructed	ADJ
dpc-2357	244	22	and	and	CCONJ
dpc-2357	244	23	ex	ex	PRON
dpc-2357	244	24	vivo	vivo	ADJ
dpc-2357	244	25	skin	skin	NOUN
dpc-2357	244	26	models	model	NOUN
dpc-2357	244	27	.	.	PUNCT
dpc-2357	245	1	dermatol	dermatol	NOUN
dpc-2357	245	2	ther	ther	ADV
dpc-2357	245	3	(	(	PUNCT
dpc-2357	245	4	heidelb	heidelb	NOUN
dpc-2357	245	5	)	)	PUNCT
dpc-2357	245	6	.	.	PUNCT
dpc-2357	246	1	2017;7(8):213–225	2017;7(8):213–225	X
dpc-2357	246	2	.	.	PUNCT
dpc-2357	247	1	doi	doi	NOUN
dpc-2357	247	2	:	:	PUNCT
dpc-2357	247	3	10.1007	10.1007	NUM
dpc-2357	247	4	/	/	SYM
dpc-2357	247	5	s13555	s13555	PROPN
dpc-2357	247	6	-	-	PUNCT
dpc-2357	247	7	017	017	NUM
dpc-2357	247	8	-	-	PUNCT
dpc-2357	247	9	0176	0176	NUM
dpc-2357	247	10	-	-	PUNCT
dpc-2357	247	11	3	3	NUM
dpc-2357	247	12	.	.	PUNCT
dpc-2357	248	1	pmid	pmid	NOUN
dpc-2357	248	2	:	:	PUNCT
dpc-2357	248	3	28243927	28243927	NUM
dpc-2357	248	4	.	.	PUNCT
dpc-2357	249	1	pmcid	pmcid	ADJ
dpc-2357	249	2	:	:	PUNCT
dpc-2357	249	3	pmc5453918	pmc5453918	NOUN
dpc-2357	249	4	.	.	PUNCT